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SUMMARY
This work was aimed at advancing knowledge of the heat-labile 
toxin (HLT) of Bordetella pertussis along several lines, ultimately 
directed at gaining a better understanding of the possible roles of the 
toxin in the pathogenesis of B, pertussis infections and in the develop­
ment of immunity* The following observations were made:
1 Assay and stability of the toxin
1*1 When assaying the lethal toxicity of HLT in the mouse, neither 
the sex nor the weight of the animal had a significant influence on the 
result*
1*2 The assay of HLT by its haemorrhagic activity in 4 d old mice
was at least 10 times as sensitive as the LD^^ estimation in 3-4 wk old
mice,
1,3 Contrary to the report of Violle (1950, cited by Munoz, J*J*, 
1971* ^  : Kadis, S*, Montie, T*C* and Ajl, S*J* (editors)* Microbial
toxins* Vol*2Ao p*271-300* Academic Press* New York and London) adult 
mice (strain Hr/Hr) were found to be susceptible to the dermonecrotic 
activity of HLT*
1*4 HLT was not haemolytic for sheep, rabbit, horse, human or cod
red cells, even in doses as large as 2*5 mouse LD^^ per ml* There was
no hot-cold lysis*
1*5 Circumstantial evidence is presented that HLT may exist in an 
inactive form which can be converted by proteases into an active form*
1*6 For storing HLT, freezing (-20°C) was found to be satisfactory*
The mean rate of inactivation of 4 preparations tested over periods up to 
3 yr was 10% per annum*
2 Production of HLT
2*1 HLT production was suppressed during growth of cultures in a
high magnesium medium that yielded antigenically modulated (C-mode) cells*
II
These cells contained only 4-5% of the toxicity of X-mode cells, ie, cells 
that had been grown in normal medium* The lowered toxicity of the C-mode 
cells was not due to excretion of HLT into the culture medium* In X-mode 
cells, it was confirmed that HLT was mainly cytoplasmic but with some 
evidence of exposure on the bacterial surface* By affecting HLT, 
antigenic modulation causes changes in at least one component of the 
organism which, unlike the other reported changes associated with the X- 
to C-mode transition, is not principally a component or feature of the 
cell-surface or envelope. However, this may not be unique since C-mode 
colonies lack the zone of haemolysis shown by X-mode colonies (Lacey,
B*Wo, 1960, JoHyg,(Camb*)o _5£, 57-93), which is presumably due to a 
diffusible haemolysin*
2*2 Contrary to published results (Pusztai, Z* and Joo, I*, 1967, 
Ann*Immunol *Hung* 10, 63-67) there was a significant reduction in the 
toxicity of cells modulated by growth in media containing high levels of 
nicotinic acid, although the reduction was less than that observed by 
growth in a high magnesium medium (60% reduction cf 95%)*
2*3 Fourteen B, pertussis strains, some of which had been pre­
selected as potentially highly toxigenic, were compared for toxicity*
There was only about a 3-fold difference between the least and most toxic 
of these strains* The Pillemer strain 134 was chosen for routine 
production of cells rich in HLT*
2*4 Bordet-Gengou medium, charcoal agar, modified Hornibrook 
medium, and Stainer and Scholte (12G) medium differed little in their 
ability to support toxin production by B* pertussis strains 134, 18334 
and 77/18319* The time of harvesting the cells was more important*
On the solid media, cells were more toxic after 24 h growth than 72 h, 
whilst the converse was true with cells grown in the liquid media*
Ill
2o5 Although the level of iron in the medium is critical for the 
production of several bacterial toxins, HLT yields were independent of 
the iron content of the medium over a range of concentrations which 
with other bacterial species causes marked effects on toxin production*
3 Purification of HLT
3*1 Little success was achieved in attempting to purify HLT by 
the method used to obtain the purest HLT preparation to date (Nakase, Y,, 
Takatsu, K*, Tateishi, M* , Sekiya, K* and Kasuga, T*, 1969, Jpn*J* 
Microbiol* 359-366)* However it was demonstrated that the HLT in
lysates of B* pertussis could potentially be purified 20-fold by the 
following steps; preparative ultracentrifugation, fractional ammonium 
sulphate precipitation and gel filtration on Ultrogel AcA 44* These 
procedures in combination had the potential to give an HLT preparation 
containing 1000 LD^^ per mg protein which is roughly one-quarter as pure 
as the HLT which was reported by Nakase aT (1969) to be completely 
homogeneous *
3*2 For the first time a molecular weight value is reported for 
HLT, namely 89,000 daltons ( ^  10% ) as estimated by gel filtration on 
Ultrogel AcA 44*
4 Toxoiding HLT
4*1 HLT in lysate supernatant fluids was toxoided by 15 d 
incubation at 4°C with 0*1% (w/v) formaldehyde* Sterile, control toxin 
without formaldehyde kept 15 d at 4°C did not lose any toxicity (a 
necessary control not reported by previous investigators)*
4*2 Toxoiding with formaldehyde had the unexpected effect of 
appearing to increase the histamine-sensitizing (HSF) and lymphocytosis- 
promoting (LPF) activities of B* pertussis lysate supernatant fluids
IV
by about 2-fold * However to make this comparison required the super­
natant fluid with no added formaldehyde to be heated 30 min at 56°C 
before injection into mice* It was suggested that formaldehyde treat­
ment made the HSF/LPF more resistant to degradation by tissue enzymes 
in the mouse*
5 Role of HLT in immunity
5*1 Toxoided HLT was immunogenic in rabbits^ giving rise to anti­
toxin that neutralized the haemorrhagic activity of HLT in suckling mice* 
The same toxoid was not immunogenic in mice although the animals 
responded by producing precipitins to other antigens in the crude prepara­
tion, This confirms the previously reported lack of immunogenicity of 
HLT toxoid in mice and the responsiveness of rabbits,
5,2 Mice passively immunized with crude, rabbit antitoxin were 
protected against intracerebral challenges with B, pertussis but only if 
the antitoxin was given before, and not with, the challenge dose.
Against intranasal challenges, antitoxin was also protective if given 
before the challenge but was even more effective if given with the 
challenge organisms (ie, IN/mix test). However, once the crude antitoxin 
was absorbed with liVe B, pertussis cells it lost its protective activity 
as measured in the IN/mix test. It seems unlikely that anti-HLT was 
acting, in this or the other infection tests, as a protective antibody. 
Nevertheless, it is still possible that HLT is involved in the patho­
genesis of Bo pertussis infections and that antibodies directed against 
HLT could be protective. For instance, the possibility should not be 
discounted that the toxin may have a ciliostatic, or local necrotic, or 
permeability-altering activity, and that local secretory antibodies 
(IgA or IgE) may be significant in immunity to B, pertussis infections 
of the respiratory tract, both in mouse and in man.
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INTRODUCTION
SECTION I BORDETELLA PERTUSSIS
1 Taxonomy of the genus Bordetella
The genus Bordetella, proposed by Lopez (1952) and accepted in 
the 7th and 8th editions of Bergey's Manual of Determinative Bacteriology 
(Pittman, 1957 and 1974), consists of B, pertussis, B, parapertussis and 
B. bronchiseptica. The salient features of the members of this genus, 
of uncertain family affiliation, have been described by Pittman (1974),
All 3 species are minute Gram-negative coccobacilli (0„2-0o3 pm by 
Oo5-loO pm) found arranged singly, in pairs or more rarely short chains. 
Colonies as formed on Bordet-Gengou medium are "smooth, convex, pearly, 
glistening, nearly transparent, surrounded by a zone of haemolysis 
without a definite periphery". The organisms are strict aerobes with 
a temperature optimum of 35-37°C, Carbohydrates are not utilized but 
certain amino acids are oxidatively metabolized. Nicotinic acid (or 
nicotinamide) and a sulphur source (eg, cysteine or methionine) are 
necessary growth factors. All species possess a common, heat-stable 
0 antigen, heat-labile agglutinogen (no,7) and heat-labile, dermonecrotic 
toxin (HLT),
Features for differentiating the species within the genus are 
outlined in table 1, Recently however the validity of considering the 
3 members of the genus Bordetella as distinct species has been questioned, 
in particular the distinction made between B, pertussis and B, para­
pertussis (Kumazawa and Yoshikawa, 1978; Kloos et al, 1979), By 
treatment with N-methyl-N'-nitro-N-nitrosoguanidine B, pertussis strains 
have been converted into mutants resembling B, parapertussis.
2 Pertussis - the disease
The terms pertussis and parapertussis have been proposed to
Table 1 Differential characteristics of Bordetella species
Differential characteristics B. pertussis B.parapertussis B.bronchi-
septica
Appearance of colonies on
Bordet-Gengou agar (days) «4 2-3 1-2
Growth on MacConkey agar - + +
Growth/browning on peptone agar -/- +/+ +/-
Urease activity - + h
Citrate utilization - + +
Oxidase activity - +
Nitrate reduction - - +
Flagella - - +
Specific heat-labile agglutinogen 1 14 12
Ability to sensitize mice to
histamine h - -
G +  C content, moles % 61 61 66
Adapted from Pittman (1974) and Pittman and Wardlaw (personal communication)
describe the infections produced by B, pertussis and B, parapertussis 
(Lautrop, 1960), These infections are usually recognized when they 
give rise to the clinical syndrome of whooping cough with parapertussis 
typically being a milder and less frequently diagnosed form of the 
disease than pertussis (Lautrop, 1960; Linnemann and Perry, 1977).
Bo bronchiseptica may also on rare occasions give rise to whooping 
cough although it is primarily an animal parasite and pathogen (Lautrop, 
1960), Adenoviruses have also been implicated as a causative agent of 
whooping cough (Olson, 1975; Linnemann, 1979),
Pertussis, as described by Pittman (1970) and Olson (1975), 
is an acute respiratory tract infection most common in infants and young 
children. It is sometimes accompanied by pulmonary and/or neurological 
complications and may be fatal. In its typical form it is character­
ized by episodes of paroxysmal coughing and a marked lymphocytosis.
After an average incubation period of 7 d (limits 6-20 d) the disease 
enters the catarrhal stage. There is rhinorrhea, some conjunctival 
injection and tearing, occasional sneezing and a mild cough, all of which 
may be accompanied by a low-grade fever. After 1-2 wk of the catarrhal 
stage the characteristic symptom of paroxysmal coughing may appear. 
Initially the episodes of paroxysmal coughing increase in severity with 
increasing numbers of coughing bouts and coughs per bout. These 
episodes may end in an insipatory "whoop" and vomiting may occur. The 
symptoms gradually subside during the convalescent stage of the disease 
but it may be months before the bouts of coughing disappear,
A characteristic feature of the disease is the confinement of 
bacterial multiplication to the ciliated epithelium of the respiratory 
tract without invasion of the underlying tissues (Mallory and Hornor, 1912) 
Furthermore it is only possible to isolate the organism during the
catarrhal and early paroxysmal stages of the disease even although the 
symptoms persist much longer (Pittman, 1970),
Antibiotic therapy is generally of little value in the treatment 
of pertussis although it may modify the course of the disease if given 
early enough. The main benefits seem to be in cutting the risk to 
those in contact with the patient by shortening the infectious period and 
in reducing complications from secondary infections (Pittman, 1970; Olson,
1975)o Erythromycin is the antibiotic of choice (Olson, 1975; Altemeier 
and Ayoub, 1977), Antipertussis serum has been used both prophylactic- 
ally and therapeutically but its effectiveness is doubtful (Pittman,
1970 cfo Olson, 1975), In the absence of completely effective treatment 
for pertussis, preventative measures are of paramount importance, viz. 
vaccination and improvements in socio-economic conditionso
Man is the only known reservoir for B. pertussis. The organ­
isms are spread by symptomatic patients, there being no proven chronic 
carrier state,although subclinical and clinically unrecognized infections 
do occur (Linnemann, 1979), Transmission is primarily by Infectious 
droplets expelled during coughing (Linnemann, 1979) and communicability 
is very high for home exposures, having been measured at 877, in un­
vaccinated children (MRC Report, 1951), Although adults may contract 
pertussis (Linnemann and Nasenbeny, 1977) the incidence and severity of 
pertussis is greatest in infants and young children. In the USA in the 
8 yr period between 1960 and 1967, 727, of reported pertussis deaths were 
in children in their first year of life (Brooks and Buchanan, 1970),
Unlike other infectious childhood diseases there is an apparent lack of 
transfer of maternal protective substances to the newborn baby (JCVI 
Report, 1977), Also notable is the slightly higher incidence, 557, of 
cases, among females (Olson, 1975),
Pertussis has a worldwide distribution but is particularly 
serious in the developing world (World Health Statistics Report, 1977), 
Although there is no seasonal influence on its incidence (Olson, 1975), 
pertussis does follow a cyclic pattern peaking every 3-4 yr (Brooks 
and Buchanan, 1970; figure 1),
3 Intracerebral and respiratory tract infections of mice
Although not a natural pathogen for mice B, pertussis may grow 
in the lungs and brain after inoculation. At first these might appear 
to be very different environments but both provide ciliated cells among 
which the bacteria multiply,
3,1 The intracerebral infection
High intracerebral mouse-virulence is not a property of freshly 
isolated B. pertussis. Standfast (1958 ) obtained values ranging
from 10^-10^ organisms for 14 freshly isolated strains. In contrast, 
a few strains have been selected which are extremely virulent intra- 
cerebrally (Pittman, 1970) and with which very small infecting doses, 
perhaps even a single cell, are sufficient to initiate a fatal infection 
(Standfast and Dolby, 1961), The ability of vaccines to protect mice 
injected intracerebrally with such organisms (eg, strain 18323) is widely 
used to assay the protective potency of pertussis vaccines for human 
immunization.
On injecting mice intracerebrally the deposited dose is only 
about 107, of that injected (Dolby and Standfast, 1961), the greater part 
being lost into the circulation (Cairns, 1950) through a temporary break­
down in the blood-brain barrier (Dolby and Standfast, 1961), The 
remaining bacteria multiply among the cells of the ciliated layer on 
the ependymal lining of the ventricle and apparently nowhere else 
(Berenbaum, Ungar and Stevens, 1960; lida et al, 1962), When the
Figure 1 Whooping cough notifications and deaths,
England and Wales, 1940-1976.
Data from the Report of the Joint Committee on 
Vaccination and Immunization (1977),
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infecting bacteria reach 10^ or 10^ cfu the blood-brain barrier breaks 
down, becoming permeable to human serum albumin, horse gamma globulin and 
the dye Pontamine sky blue (Berenbaum, Ungar and Stevens, 1960; Holt 
^t al, 1961; lida e_t a_l, 1966) * The breakdown in the blood-brain 
barrier is closely correlated in passively and actively protected mice 
with a dramatic fall in the numbers of viable Bo pertussis (Dolby and 
Standfast, 1961)o
The pattern of growth for the highly intracerebrally virulent 
strain 18323 has been characterized by Dolby and Standfast (1961)o The 
rate of growth, which is independent of the size of the infecting dose, 
steadily decreases as the infection progresses, but nevertheless a
critical level is attained and the mouse dies* The lethal level falls
8 7
steadily from 10 cells for early (day 5) deaths to 10 for late (day 14)
deathso Doses much above the critical level are toxic and deaths occur
within hourso
3o2 The respiratory tract infection
Respiratory tract infections can be initiated in mice by 
instilling B, pertussis intranasally as described by Burnet and Timmins 
(1937), intratracheally (Bradford, 1938; Te Punga and Preston, 1958) or, 
as reported recently, by aerosol inhalation (Sato et al, 1980)o Intra­
nasal instillation has been the most widely used of these techniques but 
the other methods are considered to give more uniform and reproducible 
results (Te Punga and Preston, 1958; Sato et al, 1980),
The number of organisms needed to initiate a pulmonary infection 
varies with the strain but 100 or fewer viable organisms may be all that 
is required (North and Anderson, 1941; Andersen and Bentzon, 1958;
Dolby, ThOw and Standfast, 1961). Pulmonary infections do not spread 
between mice within a cage (Dolby, Thow and Standfast, 1961), The growth
rate in the first few days of the infection is dependent upon the size
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of the inoculum. In a study in which doses of 10 -10 viable cells 
per mouse were given^ it was noted that the larger the inoculum the 
slower the growth rate,until at doses of ca, 10^ cells there was no net 
growth. With larger doses there was a decline in the numbers of viable 
cells (Dolby, Thow and Standfast, 1961), . These findings are in general 
agreement with observations made earlier by Fisher (1955), With sub- 
lethal doses the bacteria typically achieve a maximum count between 
7-14 d, depending on the strain (Proom, 1947; Cooper, 1952; Andersen and 
Bentzon, 1958; Fisher, 195 5; Dolby, Thow and Standfast, 1961; Sato 
et al, 1980). Thereafter their numbers gradually decline. Their 
complete clearance from the lungs takes about 1-2 mth from the time of 
inoculation (Proom, 1947; Pittman, 1951; Andersen, 19 53a; Geller and
Pittman, 1973; Pittman, Furman and Wardlaw, 1980) although they have
been detected in small numbers as late as 3 mth (Dolby, Thow and Stand­
fast, 1961). The latter workers cultured B, pertussis from homogenized 
lung preparations and not from the cut surface of one area of the lung, 
thereby presumably increasing their chances of recovering the organism. 
When the infecting dose is large (eg, »  10^ cfu for strain C2621; Dolby, 
Thow and Standfast, 1961) the organisms multiply only until they reach a
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critical level of ca. 10 cells, which is more or less independent of the 
initial dose. When this occurs the mouse dies. In mice dying early in 
the course of the infection (eg, day 4) the lethal level tends to be 
slightly lower (eg, not more than 1 log unit) than for mice which die
later (eg, day 10; Dolby, Thow and Standfast, 1961), The margin between
recovery and death is a narrow one with often «=1 log unit between the 
highest sub-lethal dose and the MLD (Dolby, Thow and Standfast, 1961),
In lethal infections mice seldom die before day 5 unless the dose is so
large that it in itself is sufficiently toxic to kill or contribute to 
the killing of the mouse within 1-2 d of the challenge (Standfast and 
Dolby, 1961).
Various pathophysiological reactions have been observed in mice 
with B. pertussis respiratory tract infections. Sato e_t ^  (1980) 
reported on the changes following the infection of mice by aerosol 
inhalation of B. pertussis at a dose producing 10-20% mortality within 
14 do In infected as compared to non-infected mice, the rate of body 
weight gain was significantly reduced, and there were significant 
increases in lung and spleen weights and leukocyte numbers which corres­
ponded to increases in the number of bacteria in the lungs. Spleen 
weights were greatest slightly before the peak of the infection at day 
14 but thereafter decreased in size, although by the 21st day they were 
still heavier than those of control mice. Anderson and North (1943) 
had observed atrophy of the spleen in mice sacrificed 26 d after a 
comparable challenge in which 61% of the mice died. Pittman, Furman 
and Wardlaw (1980) classified their observations into those pertaining 
to lethal and sub-lethal infections. Lethally infected mice showed 
a loss of body weight, spleen atrophy, a pronounced hypothermia and 
hypoglycaemia, and highly elevated levels of leukocytes and serum 
immunoreactive insulin. Sub-lethally infected mice showed normal 
weight gain, practically normal temperature, spleen enlargement, lesser 
pronounced hypoglycaemia, lower but significantly elevated levels of 
leukocytes and serum immunoreactive insulin, and histamine-sensitization. 
The intensity of each reaction was related to the degree of lung 
involvement. Hypothermia and leukocytosis were highly correlated and 
the concentration of serum immunoreactive insulin was closely related 
to the level of leukocytosis but not to the level of glucose.
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The Bo pertussis infection in man is in many ways similar to 
the pulmonary infection in the mouse. Both are typified by a localized, 
non-invasive colonization of the ciliated epithelium of the respiratory 
tract (Mallory and Hornor, 1912 cf. Sato e^ aT, 1980), a marked leuko­
cytosis (Bradford, 1938; Cooper, 1952; Pittman, Furman and Wardlaw,
1980; Sato et al, 1980), hypoglycaemia (Regan and Tolstoouhov, 1936 cited 
by Pittman, Furman and Wardlaw, 1980 cf. Pittman, Furman and Wardlaw,
1980) and in that the young are the most susceptible (Pittman, Furman 
and Wardlaw, 1980; Sato et al, 1980). Moreover the onset and duration 
of the paroxysmal cough in the human infection,although it has no direct 
equivalent in the mouse, parallels the development of histamine-sensitiz­
ation in the infected mouse (Pittman, 1951; Geller and Pittman, 1973; 
Pittman, Furman and Wardlaw, 1980), Both persist after the bacteria can 
no longer be cultured from the lungs. The factor responsible for 
histamine-sensitization has been implicated as being responsible for the 
harmful effects of pertussis (Pittman, 1979). Finally the pathophysio­
logical changes observed in fatal human infections (Malloryand Hornor,
1912) are not unlike those seen in lethal respiratory infections of mice 
(Burnet and Timmins, 1937). The Bo pertussis respiratory tract infection 
of the mouse is considered an appropriate animal model for studying the 
host-parasite interaction and in evaluating prospective protective 
antigens and antibodies (Pittman, Furman and Wardlaw, 1980; Sato et al, 
1980). However, B. pertussis respiratory tract infections in rabbits 
(Preston, Timewe11 and Carter, 1980) and marmosets (Stanbridge and 
Preston, 1974) can also be used.
4 B_o__gejrtna^^ vaccines and vaccination
The use of B. pertussis vaccine, usually combined with diphtheria 
and tetanus toxoids as a triple vaccine, has been practised on a national
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scale in the UK from 1957(JCVI Report, 1977), Vaccination against 
pertussis was introduced in response to an extensive series of carefully 
controlled field trials from 1946 onwards in which different sorts of 
Bo pertussis vaccines were assessed* It was shown that vaccines could 
be made which gave a high degree of protection (90%) even in the face of 
intense infection as encountered during home exposure (MRC Report, 1951, 
1956 and 1959)* The intracerebral mouse protection test was also intro­
duced as a way of measuring the protective potency of B* pertussis 
vaccines* There was a high degree of correlation between the potency 
of vaccines as measured in the field and by their performance in this 
test (MRC Report , 1956 and 1959)*
After the introduction of widespread vaccination the incidence 
of pertussis declined (figure 1)* However the wave of pertussis during 
1963 and 1964 raised sufficient doubts concerning the efficacy of the 
vaccines in use for this to be re-assessed.(PHLS Report, 1969)* The 
protective potency of the vaccines examined in this survey has been 
estimated as less than 20% (JCVX Report, 1977)* Preston (1963 and 
1965) had shown that the dominant serotype of fresh isolates of jBo 
pertussis had changed by 1963 from the type 1,2 and less frequent type 
1,2,3 strains prevalent prior to 1958 to type 1,3 strains* These 
findings were confirmed by the PHLS (1973) and it was concluded that the 
change in the serotypic composition of the prevalent bacteria might 
have accounted for the reduction in the efficacy of vaccines in use from 
1963-19680 Indeed when vaccines including the type 3 antigen were 
compared to earlier vaccines deficient in this component they were found 
to give a better degree of protection (Preston and Stanbridge, 1972),
It was also shown that the British reference vaccine contained 2*1 
international units per single human dose and therefore many vaccines
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in use would have failed the international potency requirement for at 
least 4 lU per dose (Perkins, 1969)o Although not all vaccines 
distributed in this period exhibited these qualitative and quantitative 
defects (Griffith, 1978), from 1966 all vaccines marketed in Britain have 
contained antigen 3 and had a minimum potency of 4 lU (Perkins, 1969)* 
Alum adjuvant was also added once more to some vaccines.
By the mid 1970's there was renewed and widely publicized 
concern in the UK over vaccination against pertussis. In addition to 
the mild reactions which are associated with many vaccines, vaccination 
against pertussis may occasionally cause serious neurological compli­
cations, Stewart (1977) considered the risks of serious complications 
too high to justify continued vaccination, especially as he considered 
changing socio-economic conditions to be more important than vaccination 
in reducing the level of pertussis (Bassili and Stewart, 1976; Stewart,
1977), When the evidence available was reviewed by the JCVI (1977) a 
recommendation was made for the continued use of B, pertussis vaccines on 
the grounds that the benefits to be accrued outweighed the risks.
Although difficult to assess, the frequency of "brain damage" was 
estimated from data collected by the Committee on the Safety of Medicines 
at 1 case per 300,000 children inoculated (JCVI Report, 1977), However 
the National Childhood Encephalopathy Study was instigated to collect 
more data on this point. In the meantime it was recommended that 
vaccination of infants should begin at 3 and not 6 mth of age and that it 
was not to be used if there were medical contraindications or parental 
objections (JCVI Report, 1977), As a consequence of the allegations 
that the vaccine was unsafe there was a reduction in vaccine acceptance 
rates from 70-807, before 1974 to less than 407, by 1976 although it 
varied in different areas from 11-607, (Stuart-Harris, 1979), The very
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large epidemic of 1978 (figure 2), the highest in England and Wales 
since before 1960, upholds the view that the vaccine in use was fully 
protective (Stuart-Harris, 1979), However this has been disputed 
(Stewart, 1979),
Benefit-risk analyses of B, pertussis vaccination in the USA 
have also led to the conclusion that the benefits outweigh the risks 
(Koplan et al, 1979; Mortimer and Jones, 1979), Nevertheless the 
situation is far from being satisfactory and the need for a less reacto- 
genic vaccine is recognized. Towards this end it is important that 
there is a better understanding of the immunity and pathogenesis of 
pertussis. For such investigations respiratory tract infections of mice 
(Pittman, Furman and Wardlaw, 1980; Sato aT? 1980), rabbits (Preston, 
Timewe11 and Carter, 1980) and marmosets (Stanbridge and Preston, 1974) 
have been advocated as alternatives to the intracerebral infection in 
mice. Although the potency of vaccines are measured by their ability 
to protect mice against an intracerebral infection the test may be^  
inappropriate (Preston and Stanbridge, 1976), It is certainly a 
troublesome assay to perform and subject to much variation and therefore 
an alternative test would be desirable for these reasons alone (Cameron,
1976), It has been proposed that vaccines be evaluated by their 
agglutinogen content (Preston, 1975a and b). Another quality control 
problem is the testing of vaccines for their toxicity. How suitable 
is the mouse weight-gain test (Pittman and Cox, 1965) which has never 
been correlated with reactogenicity of vaccines in children (Perkins, 
1979)? At present attempts are being made to develop less reactogenic 
sub-unit vaccines, eg, Nagel and S, de Graaf, 1979; Helting and 
Blackkolb, 1979; Irons and MacLennan, 1979a and b; Nakase and Doi,
1979, New potency and toxicity tests may be required for monitoring 
a sub-unit vaccine.
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Figure 2 Pertussis quarterly notification rates,
England and Wales, 1960-1978,
Data from Dr, P. Lambert, Office of Population Censuses 
and Surveys, London.
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5 Pathophysiological activities and antigens
In experimental animals Bo pertussis has been demonstrated to 
give rise to a variety of pathophysiological responses* The factors 
to which many of these effects can be attributed are described briefly 
in this section as are a few non-pathophysiologically active componentso 
Detailed accounts of most of these substances and their properties are 
given by Pittman (1970 and 1979), Morse (1976 and 1977 ), Olson (1975),
Munoz (1971), and Munoz and Bergman (1977),
5.1 Heat-labile^dermonecrotic toxin (HLT)
HLT is a heat-labile, cytoplasmic protein with lethal and
dermonecrotic properties. Its role in Bo pertussis infections remains
unresolved and is discussed more fully later (Introduction; section II)o
5o2 Endotoxin (lipopolysaccharide, LPS)
Endotoxin possessing a structure different from that elaborated 
by the enterobacteria has been extracted from B. pertussis (Le Dur e_t al,
1978)o The LPS is made up of 2 polysaccharide (PSl and PS2) and 2 
lipid (lipid A and lipid X) moieties* Both PSl and PS2 are linked to 
lipid A but the position of lipid X within the endotoxic complex is 
unknown (Le Dur al, 1978; Chaby £t al, 1979)„ All the usual
biological activities associated with enterobacterial endotoxins are 
produced by B. pertussis LPS. It is toxic, possesses non-specific 
antibacterial and antiviral activity, gives a positive local Shwartzman 
reaction, has adjuvant activity and is pyrogenic but less so than entero­
bacterial endotoxins (Chaby et al, 1979). All these activities are 
carried by the lipid fractions but only lipid X is toxic, pyrogenic 
and elicits the Shwartzman reaction*
5o 3 Agglutinogens
Andersen (1953b) showed that freshly isolated B* pertussis
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exist in serologically different forms according to which heat-labile 
K agglutinogens they express* Eldering, Hornbeck and Baker (1957) 
proposed an antigenic scheme for the genus Bordetella based upon the 
14 recognized types of heat-labile agglutinogens* Types 1-7 and 13 
are found on B* pertussis with types 1-6 being species specific but 
only agglutinogen 1 occurs on all strains. There are grounds for
believing that the agglutinogens are important in protecting children 
against pertussis (Preston, 1975a and b) but how important they are in 
relation to other factors is not clear*
5*4 Haemagglutinin (HA)
B* pertussis produces 2 distinct HA's (Arai and Sato, 1976). 
There is a fimbrial HA (F-HA) which is identical with the filamentous 
fimbriae of B* pertussis (Sato ejb 1979) and the expression of which
is greatly favoured by growth in static, poorly aerated cultures (Arai 
and Munoz, 1979b)* Fimbrial fragments are asymmetrical* Only one 
end attaches to the red cell surface and haemagglutination results 
from the interaction of the free ends of fimbriae attached to adjacent 
surfaces (Sato, personal communication cited by Jones, 1977). Components 
with molecular weights of 130,000 (Arai and Sato, 1976), 127,000 and 
95,000 daltons (Irons and MacLennan, 1979b) have been identified with 
the F-HA* There is evidence that the F-HA acts as a protective 
antigen in the intracerebral mouse protection test (Sato £t al, 1979;
Irons and MacLennan, 1979b) and against B* pertussis infections of the 
lung in suckling mice (Sato ^  al, 1979) and rabbits (Irons and MacLennan, 
1979b). Sato e_t al (1979) found the adhesion of organisms to tissue 
culture cells was prevented by antipertussis-HA serum* The F-HA has 
recently been purified and crystallized (Arai and Munoz, 1979a)* The 
second HA, which may have lower HA activity (Arai and Sato, 1976), is
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identical with the cell-envelope component which induces lymphocytosis 
(LPF) and is described more fully later in this section (Introduction; 
section 1,5^0» lb should be noted however, that Morse and Morse (1976) 
detected no HA activity in their LPF preparation.
Characteristics by which the 2 haemagglutinins can be differ­
entiated are listed in table 2,
5.5 Islet-activating protein (lAP)
Rats injected with lAP exhibit an enhanced hyperinsulinemia in 
response to insulin secretagogues such as glucose (Yajima e_t al, 1978a 
and b)o lAP interacts directly with the cell membrane of the islet 
B-cells of the pancreas and produces a sustained and progressive activat­
ion of calcium ionophores located in the membrane, making more calcium 
available in an intracellular pool* This triggers insulin secretion and 
also activates adenylate cyclase and phosphodiesterase (Ui, Katada and 
Yajima, 1979; Katada and Ui, 1979).
5.6 Lymphocytesis-promoting factor (LPF)
LPF is the term used to describe the B* pertussis cell-envelope 
component which induces lymphocytosis in mice and presumably in humans* 
The lymphocytosis is- due to the failure of circulating lymphocytes to 
leave the circulation and return to lymphoid tissues rather than being 
attributable to a sudden increase in lymphocyte proliferation, although 
LPF is a potent T-cell mitogen ija vitro (Morse, 1976 and 1977 ; Morse, 
Kong and Ho, 1979)* It is not clear whether emigration of lymphocytes 
from the blood is inhibited by an effect of LPF on the lymphocytes or 
on the vessels, or whether the effect is direct or mediated by a host 
effector substance*
5*7 Histamine-sensitizing factor (HSF)
HSF is the term used to describe the B* pertussis cell-
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Table 2 Differential characteristics of B. pertussis haemagglutinins
Differential
characteristic
Haemagglutinin
F-HA
(HA)
LPF-HA
Description of agglutinated red cells 
haemagglutination dispersed by gentle
flicking
red cells firmly 
bound into coherent 
sheets and do not 
disperse on flicking
Promotion of lymphocytosis _(i) +(1-5)
Sensitization to histamine .(1) +(1-5)
Inhibited by cholesterol .(5)
Inhibited by haptoglobin .(4) +(4,5)
Susceptibility to papain sensitive^^^ resistant^
Molecular form filaments 
2 X 40 nm^^^
spherical
, j. . (1,4, 
6 nm,diameter '
2- 2*5 X 60-100 nm^^^ 
2 X 30-50 nm^^)
(3)2*8 nm diameter
1 Arai and Sato, 1976
2 Sato ejt al, 1979
3 Morse and Morse, 1976
4 Irons and MacLennan, 1979a
5 Irons and MacLennan, 1979b
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envelope component which sensitizes mice to the lethal effects of 
histamine* The mechanism by which this effect is produced is poorly 
understood but epinephrine is involved (Munoz and Bergman, 1979a)*
5*8 Interrelationship of the pathophysiological activities
Considerable evidence has now accumulated to support the 
hypothesis that lAP, LPF and HSF are one and the same component (Morse, 
1976; Muhoz and Bergman, 1977 and 1979b; Pittman, 1979). In addition 
to the activities after which these factors were named this component 
must be considered to have HA activity (Introduction; section 1,5*4), 
T-cell mitogenicity (Morse, Kong and Ho, 1979), the capacity to acceler­
ate hyperacute experimental allergic encephalomyelitis (EAE) and IgE 
adjuvanticity (Morse, 1976; Muhoz and Bergman, 1977 and 1979b)* This 
component termed PERTUSSIGEN by Muhoz (1976) and PERTUSSIS TOXIN by 
Pittman (1979) is claimed to have protective activity in the intra­
cerebral mouse protection test (Muhoz and Bergman, 1977 and 1979b)* On
the other hand the highly purified preparations of Morse and Morse 
(1976), Irons and MacLennan (1979b) and Sato e_t ^  (1979) have all lacked 
protective activity as demonstrated by this test (Pittman, 1979 cited 
Kong, personal communication, as the source of the information on the 
Morse LPF)*
The physiochemical and biological properties of highly 
purified preparations of pertussis toxin are listed in table 3* The 
relationship between these preparations is clearly illustrated although 
discrepancies do exist, LPF, HSF and lAP activities appear to be 
located on the F3 subunit described by Ui, Katada and Yajima (1979), 
although this has to be associated with either an FI or F2 sub-unit 
for expression*
Pertussis toxin, as defined by Pittman (1979), is distinct
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from HLT, endotoxin, the agglutinogens and the fimbrial haemagglutinin*
5*9 Involvement of B* pertussis components in pathogenesis/protection
The factors involved in the pathogenesis and the development of 
immunity to pertussis have not been clearly defined; Protection could 
be afforded if the infection could be prevented or controlled by 
curtailing the attachment and/or multiplication of the organisms. The
fimbrial haemagglutinin and agglutinogens must be prime candidates for 
being involved in these processes. An additional or alternative form 
of protection might be gained by the development of immunity to pertussis 
toxin* If this component is as suggested responsible for the character­
istic symptoms of pertussis, the paroxysmal cough and lymphocytosis, then by 
blocking its effect the clinical syndrome of pertussis could be prevented 
(Pittman, 1979). Less well characterized is the involvement of HLT, 
endotoxin, an extracytoplasmic adenylate cyclase (Hewlett e^ al, 1976; 
Hewlett and Wolff, 1976), polymorphonuclear leukocyte inhibitory factor 
(Utsumi ejt al, 1978; Imagawa ^  al, 1979) and the 28K and 30K poly­
peptides, the presence or absence of which is closely correlated to the 
PA, HSF, LPF, EAE adjuvant and IgE adjuvant activities (Wardlaw and 
Parton, 1979). The 28K and 30K polypeptides are distinct from the 
LPF-HA and F-HA (Irons and MacLennan, 1979b).
6 Antigenic variation
Two distinct types of variation are recognised in B* pertussis 
but both give rise to antigenic variants which are similar in that they 
are deficient in a variety of components normally associated with 
freshly isolated organisms:
i) Phenotypic variation in which the loss of cellular constituents 
is freely reversible and does not involve mutational changes* These
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variants arise in response to certain modifications which can be made 
to the growth environment*
ii) Phase variation in which the Losses are a consequence of mutation 
and selection during repeated subculture of B* pertussis*
6*1 Phenotypic variation
Two types of phenotypic variation have been described in 
Be pertussis;
i) Antigenic modulation (Lacey, 1951 and 1960)
ii) Nicotinic acid induced modulation (Pusztai and Joo, 1967).
6.1.1 Antigenic modulation
Lacey (1951 and 1960) found with every 1 of over 2,000 strains
of B* pertussis that they underwent marked phenotypic changes when grown
on a series of solid media in which the inorganic salts were varied*
When NaCl was the principal salt the cultures had the characteristics of 
freshly isolated B* pertussis on Bordet-Gengou medium* However, when 
NaCl was replaced by MgSO^ the colonies were no longer haemolytic, the 
ability to agglutinate red blood cells was lost, there were changes in 
agglutinogens, agglutinability by AuCl^ and HgCl^ was reduced, autolysis 
occurred more readily, mouse-virulence decreased and the colour of 
confluent growth changed from yellowish-ochre to pale greenish-blue* 
Lacey introduced the term "antigenic modulation" to describe the 
phenomenon and he designated the NaCl grown cells as X-mode (X = xanthic 
or ochre) and the MgSO^ grown cells as C-mode (C = cyanic or bluish)*
In addition to changes in the ionic composition of the medium, C-mode 
growth can be induced by growth at low temperatures (eg, 25°C) or in the 
presence of tellurite, fatty acids or old blood* Lacey (1960) also 
described an intermediate form of cell (l-mode) which was induced within 
a narrow range of intermediate temperatures and ion ratios*
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Lacey (1960) concluded from his extensive study with over 100 
different salts that the influence of ions is a function of their 
species and ratios and not their absolute concentrations or total ionic 
strength* Furthermore the influence of ions and temperature were shown 
to be independent since their combined influence was proportional to the 
sum of their separate influences* The action of the salts was, 
according to Lacey (1960), dependent upon growth with 7-15 cell divisions 
being required for completion of the process* Suspension in a salt 
solution was not sufficient (Lacey 1951 and 1960). Recent studies by 
Idigbe (1979) indicated that modulation was much more rapid than 
suggested by Lacey, being complete within 1-2 cell divisions*
A variety of factors in addition to these identified by Lacey 
(1951 and 1960) are now known to be lost during antigenic modulation*
These are the PA, HSF (Holt and Spasojevic, 196 8; Parton and Wardlaw, 
1975; Wardlaw, Parton and Hooker, 1976), LPF (Idigbe, 1979), the 
adjuvant(s) for reaginic antibody and for hyperacute EAE (Wardlaw eL al, 
1979), adenylate cyclase (Parton and Durham, 1978) and cytochrome d-629 
(Dobrogosz et al, 1979)*
Analysis of the protein profiles of X- and C-mode cell- 
envelopes has revealed the loss of at least 2 polypeptides from the C-mode 
cells (Parton and Wardlaw, 1975; Wardlaw, Parton and Hooker, 1976). The 
loss of these 28K and 30K polypeptides has been confirmed by Idigbe (1979) 
and Dobrogosz ^  £l (1979). However Idigbe (1979) and Dobrogosz et al 
(1979) recognized the loss of 3 (28K, 30K, lOOK) and 4 (27*5K, 30K, 88K, 
98K) bands from whole cells and outer membranes respectively* The 28K 
and 30K polypeptides are also apparent in B* parapertussis and B. bronchi- 
septica and their levels are reduced by growth in C-mode conditions 
(Dobrogosz et al, 1979)*
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It should be noted that all the components lost are either 
constituents of the cell-envelope or closely associated with it in the 
case of the extracytoplasmic adenylate cyclase* One exception may be 
the loss of a diffusible haemolysin as Lacey (1960) noted that C-mode 
colonies of B* pertussis were not haemolytic* In the face of all these 
losses altered antibiotic sensitivities have been recorded* Dobrogosz 
et al (1979) found C-mode growth to have enhanced sensitivity to peni­
cillin and ampicillin but increased resistance to streptomycin, erythro­
mycin and tetracycline*
6*1*2 Nicotinic acid induced modulation
Pusztai and Joo (1967) observed a phenomenon similar to, but 
in their view not identical with, antigenic modulation* Growth of 
B* pertussis in a medium with a high nicotinic acid content (eg, 500 
pg/ml cf* 1 pg/ml in the normal medium) resulted in reduced levels of 
PA and HSF* Also lost, in 5 of the 7 strains examined, was the capacity 
to be agglutinated by a phase 1 specific immune serum* Immunoelectro- 
phoretic analysis of extracts from disrupted variant cells revealed the 
loss of 4 precipitin bands. Unaltered by growth in a medium with 
increased levels of nicotinic acid was the germ-count, pH, oxidation- 
reduction potential, bacterial morphology and HLT content* Subsequent 
studies have indicated that the amount and antigenic specificity of LPS 
from variant cells is also unchanged (Ackers and Dolby, 1972)*
During nicotinic acid induced modulation the 28K and 30K cell- 
envelope polypeptides (Wardlaw, Parton and Hooker, 1976) and adenylate 
cyclase are lost (McPheat, 1980)* The variant cells are therefore like 
C-mode cells in this respect in addition to lacking the PA and HSF, the 
loss of which have been confirmed by Ackers and Dolby (1972) and Wardlaw, 
Parton and Hooker (1976)* However this phenomenon is claimed to differ
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from antigenic modulation in that the agglutinogen specificity does not 
alter, the agglutinogen content merely decreases (Pusztai and Joo, 1967)* 
On the other hand McPheat (1980) has shown agglutinogen factors 2 and 3 
are lost under these conditions whilst the content of factor 1 increases* 
Nicotinic acid induced modulation is not reproduced when nico­
tinamide is used to substitute for the nicotinic acid (Wardlaw, Parton 
and Hooker, 1976)* Nicotinic acid modulated cells have recently been 
shown to have a reduced uptake capacity for both nicotinic acid and nico­
tinamide* Uptake is not appreciably altered by growth in a medium rich 
in nicotinamide (McPheat, 1980)*
6*2 Phase variation
Leslie and Gardner (1931) grouped B. pertussis on the basis of 
serological and cultural characteristics into 4 groups which they desig­
nated phases I, II, III and IV* By continued subculture the virulent 
phase I form could be transformed through the intermediate phase II/III 
forms to the degraded, avirulent phase XV form which had acquired the 
capacity to grow on nutrient agar* However Standfast (1951b) found that 
freshly isolated (phase I) B* pertussis were not the homogeneous group 
suggested by Leslie and Gardner (1931). Not all freshly isolated strains 
possessed the full complement of characteristics which are usually assoc­
iated with them* Moreover when he examined the effect of repeated sub­
culture on a number of properties (such as growth requirements, agglutin­
ation, virulence, PA and HA) the order in which they degenerated or were 
lost and the rate at which they were lost differed from strain to strain* 
Field and Parker (1979) recorded a similar random loss of properties 
leading to degraded forms of B* pertussis* It is not possible therefore 
to categorize B. pertussis into 4 distinct phases but the terms phase I 
and IV can be used to represent the two extreme forms*
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In addition to deficiencies in agglutinogens a variety of other 
components are missing from phase IV variants* Table 4 lists factors 
typically present in phase I organisms but absent from the degraded phase 
IV organisms. Other changes that occur as a result of phase variation 
include increased resistance to certain antibiotics and fatty acids 
(Dobrogosz e^ 1979; Field and Parker, 1979)*
Parker (1976 and 1979) has proposed a hypothesis to rationalize 
phase variation in B* pertussis* It is assumed that B. pertussis is in 
some way metabolically abnormal, a feature which vivo is not detri­
mental and may even be helpful* However vitro a. manifestation of this 
peculiarity may be the sensitivity of freshly isolated B* pertussis to 
inhibitory substances in normal growth media* There would be strong 
selective pressures for mutations which reduced this sensitivity*
Mutations to relieve the metabolic lesion(s) could occur in any of a small 
number of genes, in any order and be cumulative* Therefore a large 
number of phenotypic forms of intermediate type strains could be formed 
leading to the fully degraded form* The effect of multiple mutations 
would be to make the process irreversible*
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Table 4 Comparison of properties of phase I and phase XV 
Bo pertussis
Property Phase I Phase IV Reference
Protective antigen (PA) + - 1,2,4
Histamine-sensitizing 
factor (HSF) + - 2,3,4
Lympho cyto sis-promoting 
factor (LPF) + - 4
27.5K or 28K, 30K, 88K 
and 98K envelope 
polypeptides + 5,6
Cytochrome d-629 + - 6
Adenylate cyclase activity + - 7,8,9
Heat-labile toxin (HLT) + (Introduction; 
section II, 1)
1 Kasuga £t al, 1954
2 Aprile, 1972
3 Kind, 1953
4 Field and Parker, 1979
5 Parton and Wardlaw, 1975
6 Dobrogosz ^  al, 1979
7 Parton and Durham, 1978
8 Hewlett al, 1979
9 Endoh, Takezawa and Nakase, 
1980*
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SECTION II THE HEAT-LABILE TOXIN OF BORDETELLA PERTUSSIS
1 Discovery
As early as 1909 Bordet and Gengou reported in a paper 
entitled "L'endotoxine coquelucheuse" that B* pertussis produced a heat- 
labile toxic substance. They described several of the salient features 
of the toxin which have been amply confirmed by later workers viz, it is 
mainly cell-associated; is released in soluble form in saline extracts 
from ground bacteria; is lethal to guinea pigs and rabbits; is dermone­
crotic in small doses and is inactivated by heating at 55°C or by treat­
ment with certain organic solvents* Implicit in this work was the idea 
that HLT was an important contributor to the pathogenesis of pertussis*
2 HLT - pathohistological changes produced and significance in the 
pathogenesis of pertussis
The parenteral administration of HLT gives rise to widespread 
pathological symptoms and death may result as has been noted in mice, 
guinea pigs and rabbits* Wood (1940) gave one of the most detailed 
accounts of the pathological effects of the toxin* In mice dying after 
being injected intraperitoneally with a toxic filtrate there was marked 
congestion of subcutaneous blood vessels and there were small haemorrhages, 
particularly in the abdominal musculature* The inguinal lymph glands 
were dark and haemorrhagic, the reproductive organs markedly congested 
and in the liver there were occasional small areas of necrosis* Where 
mice were challenged with a sub-lethal dose of HLT these acute reactions 
were not observed any later than the 3rd week. However in such mice and 
for a period of at least 3 mth the spleen was very small, bloodless and 
frequently no more than one-quarter the weight of a normal spleen*
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The liver was also very much smaller than normal and was irregular and 
scarred in appearance* The abdomen was often distended with ascitic 
fluid and the testicles were generally small and atrophic* Microscopic­
ally there was thickening of the peritoneum, atrophy of the spleen with 
almost no pulp cells to be seen and the spaces between the few remaining 
Malpighian bodies were filled with connective tissue. There was also 
evidence in the spleen of previous haemorrhaging. The testicles were 
atrophied with degeneration of the cells lining the tubules and diminished 
spermatogenesis* No specific lesion was demonstrable in the liver other 
than slight cellular atrophy* Heart, lungs and kidneys appeared normal* 
Except for the absence of the haemorrhages in the abdominal 
musculature and peritonitis the same changes, but with a much more rapid 
onset, were produced by intravenously injected toxic filtrates* Even 
mice dying within 48 h exhibited small pale spleens and considerably 
shrunken livers. Atrophied spleens were also evident, to a lesser extent, 
when HLT was injected subcutaneously but no hepatic damage was apparent.
It should be stressed that the systemic effects attributed to HLT must be 
regarded with caution until verified with pure preparations of toxin. 
However it is likely that the atrophy of the spleen which has been 
observed by various workers (Wood, 1940; Katsampes, Brooks and Bradford, 
194%; Anderson and North, 1943; Munoz and Bergman, 1977) including some 
who used highly purified HLT (Nakase et al, 1969; lida and Okonogi, 1971) 
is produced by HLT and not by other factors* . lida and Okonogi (1971) who 
followed the development of the pathological changes induced in the spleen 
suggested HLT is selectively toxic for splenic tissue ie, lienotoxic 
(Introduction; section II, 3,3)* However the highly purified toxin of 
Nakase e_t ^  (1969) gave rise to significant necrosis, haemorrhage, 
congestion and degeneration in spleen, liver and kidney. Renal damage
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was also attributed to HLT by Bordet and Gengou (1909). There may also 
be damage to the adrenal glands (Bordet and Gengou, 1909; Evans and 
Maitland, 1937), lungs (Asada, 1953c; Hatsuda, 1960) and nerve tissue 
(Hatsuda, I960).
A dermonecrotic/haemorrhagic reaction is elicited when HLT is 
given sub- or intra-cutaneously. to sheep, pigs, chickens (Violle, 1950 
cited by Munoz, 1971), guinea pigs, rabbits (eg, Bordet and Gengou, 1909; 
Evans and Maitland, 1937) and suckling mice (eg, Katsampes, Brooks and 
Bradford, 1942). Violle (1950, cited by Muhoz, 1971) found mice to be 
resistant to the dermonecrotic action of HLT. The development of the 
skin reaction in the rabbit has been fully described by Evans and Maitland 
(1937): "There is in 18-24 h a pale flat indurated area that may be 
20-25 mm across. In the centre of this is an irregular mottled area of 
necrosis made up of isolated or irregularly coalescing patches, reddish- 
to blackish-purple, dry and slightly depressed. These cover an area 
from a few mm to 15 mm or more in diameter and often there is a yellowish- 
white base. Pus however does not form. Within the next 48-72 h the 
smaller patches of necrosis coalesce, the area spreading slightly and 
becoming darker and drier. The induration usually disappears after a 
few days and the necrotic plaques finally separate leaving a shallow 
ulcer." Similar macroscopic observations have been made by Silverthorne 
and Cameron (1942), Kurokawa, Ishida and As akawa (1969) and, for the 
response in the guinea pig, Bordet and Gengou (1909). However in guinea 
pigs and suckling mice the haemorrhagic component is a much more prominent 
feature of the reaction. Furthermore the pale spot is much more 
transient in the guinea pig and absent from the suckling mouse (Kurokawa, 
Ishida and Asakawa, 1969), The microscopical features of the reaction 
as described for the rabbit reveal that the pale spot is associated with
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fluid accumulation in the subcutaneous tissue and a poor blood supply in 
the tissue overlying the fluid. The petechial haemorrhages are the 
consequence of haemorrhages in capillaries in the connective tissue. 
Necrosis was noted in the epidermis only when these haemorrhages were 
severe (Kurokawa, Ishida and As akawa, 1969).
HLT has also been demonstrated to be harmful to tissue cultures 
(Angela, Rosso and Giuliani, 1962a and b; Strizova and Trlifajova, 1964). 
However in contrast to the findings of Angela, Rosso and Giuliani 
(1962a and b), Strizova and Trlifajova (1964) did not find HeLa cells to 
be sensitive to HLT. Instead, of the 14 types of tissue culture 
examined the most sensitive to the cytotoxic effect of HLT were the KB 
cell line and primary cultures of mouse embryonic tissue.
The aforementioned toxic effects of HLT are of limited relevance 
to any involvement the toxin may have in B. pertussis infections in 
children. Nevertheless it has been suggested that the dermonecrotic HLT 
is responsible for the necrosis which has been observed in the respiratory 
tract epithelial tissue in cases of pertussis (Bordet and Gengou, 1909). 
Similarly Munoz (1971) speculated that the toxic action of HLT on the 
spleen and lymph nodes may interfere with the development of immunity. 
There is in fact n o ‘conclusive evidence for HLT being a significant 
component in the pathogenesis of pertussis, merely implications^ For 
instance the parallels which have been drawn between the pathohistological 
changes observed in the lungs of children that have died from pertussis 
and in animals given crude HLT preparations (Sprunt and Martin, 1943; 
Asada, 1953a, b and c). In B. pertussis infections of the mouse lung,
HLT has been considered to act as an aggressin (Kobayashi, 1961). .
However Anderson and North (1943) found intranasal instillation of sub-
3 7
lethal (5 x 10 ) and lethal (5 x 10 ) doses of B. pertussis in 2.5
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mouse MLD of HLT increased neither the killing power nor the intensity of 
infection as assessed from data on groups of 5 mice* In contrast,
Standfast (1958) noted that the toxin (10 mouse MLD) may enhance the 
virulence of B. pertussis strains in mouse lung infections, but only under 
certain conditions. The HLT when mixed with strains of medium virulence, 
as estimated by LD^g values, markedly increased the death rate in the 
smaller (10^, 10^) but not the larger (10^, 10^) dose groups. He considered 
that since the addition of HLT did not automatically increase virulence it 
was not the only virulence factor. The addition of HLT would not therefore 
aid the organism where the conditions for full virulence already existed 
(ie, high virulence strains and very large doses of medium virulence strains), 
nor where the organisms were defective in some other aspect of virulence 
(ie, low virulence strains). Virulence would only be enhanced if HLT was 
mixed with the challenge and was the only limiting factor. When given up 
to 4 h before or after the intranasal instillation of the organisms it was 
ineffective. Standfast (1958) concluded that HLT played a part in the 
primary lodgement of the organism. Furthermore he provided evidence of a 
mechanism by which this could occur, namely by paralysis of cilia in ciliated 
epithelia. This was demonstrated through the failure of india ink 
particles to migrate"in toxin treated sheep-lung preparations but relatively 
large amounts of toxin had to be used. It was not established whether this 
effect, which was probably irreversible, was mediated by HLT acting on the 
cilia directly or on the ciliated cell. Ciliostasis was not evident with 
heated toxin (lOO^C, 1 h) or toxin mixed with absorbed antitoxic sera free 
from agglutinins. In contrast to the findings of Standfast (1958), evi­
dence gathered from experimental B. pertussis infections on rabbit tracheal 
mucous membrane (Matsuyama, 1977) and hamster tracheal organ cultures 
(Collier, Peterson and Baseman, 1977) show that ciliostasis is not necessary fc 
the establishment of infections on these ciliated epithelia. Matsuyama (1977'
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did not observe any clliostatic effect and the earliest that Collier, Petersor 
and Baseman (1977) observed ciliostasis was 48 h after the initiation of 
the infection. Furthermore the capacity to lodge at the point of 
inoculation could not be conferred upon cells unable to resist mucociliary 
clearance by co-inoculation with cells able to do so (Matsuyama, 1977).
This might have been expected if a ciliostatic toxin was in action. More­
over sterile culture fluids from infected tissues at various stages during 
infection had no effect on the ciliary activity, or amino acid uptake, of 
the respiratory tissue (Collier, Peterson and Baseman, 1977). Matsuyama 
(1977) did not however rule out the possibility that HLT may have some 
role after the infection is established, perhaps in the spread of the 
infection to the lower respiratory tract. Serological evidence on the 
involvement of HLT in B. pertussis infections is unfortunately also rather 
scanty and inconclusive (Introduction; section II, 8).
In addition to the possible involvement of HLT at the site of the 
infection in the upper respiratory tract, it has also been implicated in 
producing damage in the central nervous system. The pathological changes 
which occur when HLT is injected intracerebrally into guinea pigs have 
been compared to the neurological damage evident in children who died of 
encephalitis complicating pertussis (Fonteyne and Dagnelie, 1932 cited 
by Munoz, 1971; Gabrielesco eJt al, 1958 cited by Munoz, 1971). It has 
also been proposed that the toxin by acting directly on the respiratory 
centres can provoke disturbances in the nervous control of respiration 
(Abrosimov, 1961). Pathological changes in the hypothalamic region have 
been recorded after intramuscular and intravenous injection of HLT into 
rabbits (Hatsuda, 1960). Whether these effects on the central nervous 
system can be brought about by toxin released in the respiratory tract 
remains to be seen, but Anderson and North (1943) noted that damage to the
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spleen was less prominent when HLT was given intranasally compared to 
intravenously, even when 80 times as much toxin was given by the former 
route* The implication is that very little toxin finds its way into the 
sy-stemic compartment of the body.
Heat-labile toxin and mouse virulence may be lost together as 
in phase variation (Introduction; section I, 6*2) but it is not surpris­
ing to find that they may vary independently (Standfast; 1951a, b and 
1958)* Pittman (1970) even found the toxin content of organisms varied 
inversely with their intracerebral virulence. Further evidence that would 
suggest HLT has at most a limited role in B, pertussis intracerebral
infections of mice was the finding by Standfast (1958) that when 0*3 mouse
MLD of toxin was given with the challenge organisms there was no enhance­
ment of their virulence*
Finally, although the pathohistological damage produced by HLT 
and the role of HLT in B* pertussis infections is far from being clearly 
defined, knowledge on its mode of action at the molecular level is almost 
non-existent* It has been suggested however that the phenomena observed,
when isolated hearts (rabbit, cat and hen) are perfused with HLT are due
to impaired oxidative phosphorylation (Raskova, Stf'izova and Van^cek,
1961 cited by Raskova and Masek, 1970)*
3 Assay of toxicity 
3*1 Lethality
Mice, guinea pigs and rabbits are all susceptible to the lethal 
effect of HLT but mice are the most widely used to assay lethality*
There are few data permitting direct comparison of inter-species suscept­
ibility but rabbits and guinea pigs are estimated from the results of 
Ospeck and Roberts (1944) and Anderson and North (1943) to be 4 and
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2.5 times respectively more sensitive than mice on an equal body weight 
basis. The injection route also influences susceptibility to HLT.
Guinea pigs and mice survived larger doses of toxin when it was given 
subcutaneously (SC), rather than intravenously (IV) or intraperitoneally 
(IP) (Bordet and Gengou, 1909; Wood, 1940). The IV route has been 
found to be marginally (1.5 times) more sensitive than the IP route for 
administering HLT to mice (Anderson and North, 1943), although Wood (1940) 
found no difference. Similarly, guinea pigs have been observed to die 
sooner when the toxin is given intravenously rather than intraperitoneally 
(Evans and Maitland, 1937), In a 3 way comparison of the intranasal 
(i n ), intraperitoneal (IP) and intracerebral (IC) routes for injecting 
HLT, the ratios for the sensitivities of the respective methods were in 
order of increasing sensitivity 1:10:100 (Standfast and Dolby, 1961;
Dolby and Standfast, 1961). Anderson and North (1943) had previously 
recorded the ineffectiveness of HLT given intranasally, ie, mice dosed 
with 10 MLD, as measured by intraperitoneal injection, showed no obvious 
signs of ill health.
In none of the aforementioned comparisons has the limit on the 
volume of injectable material been taken into consideration. This could 
for instance effectively nullify the apparently superior sensitivity of 
the IC route relative to the IP route.
When assaying HLT by the IP route of injection into mice a 3 d 
post-injection observation period has been recommended (Ishida, 1968),
Most investigators have taken 2 or 3 d as a suitable time.
The IP route has been used to assay the toxicity of live 
B. pertussis cells as well as HLT extracts, Bordet and Gengou (1909) 
established that B. pertussis does not multiply in the peritoneal cavity 
of guinea pigs and attributed the death of such animals to the toxicity
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of the injected dose rather than to active infection. Their observation 
has been confirmed in both guinea pigs (Leslie and Gardner, 1931) and 
mice (Anderson and North, 1943; Gray, 1946 cited by Standfast, 1958;
Proom, 1947; Geller and Pittman, 1973). Further support for the IP 
route as a measure of the organism's toxin content rather than their 
virulence was provided by Anderson and North (1943), Ospeck and Roberts 
(1944) and Proom (1947). Passively administered antitoxin afforded good 
protection to mice against an IP challenge with live B. pertussis whereas 
antibacterial sera had little or no protective activity. In assaying 
the toxicity of B. pertussis cells in this manner the weights of the mice 
employed do not appear to be of much importance (Standfast, 1958). There 
is less evidence on the suitability of the IV route as a method for 
assaying the toxin content of live B. pertussis. Bordet and Gengou (1909) 
reported the failure of IV injected organisms to multiply in rabbits and 
Ospeck and Roberts (1944) showed rabbits with high antitoxin titres were 
protected against a lethal IV challenge.
3.2 Dermonecrotic/haemorrhagic activity
Although the skin reaction which develops in response to sub- or 
intra-cutaneously injected HLT is commonly described as "dermonecrotic" 
the type of response varies from species to species (Kurokawa, Ishida and 
Asakawa, 1969). With rabbits and guinea pigs the feature of the response 
chosen by most investigators for measurement is the necrotic lesion itself. 
However, Kurokawa, Ishida and Asakawa (1969) found the most suitable 
features were a pale ischemic-like spot in rabbits and the haemorrhagic
t
reaction in guinea pigs. With suckling mice it is the purple-black 
haemorrhagic spot which is used (Katsampes, Brooks and Bradford, 1942; 
Andersen, 1952 and 1953b; Kurokawa, Ishida and Asakawa, 1969; Cowell, 
Hewlett and Manclark, 1979; Field et al, 1979).
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Contaminating constituents inan HLT preparation may influence 
the type of reaction produced ; induration as well as necrosis being 
produced by whole bacilli (Evans and Maitland, 1937) but being virtually 
absent from toxic culture filtrates (Wood, 1940), These authors contend­
ed that "bacterial antigen" was responsible for the induration. Kurokawa, 
Ishida and Asakawa (1969) noted that LPS increased the haemorrhagic 
reaction in guinea pigs and suckling mice by 2.8 and 1.6 times respect­
ively (the effect seemed to be independent of the relative concentrations 
of LPS and HLT). Lipopolysaccharide had little, if any, effect on the 
response in rabbits and LPF had no effect on the response in any of the ■
3 species of animal. ■;
Individual rabbits vary in their skin reactivity to HLT (Flosdorf, 
Bondi and Dozois, 1941; Anderson and North, 1943; Roberts and Ospeck,
1942; Yamamoto, Zenyoji and Kato, 1952a) by a factor of 2-or 3-fold 
(Roberts and Ospeck, 1942; Yamamoto, Zenyoji and Kato, 1952a). Differ­
ences between guinea pigs are even less than those between rabbits (Yama­
moto, Zenyoji and Kato, 1952a) with the variation between animals usually 
being within 50% (Onoue, Kitagawa and Yamamura, 1963).
Skin reactions are usually measured within 24-48 h of injection 
of the toxin.
3.3 Lienotoxicity
The term lienotoxicity was coined by lida and Okonogi (1971) to 
describe the atrophy of the spleen in mice injected intravenously with HLT 
preparations. The extent of the atrophy 7 d after the injection was 
taken as a measure of the lienotoxicity of a preparation.
3.4 Body weight loss
HLT can be assayed by following the body weight loss in mice 
over a 2 d period subsequent to intraperitoneal injection with HLT
38
(Ishida, 1968)0 However, weight loss may also be affected by the 
presence of LPS and/or LPF.
3.5 Toxicity to tissue cultures
Strizova and Trlifajova (1964) screened 14 different tissue 
culture lines to establish their possible susceptibility to killing by 
HLT. The KB line and primary cultures from mouse embryonic tissue were 
the most sensitive but the former tended to undergo spontaneous degener­
ation. Therefore primary cultures of mouse embryonic tissue were used 
to assay the cytotoxic effect of the toxin. i
3.6 Relative merits of the assay methods
The various methods for assaying HLT have their advantages and 
disadvantages. For instance, the assays differ in their sensitivity ie, 
how little toxin they can detect. The most sensitive method is reported 
as being the haemorrhagic assay for HLT using suckling mice (Gardner, 
cited by Pittman, 1970). However the difference in sensitivity between 
this assay and that in which the dermonecrotic activity of HLT is 
measured in adult rabbits is only marginal, disregarding differences in 
body weight (Kurokawa, Ishida and Asakawa, 1969), Guinea pigs are less 
sensitive than either rabbits or suckling mice (Evans, 1947; Kurokawa, 
Ishida and Asakawa, 1969) eg, suckling mice have been found to be 40 times 
more sensitive than guinea pigs (Ishida, 1968), The measurement of 
dermonecrosis/haemorrhage in rabbits (Strean, 1940; Strean and Grant,
1940; Roberts and Ospeck, 1942; Evans, 1947; Yamamoto, Zenyoji and Kato, 
1952a), guinea pigs (Kuwajima, Iwamura and Hirai, 1951; Yamamoto, Zenyoji 
and Kato, 1952a; Onoue, Kitagawa and Yamamura, 1963; Ishida, 1968) or 
suckling mice (Ishida, 1968) is more sensitive than the other principal 
method of assaying HLT viz. by recording lethality in mice. In relation
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to the aforementioned assays, the assay based on body weight loss in mice 
is of intermediate sensitivity. It is 17.5 times less sensitive than 
the haemorrhagic assay in suckling mice, but 2-3 times more sensitive than 
either the haemorrhagic assay in guinea pigs or the assay of lethality in 
mice (Ishida, 1968). Finally, the cytotoxic assay of HLT, using mouse 
embryonic tissue culture cells, is about twice as sensitive as the assay 
of lethality in mice (Strizova and Trlifajova, 1964).
When assaying low levels of HLT it has to be remembered that in 
actual practise the most sensitive assay need not necessarily be the most 
appropriate; using a less sensitive assay it may be possible to detect as 
low or lower levels of HLT in solution. This apparent contradiction can 
be illustrated by the following: suppose that for a given toxin preparation
the MRD is 0.1 pg protein in suckling mice whilst the MLD for adult mice 
is 1.0 pg, the first of these assays is the most sensitive. However, if 
the limit on the volume injectable in each assay is 0.05 ml. and 1.0 ml 
respectively, it follows that in the first instance HLT can be detected 
at a level of 2 pg/ml whereas in the latter example 1 pg/ml can be 
detected.
Criteria other than sensitivity may have to be considered when 
choosing the way in which to assay HLT. For instance although the IV 
route may be marginally more sensitive than the IP route for measuring 
HLT by its lethal effect in mice most workers have preferred the more 
convenient IP route (eg, Billaudelle ab, 1960). There again Anderson 
and North (1943) preferred the mouse lethal (IV) assay to the dermonecrotic 
assay in rabbits due to less variation in the responses with the former.
With the dermonecrotic/haemorrhagic assays there is not much difference
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in precision between the 3 species but assays with guinea pigs and 
suckling mice are sometimes not so accurate, according to Kurokawa,
Ishida and Asakawa (1969). Evans and Maitland (1937) found the reaction 
end point easier to read in rabbits than guinea pigs.
4 Antigenic variation and HLT production 
4o1 Antigenic modulation
Lacey (1960) noted that when X- and C-mode cells of B. pertussis
8 9
H5 were injected IP into mice LD^^ values were about 2 x 10 and 2 x 10 
organisms respectively. From this it can be inferred that the X- to 
C-mode transition, induced by substituting MgSO^ for NaCl as the chief 
salt in a growth medium, produces a reduction in the toxicity of 
B, pertussis cells. This has not been confirmed.
4.2 Nicotinic acid induced modulation
Most strains of B. pertussis grown in media with high levels 
of nicotinic acid lose several of the properties normally associated with 
freshly isolated cells (Pusztai and Joo, 1967; Wardlaw, Parton and 
Hooker, 1976). They are reported however as retaining their full 
toxicity (Pusztai and Joo, 1967).
4.3 Phase variation
HLT production seems to be a property of freshly isolated 
B. pertussis that is lost, along with other properties, during the 
process of phase variation. Leslie and Gardner (1931) tested the 
toxicity of 11 phase I, 8 phase III and 4 phase IV strains by intra­
peritoneal injection into guinea pigs. Phase III and IV organisms 
could be tolerated in doses 20-30 times that required with phase I strains 
Similarly strains in phases III and IV when tested for their ability to
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produce necrosis were only one-tenth as toxic as a phase I strain 
(Flosdorf, Bondi and Dozois, 1941). This loss of toxicity has been 
reported for the toxin content of both cell and culture fluid (Lawson,
1933; Wood, 1940; Shibley and Hoelscher, 1934 cited by Wood, 1940;
Ungar and Muggleton, 1949a and b). Japanese workers who have followed 
a different classification of the phase variants have nevertheless 
recorded results consistent with those already reported (Kasuga eh al,
1954; Nakase and Kasuga, 1962).
Roberts and Ospeck (1942) who recognized phase IV strains to 
be less toxic (dermonecrotic) than phase I strains did however, after 
screening many strains for their ability to produce strongly toxic 
culture filtrates, identify the 2 best producers as being in the inter­
mediate phase (either II or III). When the toxicity of the cells of the 
more potent strains were titrated these were as toxic as phase I organisms.
5 Other aspects of HLT production
5.1 Organism
With some toxigenic bacteria there are classical strains which 
yield high levels of toxin eg, the PW8 strain of Corynebacterium diphtherias 
or the Staphylococcus aureus strain Wood 46 for a-toxin production (Pappen- 
heimer, 1965, cited by Zabriskie, 1970; Bernheimer, 1970), So far no 
B. pertussis strain appears to have been identified as an outstanding 
producer of toxin. Kuwajima e_t ^  (1958) described an intermediate 
strain of B. pertussis No. 33 as a classical toxin-producer but there is 
little to substantiate such a claim. Since the strain was selected by 
Roberts and Ospeck (1942) for producing strongly toxic culture filtrates 
it has been used by relatively few authors (Kuwajima 1958; Nakase
and Kasuga, 1962; Strizova and Trlifajova, 1964). Nakase and Kasuga
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(1962) found it only produced as much toxin as ordinary phase I organisms, 
Nevertheless some B. pertussis strains contain more toxin than others 
(table 5). Most strains are rather similar in their toxicity but there 
was a 13-14 fold difference in toxicity between the least and most toxic 
strains in the extensive survey of 201 strains by Spasojevic (1977).
Her most toxic strain was B-1593/57.
Others have examined strains for their ability to release a 
soluble toxin into the culture medium eg, Joslin and Christensen, 1940; 
Weichsel ^  al, 1940; Roberts and Ospeck, 1942. The latter workers 
found culture filtrates from B. pertussis strains to range from being 
atoxic to being lethal at dilutions of 1 in 20 and perhaps higher ie, 
filtrates from cultures of the intermediate strain No. 33.
On repeated subculture many toxigenic bacteria lose their 
ability to produce toxin (van Heyningen, 1970). This phenomenon has 
been noted, for instance, with Clostridium septicum and Staphylococcus 
aureus (a toxin production) (Bernheimer, 1944; Arbuthnott, 1970). Like­
wise with Bo pertussis the levels of HLT are considerably reduced in the 
process of phase variation which is induced by repeated subculturing 
(Introduction; section II, 4.3). However reduced levels of HLT have 
also been noted in a strain which had been under cultivation for 18 mth 
but was still serologically phase I (Leslie and Gardner, 1931). It is 
not clear how rapid or permanent is the loss of HLT although Standfast 
(1951a) cited Evans as finding toxin production to be one of the more 
stable characteristics of B. pertussis. Field and Parker (1979) sub­
cultured 3 fresh isolates on tryptic soy agar with decreasing amounts of 
blood until they would grow without added blood. Two of the 3 variants 
when injected subcutaneously into suckling mice were no longer dermone­
crotic, The toxic variant at the time of testing had undergone 15
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subcultures since its isolation and the atoxic variants 16 and 32, By 
the 43rd subculture there was preliminary evidence that the first of the 
2 atoxic strains had recovered its toxicity.
The levels of HLT in culture supernatant fluids have also been 
examined. They are reported as being erratic during the 1st subculture 
of Bordet-Gengou grown cells in a liquid medium (Kuwajima, Iwamura and 
Hirai, 1951) and of being reduced after as little as 5 subcultures (Imamura,
1952).
Finally Andersen (1952) noticed that small and large colony 
variants were produced on intracerebral passage of B. pertussis in mice.
The small colony variants were invariably toxic and the large colony 
variants atoxic.
5.2 Culture medium
With some bacterial toxins the composition of the culture medium 
is critical for toxin production. For example, with at least 6 bacterial 
toxins (diphtheria, tetanus, Shigella dysenteriae neurotoxin. Strepto­
coccus pyogenes erythrogenic toxin, Clostridium perfringens a toxin and 
Pseudomonas aeruginosa exotoxin A) toxin production is inhibited if there 
is more than a low level of iron (0,1-1.0 mg/1) present (van Heyningen,
1970; Bjorn ejt al, 1978), With the HLT of B. pertussis there are few 
pertinent reports on the influence of the culture medium on toxin pro­
duction. There is, for instance, no preferred medium for HLT production. 
Most workers appear simply to have taken a medium which supported satis­
factory growth. However, a few authors have indicated a preference for 
a particular medium (table 6). Wood (1940) experimented with a variety 
of media. For instance, she modified the medium recommended by Lawson 
replacing the serum with laked blood, tried different kinds of peptone,
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tried semi-solid starch agar made from soluble or potato starch and 
potato-extract serum broth. However the toxin was not produced any­
more rapidly or in greater concentrations than in the medium of Lawson. 
Finally, Imamura (1952) referred to a synthetic liquid medium in which 
superior yields of HLT were achieved in the culture supernatant fluid 
than with a modification of Verwey's medium.
Little is known of the components in a medium which influence 
toxin yields but the amino acid content may be important, Imamura (1952) 
found that by increasing the concentration of the 7 amino acids in a 
synthetic medium growth improved and toxin became detectable in the 
culture supernatant fluids. Whether this was merely the consequence 
of better growth was not specified. Supplementing the synthetic medium 
with any one of 8 additional amino acids did not however affect growth 
or toxin production. More recently Stainer and Scholte (1971) devised 
a synthetic medium with only 3 amino acids; glutamate, proline and 
cystine. By increasing the levels of either glutamate or proline 
between 12-32 times those given in their basic *GP' medium (ie, 670 mg 
and 240 mg per litre respectively) the HLT content of cultures was 
increased (Stainer 1977, personal communication). Yet when the casein 
hydrolysate in Cohen and Wheeler medium was replaced with increasing 
amounts of glutamate the toxicity of the cells was reduced (Lane, 1970).
In broth in which 60% of the carbon was supplied as glutamate the effect 
was not alleviated by the addition of any one of serine, proline, glycine, 
aspartate or alanine to a concentration of O.OIM.
The possible significance of the salts present in a medium on 
HLT production has already been discussed (Introduction; section II, 4.1)
5.3 Cultural conditions
There have been a few reports on the effect of aeration on HLT
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production. Wood (1940), who was interested in obtaining highly toxic 
culture filtrates, distributed medium in shallow layers for optimizing 
toxin production. However it has also been stated that the toxicity 
of organisms is not promoted by improving the aeration of cultures 
(Akama e^ ab, 1953). Indeed the combined influence of vigorous 
aeration and elevated pH may be responsible for the detoxification of 
sparge- and vortex- aerated cultures, whereas shake-flask cultures are 
invariably toxic (Lane, 1968a),
Incubation in an atmosphere of 80% 0^ and 20% CO^ has been used 
in the production of toxic filtrates (Weichsel ejt 1940; Roberts and
Ospeck, 1942) but Wood (1940) found incubation with 30% CO^ did not 
enhance the toxicity of filtrates.
Kuwajima, Iwamura and Hirai (1951) followed growth and the 
production of toxin in culture supernatant fluids at a variety of tempera­
tures. Toxin was produced just as effectively at 32°G as at 37°C but was 
poor at 30°C as was the growth of the organisms. Most workers have 
incubated at temperatures between 35°C and 38°C but 32°C was used by 
Roberts and Ospeck (1942) and Weichsel e_t ^  (1940).
5.4 Time characteristics of HLT production
Very little is known about the time characteristics of HLT 
production. Lane (1968b) followed the toxicity of whole cultures.
During very early exponential growth high levels of HLT were already 
apparent and peak toxicity had been reached before the end of exponential 
growth. Heat-labile toxin levels remained fairly constant or declined 
slowly during the stationary and decline phases of growth. Stainer 
(1977, personal communication) observed that higher levels of HLT could 
be obtained per cell when cultures were harvested prior to reaching peak 
opacity.
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5.5 Intracellular versus extracellular location
Heat-labile toxin was first identified in extracts of B. per­
tussis cells after a failure to detect the toxin in culture supernatant 
fluids (Bordet and Gengou, 1909). This is consistent with HLT being 
predominantly cell-associated. It has been suggested that HLT is a 
capsular, cell-surface or envelope component (Wood, 1940; Katsampes, 
Brooks and Bradford, 1942; Yaguchi, 1954 cited by Yamamoto aj^ , 1957; 
Yoshida e_t 1955 cited by Billaudelle eh al^ , 1960) and it can be 
obtained from washings or extracts from cells (appendix 1). However 
it has now been established that HLT is predominantly associated with 
the cytoplasm of B. pertussis cells.
When Bo pertussis cells are lysed there is a marked increase 
in their toxicity (Evans and Maitland, 1937; Smolens and Flavell, 1947; 
Munoz, Schuchardt and Verwey cited by Munoz, Ribi and Larson, 1959; 
Novotny, 1977, personal communication; Cowell, Hewlett and Manclark, 
1979). This was interpreted by Munoz, Ribi and Larson (1959) as 
indicating that HLT is an internal substance which when released is more 
effective than when contained in the intact cell. They found support 
for the idea that HLT is a cytoplasmic constituent by disrupting 
washed cells and separating the cell-envelopes from the cytoplasmic 
fraction in which the HLT was almost exclusively found. The slight 
toxicity of the washed cell-envelopes was attributed to contamination 
with cytoplasmic material. These results agreed with those later 
obtained by Billaudelle _et ^  (1960) and Cowell, Hewlett and Manclark 
(1979). These latter workers went one step further and established 
that the HLT in these cytoplasmic fractions was truly cytoplasmic in 
origin and did not arise from the periplasmic space. The HLT was not 
inactivated by trypsin treatment of whole cells nor was it released
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when cells were subjected to osmotic shock treatment (Cowell, Hewlett and 
Manclark, 1979), It has been suggested that intracellular HLT may exist, 
as a precursor which is not toxic until activated (Anderson and North,
1943; Morse, 1976).
HLT can also be derived from culture filtrates and supernatant 
fluids (appendix 1). It has been proposed that such toxin arises, in the 
main, as the result of autolysis of the organisms (Pittman and Cox, 1965) 
and conversely as a product of actively growing cells (Wood, 1940; Roberts 
and Ospeck, 1942; Lane, 1968b), It has even been suggested that small 
vesicles seen on the outer surface of B. pertussis cells are involved in 
the release of HLT (Lane, 1968b), Golubeva and Kushnarev (1974) isolated 
HLT from such vesicles. An indication that yields in the culture fluids 
are considerably lower than those obtained from extracts of disrupted 
cells can be gathered from the observation that most workers have used 
cell extracts as their source of HLT (appendix 1). Culture supernatant 
fluids may even have to be concentrated before the toxin can be detected 
eg, Cowell, Hewlett and Manclark (1979) who could detect less than 0,017. 
of the HLT associated with the cell-lysates in the corresponding culture 
supernatant fluids. ,
5.6 Production by B, parapertussis and B. bronchiseptica
B. parapertussis and B, bronchiseptica produce toxins indisting­
uishable from the HLT of B. pertussis. All 3 are lethal, dermonecrotic/ 
haemorrhagic toxins (Evans and Maitland, 1939; Bruckner and Evans, 1939) 
which are cytotoxic for mouse embryo tissue cultures (Strizova and Trlifa­
jova, 1964). They are similarly affected by heat, formalin and filtra­
tion (Evans and Maitland, 1939; Bruckner and Evans, 1939),and antisera 
raised to one will neutralize the dermonecrotic or lethal effects of all 
3 (Evans, 1940; Andersen, 1953b).
50
Bo parapertussis would seem to produce less toxin than 
Bo pertussis (Bruckner and Evans, 1939; Flosdorf, Bondi and Dozois,
1941; Andersen, 1953b) although the strain tested by Roberts and Ospeck 
(1942; Ospeck and Roberts, 1944) for its ability to produce toxic 
filtrates was of intermediate toxicity compared to B. pertussis strains.
B. bronchiseptica strains have been found to be less or similar in toxic­
ity to B. pertussis (Evans and Maitland, 1939; Andersen, 1953b). How­
ever too few strains of each species have been compared for the afore­
mentioned differences to be any more than indications as to the relative 
toxin producing capacities of these species. Moreover the levels of toxin 
produced can vary as is illustrated by the observation that B. parapertussis 
and B. bronchiseptica grown on Bordet-Gengou medium are markedly more 
toxic than their nutrient agar grown counterparts (Evans and Maitland,
1939; Bruckner and Evans, 1939).
6 Purification
6.1 Disruption of bacteria and release of HLT
B. pertussis cells as opposed to culture fluids have been used 
most often as a source of HLT for which purpose they are invariably dis­
rupted by one of several methods. For instance, in an extensive review 
of the literature in which 59 references are cited (sometimes more than 
once giving 67 citations in all), the cell was taken as the source of HLT 
87% of the time. In 88% of these cases the cells were lysed (appendix 1). 
The 3 main methods which have been used to lyse the bacteria are grinding, 
freeze-thawing and sonication which account for 73% of these citations. 
Grinding and freeze-thawing although once widely used have now been 
replaced, to a large extent, by more convenient/effective methods 
(appendix 1),
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When B. pertussis cells are lysed there is an increase in 
their toxicity (Evans and Maitland, 1937; Smolens and Flavell, 1947;
Munoz, Schuchardt and Verwey cited by Munoz, Ribi and Larson, 1959;
Novotny 1977, personal communication; Cowell, Hewlett and Manclark,
1979). The values given for the size of this increase vary viz, a 4- 
fold increase by grinding (Evans and Maitland, 1937); a 20-fold increase 
by sonication compared to that (unspecified) achieved by freezing and 
thawing (Smolens and Flavell, 1947) and a 20-25 fold increase by the 
lysozyme freeze-thaw technique of Cowell, Hewlett and Manclark (1979),
HLT can also be obtained from cells without actively disrupting 
them but only part of the toxin available is recovered (Roberts and 
Ospeck, 1942), For instance, when extracts were made from live and 
freeze-thawed, ground B, pertussis preparations the former extract con­
tained only 10% of the toxicity detectable in the latter (Evans and 
Maitland, 1937), Similarly, Robbins and Pillemer (1950) recovered in a 
water extract from freeze-dried B. pertussis only 21% of the HLT obtained 
from the cells when sonicated,
6,2 Purification procedures
The first serious attempted purification seems to be that of 
Robbins and Pillemer (1950). They extracted the HLT from cells with 
CaCl2 and fractionated this by selectively precipitating out the toxin 
under 2 different sets of conditions (figure 3). In the final fraction 
(Pll) 66% of the HLT from the CaCl^ extract had been recovered whilst 
achieving a 13.2 fold increase in purity but the material was still 
heterogeneous on analysis by electrophoresis. The LD^^ of Pll to 12-15 g 
mice was 0,19 (ig N,
Penne1 and Thiele (1951) fractionated extracts of sonically 
disrupted B, pertussis with ethanol at -5^C but lost much of the toxic
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Figure 3 Purification procedure of Robbins and Pillemer (1950).
1 A 2.5% suspension of freeze-dried B. pertussis was 
prepared in 0.05M CaCl2 at pH 6.5 and then centrifuged to 
remove bacterial debris and a mucin like material.
2 The precipitate formed from the CaCl^ extract under
the conditions specified was dissolved in 0.3M sodium acetate 
at pH 7.0 and this solution clarified by centrifugation.
3 HLT was precipitated from PI as indicated, the
precipitate dissolved in 0.15M sodium acetate at pH 7.0 
and this solution clarified by centrifugation.
Freeze-dried B. pertussis
1, Extraction with CaCl,
CaCl^ extract
2. Precipitation at pH 4.4 
in 15% methanol, -5°C, 
ionic strength 0.13
3. Precipitation at pH 5.3, 
0°C, ionic strength 0.15
PI
Pll
4,1— fold purification, 
82% recovery
3,2-fold purification, 
81% recovery
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activity, This inactivation was more pronounced if the pH or ionic 
strength was lowered, if the mixture was diluted,or had been clarified 
with CaClgc
Yamamoto and coworkers began their purification studies with 
extracts from freeze-thawed cells (Yamamoto, Zenyoji and Kato, 1952a; 
Yamamoto £t al, 1952, 1953 and 1957) or washings from cells (Yamamoto, 
Zenyoji and Kato, 1952c). They used combinations of the following 
techniques: extraction with CaCl^ (Yamamoto, Zenyoji and Kato, 1952c;
Yamamoto e_t 1952 and 1953), precipitation with acetic acid (Yamamoto
Zenyoji and Kato, 1952a and c; Yamamoto eJt al, 1952; Yamamoto e_t al,
1957), precipitation with 20% methanol at -5°C (Yamamoto nt 1952 and 
1953) or with ammonium sulphate (Yamamoto ^  1957). In their most
successful attempt an extract from freeze-thawed cells was fractionated 
by precipitations with ammonium sulphate and by the addition of acetic 
acid (figure 4). The final fraction F-0.4 was 60 times more active than 
the original toxic extract ie, 1 rabbit MRD = 50 ngN (cf. 3 pgN),
However this mainly protein fraction (F-0.4) was still heterogeneous 
when analysed electrophoretically and contained agglutinogen. Subse­
quently Yamamoto and his coworkers managed to prepare a marginally more 
active preparation with an MRD of 20 ngN (Yamamoto e^ 1959 cited
by Onoue, Kitagawa and Yamamura, 1963),
Billaudelle e_t aj^  (1960) experimented with the use of ion- 
exchange chromatography on DEAE-cellulose and preparative electrophoresis 
for purifying HLT from cell-lysates or cell-washings but had problems 
with inactivation of the toxin. They did however report being able to 
separate the dermonecrotic activity from the lethal activity by electro­
phoresis although the lethal effect, which was largely destroyed during 
the process, did contain dermonecrotic activity.
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Figure 4 Purification procedure of Yamamoto £t ^  (1957).
The starting material was a filtered, supernatant fluid 
obtained from B. pertussis suspended in 0,15M sodium acetate 
(280 g wet weight in 2 1) which had been freeze-thawed 15 times,
1 The toxin was precipitated out of the filtrate by the
addition of ammonium sulphate to 40% saturation (pH 7.0, -5°C)o 
This procedure was repeated 3 times and the final precipitate 
suspended in and dialysed against saline at pH 7.0.
2 The pH of the ammonium sulphate fraction was brought to 
4,4 with IN acetic acid, the precipitate collected, dissolved 
and dialyzed with saline at pH 7.0.
Filtered supernatant fluid from a 
suspension of freeze-thawed B. pertussis
1. Fractional precipitation 
with ammonium sulphate
2o Precipitation at pH 4.4 
by the addition of 
acetic acid
fraction 1
F - 0.4
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DEAE-cellulose was also used by Banerjea and Muhoz (1962) to 
separate HLT from other constituents in cell lysates. The toxin was 
adsorbed onto the column and then eluted using a continuous NaCl gradient 
(0-lM) in pH 7.1, 0.15M phosphate buffer. Due to the instability of the 
eluted toxin its specific activity was not determined. Toxic fractions 
were mainly protein but traces of RNA, DNA and carbohydrates were also 
present in most fractions. In 1963 Onoue, Kitagawa and Yamamura 
described a method for obtaining HLT in a highly active form. An extract 
from B. pertussis cells disrupted by grinding,was purified successively 
by calcium phosphate gel treatment, ammonium sulphate fractionation, 
precipitation with potassium phosphate, and chromatography on a DEAE- 
cellulose column (figure 5),The calcium phosphate gel step was essentially 
preparative, to reduce the viscosity of the extract for subsequent
purification. The precipitation with potassium phosphate produced no 
net purification in terms of pg dry weight or nitrogen but nucleic acids 
were eliminated. The overall process resulted in a 60-80 fold purifi­
cation of the crude extract with a 5-107. recovery of toxicity. The 
final F2 fraction was a highly active protein solution (1 guinea pig 
MRD = 1 - 1 , 3  ngN and 1 mouse LD^q = 44 ngN ) but was still hetero­
geneous containing agglutinogen and exhibiting 3 lines in gel diffusion 
tests.
A modification of the method of Onoue, Kitagawa and Yamamura 
(1963) was employed by lida and Okonogi (1971; figure 6). The final 
fraction was highly active with a guinea pig MRD of 0.9 ngN and a 
mouse MLD of 50 - 100 ngN. Compared to the starting material or
sonicate these figures represent purifications of about 90 and 6-12 times 
in terms of dermonecrotic and lethal activities respectively. Recovery 
of HLT, assuming 1007. recovery in the supernatant fluid from the sonicate,
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Figure 5 Purification procedure of Onoue, Kitagawa and Yamamura (1963),
1 HLT was extracted from the disrupted cells by mixing with 
0.15M NaCl at pH 8.0 and centrifuging out the cellular debris.
2 Crude extract diluted 1 in 1.5 with distilled water was 
mixed with calcium phosphate gel. This was filtered, the filter 
cake washed with 0.15M NaCl and the HLT eluted with Ool5M, pH 8.0 
phosphate buffer. The supernatant fluid was collected and 
combined with that obtained on re-extraction of the gel.
3 Ammonium sulphate was added to the gel eluate (9.12 g/100 ml) 
The precipitate was removed and further ammonium sulphate added 
(15.2 g/lOO ml). The resultant precipitate was collected, 
dissolved and dialysed with 0.005M, pH 8.0 phosphate buffer, 
clarified and brought to one-tenth the volume of the original 
crude extract,
4 To the ammonium sulphate fraction was added potassium 
phosphate (18% (w/v)). The precipitate formed was collected, 
dissolved and dialysed with distilled water, and freeze-dried.
5 KP18 was reconstituted in pH 7.4, 0.2M phosphate buffer +
O.OlM NaCl and adsorbed to a column of DEAE-cellulose equilibrated 
in the same buffer. After elution of unadsorbed material HLT was 
eluted with pH 7.4, 0.04M phosphate buffer +  0.05M NaCl,
Ground B. pertussis cells
lo Extraction of toxin 
with saline
2. Fractional adsorption 
with calcium phosphate 
gel
Crude extract
1.5-2 fold purification, 
45-60% recovery
Gel eluate
3. Fractional precipitation 
with ammonium sulphate
5-fold purification 
70% recovery
Gel eluate derived fraction
4. Fractional precipitation 
with potassium phosphate
KP18
no net purification in 
terms of jig dry weight 
or of nitrogen,
55-80% recovery
5. Ion-exchange
chromatography on 
DEAE-cellulose
9-10 fold purification, 
40% recovery
F2
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Figure 6 Purification procedure of lida and Okonogi (1971).
The starting material was the supernatant fluid from a 
sonicated B. pertussis suspension (100-250 mg cells/ml 
distilled water)*
1 The supernatant fluid was diluted 1 in 1*5 in distilled
water and mixed with calcium phosphate gel* The gel was
collected by centrifugation and extracted with O.IM, pH 8,0 
phosphate buffer. The gel d.uate was collected by centrifugation,
2 A saturated solution of ammonium sulphate was added to the
gel eluate to a final concentration of 31%. The precipitate 
was collected by centrifugation, dissolved in distilled water 
and dialysed against 0*001M, pH 7,4 phosphate buffer*
3 The ammonium sulphate fraction was fed onto a DEAJE-
cellulose column equilibrated in OoOOlM, pH 7*4 phosphate buffer* 
This was followed by stepwise elution with the following 
buffers: 0.005M, pH 7*4 phosphate buffer +  OoOlM HaCl: 0.02N,
pH 7o4 phosphate buffer +  O.OIM NaCl: 0*04^ pH 7*4 phosphate
buffer + 0o05M NaClç. The fractions eluted with the final 
buffer were pooled, precipitated with ammonium sulphate (50% 
saturation), dissolved in distilled water and dialysed against 
0a005M, pH 7*4 phosphate buffer* This material was further 
purified by rechromatography on a smaller column and then 
reconcentrated with ammonium sulphate (50% saturation).
Supernatant fluid from sonicated B. pertussis suspension
lo Fractional adsorption 
with calcium phosphate 
gel
N/
Gel eluate
2o Fractional precipitation 
with ammonium sulphate
Gel eluate derived fraction
3. Ion-exchange chromato­
graphy on DEAE-cellulose
N k
DEAF fraction
58
was in the region of 11% and 1% according to whether calculations were 
based on dermonecrotic or lethal activity. The purified material was 
still heterogeneous as shown by the formation of more than 1 precipitin 
line on Ouchterlony gel diffusion and immuno-electrophoresis* On intra­
venous injection of the purified toxin into mice a marked leukocytosis 
developed but this peaked at day 1 and not between days 3 and 5 as is 
characteristic for that induced by LPF (Morse and Morse, 1976)*
Nakase e_t al (1969) also obtained a highly active preparation 
by fractionating the supernatant fluid from a sonicated B* pertussis 
cell suspension by chromatography on a DEAE-cellulose column, precipi­
tation with ammonium sulphate and preparative acrylamide gel electro­
phoresis (figure 7). This was a development of earlier work (Nakase 
and Kasuga, 1962), The purified material had an MRD for guinea pigs 
of 1.6 ngN, an increase in purity over the sonic extract of 80 times*
This preparation was shown to be homogeneous by ultracentrifugation, 
thin layer acrylamide electrophoresis, electron microscopy and in agar 
gel diffusion tests with antitoxin or an antitoxin containing antisera 
against phase 1 B* pertussis* It was free of the intracerebral mouse 
protective antigen, HSF and haemagglutinin (1 mg amounts tested^ but 
agglutinins could be detected in some antitoxic sera made to the purified 
HLT,. An increased leukocytosis was produced in mice injected intra­
venously with the purified toxin but the peak of leukocytosis was at 
day 1 and not between days 3 and 5 as is found with LPF (Morse and Morse, 
1976)* This purified HLT is capable of stimulating interferon pro­
duction in rabbits and rabbit cell cultures (Kojima, Yoshida and Nakase, 
1973).
Table 7 summarizes the pertinent points from these attempted 
purifications of HLT* The 3 most promising methods are those of Onoue,
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Figure 7 Purification procedure of Nakase ^  ^  (1969),
The starting material was the supernatant fluid from a
9
sonicated suspension of B. pertussis (1,5 x 10 cells/ml 
distilled water),
1 The HLT was adsorbed onto a column of DEAE-cellulose 
equilibrated with 0*005M, pH 8*0 phosphate buffer and eluted 
in a stepwise manner with increasing concentrations of pH 7*6 
phosphate buffer ie, OoOlM, Oo02M, 0*05M* Selected toxic 
fractions eluted with the 0*05M buffer were concentrated by 
ultrafiltration (ie, F2),
2 Ammonium sulphate was added to F2 to give a 10% (w/v) 
solution. The precipitate formed was removed and further 
ammonium sulphate added to give a 20% (w/v) solution. The 
precipitate formed in this solution was collected and this 
salt fractionation step repeated twice more. The final 
precipitate was dialysed against O.GIM phosphate buffered 
saline and then freeze-dried.
3 The above product was dissolved in 0,3M, pH 8.2 borate 
buffer (50 mg in 3.3 ml), mixed with a small amount of 
sepharose 4B gel and electrophoresed in borate buffer on an 
acrylamide gel column (60-70V, 40mA, 35-48h, 1-2^C).
Selected toxic fractions were pooled, dialysed and freeze- 
dried.
Supernatant fluid from sonicated B* pertussis suspension
1. Ion-exchange chromatography 
on DEAE-cellulose
F2
2, Fractional precipitation with 
ammonium sulphate
\ k
F2 derived fraction
3o Preparative acrylamide gel 
electrophoresis
Nk
PAE fraction
60
1^
(Ü
f— i
cd
E-^
fi O
o g 44 fi
Cd Cd 1 •H fi O Cd
•H ‘ H 1— 1 Cd •H Cd •i4 •H
Cd Cd Cd f i fi fi Cd Cd
CD CD 4J fi 1 •f4 CD fi CD
fi fi Cd CD cd 64 44 Cd (44 fi
g O CD cd fi •H f i (44 O
Æ rG 4-1 4-J rfi î>^ 1-4 Ü •H rfi
CL. CL. fi 1—1 CL, 60 *r4 T3 CL
O O fi CD f i r4 O X O
fi fi O CD CD o r-4 fi
4-1 4J •p4 cd 60 Cd 44 CD 44
î>^ O o Cd 1-1 Cd O •H 6 0 CD
4-J CD CD 4J f i ■P •H f i f i 4J CD
•H 1—t r—4 fi CL4 fi f i Cd Cd O <3 f i f i r-4
f i CD CD CD 14-1 CD •H CD 60 "H œ cd fi •H CDfi Cd •H Cd rfi f i cd B •r4 1
D h fi fi CD TD CD 4-J O CD X CD O
O O fi fi Dfi fi ffi B o f i f i
cw Cu 1—1 O , CL f i o t o O 44 •r4 f i
o Cd Cd CD rO O o f i K Cd r 4
f i f i f i 60 f i f i •H 4-4 T3
Cd o O CD CD Cd 4-J 4-J O fi CD r-4 *r4
CD g CD 60 f i 60 f i O cd CD <3 •H •H
CD fi fi O •H g O CD 60  r-4 p4 (44 f i " f i
•H CD CD f i f i g r 4 f i CD TD •H Cd f i
g àû bD •H Cd •H fi CD (44 (44 CD fi Æ Cd
fi O O 4J g 4-4 CD •H O 44 fi 44
M fi fi fi fi fi 60 CD fi Cd CD C L Cd
CD CD t—4 ♦H r-! g 'V 4-4 4-J. (D CD CD 44
4-1 4-4 60 rM 60 B •H f i Cd CD 44 CD f i Cd
CD CD 60 60 o B CD CD f i CD rfi o CD32 f i: Cd r o Cd cd O 4-J P4 TD 44 s 44
r I^— I -
t-J 0)
X -H •
CDCO
Cd
CD
o
fi
M
I
•H
4-1
O
•H
Xo
H
4->
•H
U
fiCL.
CD
fi
CD
M
CD
M-l
S
vO
UD
CM
O
o\
O
m
o
TD t—1
fiCd A
fi 6
•H CD 
.43 r-4 
rû «— I
O  * H  PÜ P4
g
o
v O
ê
o
m
I
m
o
00
Io
vfi
-fi-
O
CX)
ir,
o t3
O  C M  
O  .-I 
CJN I 
v O
Oo
Io
m
CJN
o
00
vO VJC5
(T. •i4cd I— 1 r-4 60
r-4 1 [3 O
CCJ|1 cd «' fi
60 cd r-4| O
44]i cd fi cd| r ^
cd|1 p  fi O
•H a P|
O g CD| ro
4 4 B fig A Cd CD fi
B CD Cdçd 6- fi fi fi r4
B (O O TD rX T3 r-cd CT' fi fi fi •i4 tr.>-•1-4 O Cd z M  r-4
Q
fi
>
•H
W)
cd
4-1
cd
T3
ê
§
>
• H4J
O
CDa.
Cfl
CDfi
w
CD
•H
4-1
• H
>
• H
4J
Ü
Cd
I— 1
I
CD
'U
ficd
o•iH
4-4
Ofi
0
CD
fi
1
CD
X)
ifi14-4
Tî
CD
4-4
Cdr4
fi
O
r-i
Cdo
61
Kitagawa and Yamamura (1963), the modification of this by lida and 
Okonogi (1971) and the method of Nakase e_b ^  (1969). All produced HLT 
preparations of a similar high activity. The method of Nakase e_t al_ 
(1969) seems to be best in that their material was essentially free from 
impurities.
7 Nature
7 o1 Relationship between lethal and dermonecrotic activity
Bordet and Gengou (1909) discovered that extracts prepared from 
B, pertussis cells had dermonecrotic and lethal activity, an observation 
which has been amply confirmed. These activities are regarded, almost 
without exception, as manifestations of the same heat-labile toxin. Both 
properties were inactivated together after treatment with antitoxin or by 
heating (Katsampes, Brooks and Bradford, 1942; Roberts and Ospeck, 1942 
and 1944). Furthermore determinations of the relative potencies of 
toxic extracts or antitoxic sera have given the same results irrespective 
of the activity monitored (Evans and Maitland, 1937; Evans, 1940; 
Anderson and North, 1943; Roberts and Ospeck, 1944). Finally, Onoue, 
Kitagawa and Yamamura (1963) have demonstrated the presence of both 
activities in their highly active semi-purified HLT preparation.
In contrast to the aforementioned view Billaudelle e^ ah (1960) 
considered the lethal and dermonecrotic activities of B, pertussis to be 
attributable to 2 distinct factors. They separated the dermonecrotic 
and lethal activities although the fraction which contained the more 
readily inactivated lethal activity also expressed dermonecrotic 
activity. . Further data which could be interpreted as supporting the 
view of Billaudelle ejt ^  (1960) was provided by lida and Okonogi (1971) 
ie, during their purification of HLT there were 90 and 6-12 fold
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purifications in terms of dermonecrotic and lethal activities respect­
ively* However the expressions of the lethal and dermonecrotic 
activities may be affected by other constituents of B. pertussis (Ishida, 
1968; Kurokawa, Ishida and Asakawa, 1969) and therefore not always run 
hand in hand* Consequently when Cravitz and Williams (1946) observed 
that per MLD the dermonecrosis produced by toxin extracted from cells 
was greater than that of toxic culture filtrates they were probably 
witnessing this effect* This could also account for Sauer vaccinated 
mice being partially protected against extracted toxin but not toxic 
filtrates. An alternative interpretation of these data proposed by 
Cravitz and Williams (1946) was the existence of a dermonecrotic factor 
in addition to HLT*
7*2 Chemical nature
Nakase et al (1969) obtained HLT in a highly active and 
purified form* They showed it to be homogeneous and free of several of 
the other pathophysiological activities expressed by B. pertussis (table 7)* 
On chemical analysis positive tests for protein, amino acids and sugars 
were obtained* The UV absorption spectrumfor the toxin was also 
characteristic of a protein* Tests for nucleic acids, lipids, and 
phosphorus were negative* Their HLT preparation was 14-16% nitrogen, 1.4% 
reducing sugar, and contained at least 13 different amino acids, mannose 
and an additional unidentified reducing substance* In short HLT appears 
to be a protein with a sugar moiety*
The findings of Nakase eJL aT (1969) confirmed earlier reports, 
based on less highly purified material, that protein was a major con­
stituent of HLT (Strean and Grant, 1940; Yamamoto et al, 1957; Kuroya 
et al, 1959 cited by Nakasé et al, 1969; Nakase and Kasuga, 1962;
Banerjea and Munoz, 1962; Onoue, Kitagawa and Yamamura, 1963; Nakase
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1965). In addition to physiochemical data on the chemical 
nature of HLT the toxin has been shown to be destroyed by the proteolytic 
enzyme trypsin (Banerjea and Muhoz, 1962; Cowell, Hewlett and Manclark, 
1979) but not by DNase or RNase (Banerjea and Munoz, 1962). In contrast 
toxin preparations prepared by Yamamoto et. (Yamamoto, Zenyoji and 
Kato, 1952a and c; Yamamoto ejb al, 1952 and 1953) were considered to be 
nucleoproteins with DNA as the active principle since DNase destroyed 
toxic activity (Yamamoto et al, 1953). However the purity of the DNase 
was suspect and in a subsequent study HLT was considered to be a simple 
protein (Yamamoto e_t Êl.) ^957).
7.3 Parameters defining the physical nature of HLT
No estimations have been made of the molecular weight of HLT
although values have been given for the sedimentation coefficient. The 
latter is a function of molecular weight but is also dependent upon shape 
and density. Results so far are inconclusive and range from 1.4S 
(Nakase e_t a]^ , 1969), to 13S (Sato e_t unpublished, cited by Nakase
et al, 1969), to 20S (Kuroya e_t al, 1959 cited by Nakase e_t a^, 1969).
It has been suggested by Nakase ^  ^  (1969), who obtained the low S value 
with their purified HLT preparation, that the higher values reported may 
be due to aggregation of HLT with other constituents of B. pertussis cells
The isoelectric point of the toxin appears to be within the pH 
range of 4.0-4.8, as between these values it precipitates out of 
solution (Burrell, Robbins and Pillemer, 1948). Several workers have 
taken advantage of this property in attempts to purify the toxin by 
adjusting the pH to between 4,0 and 4.5 (Evans, 1940; Flosdorf and 
Kimball, 1940; Strean and Grant, 1940; Pennell and Thiele, 1951; 
Yamamoto, Zenyoji and Kato, 1952a and c; Yamamoto et al, 1952 and 1957).
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Further confirmation that the pi is in the acidic pH range is the 
adsorption of HLT onto the anion-exchange resin, DEAE-cellulose at pH 
values near neutrality (Billaudelle ^  al j 1960; Banerjea and Munoz,
1962; Nakase and Kasuga, 1962; Onoue, Kitagawa and Yamamoto, 1963;
Nakase e^ aT, 1969; lida and Okonogi, 1971) but not onto the cation- 
exchange resin, CM-cellulose (Onoue, Kitagawa and Yamamura, 1963). 
Similarly on electrophoresis at pH 7.4, 7.8 and 8.2 the toxin migrated 
to the anode (Billaudelle ^  al, 1960; Onoue, Kitagawa and Yamamura,
1963; Nakase e_t al^ , 1969).
7.4 Stability
Strean and Grant (1940) reported HLT as being stable at 4°C 
for several months. Indeed it may retain its full potency for 4 d 
(Kuwajima, Iwamura and Hirai, 1951) to a week (Wood, 1940), possibly even 
10 d (Katsampes, Brooks and Bradford, 1942) at 3-5°C. By 1 mth there 
may be a 50% loss of activity, it taking 1 yr for full inactivation 
(Roberts and Ospeck, 1942). In contrast to all these results,Evans 
and Maitland (1937)* measured a 75% loss in toxic activity in 2 d and by 
2-4 wk almost all activity had gone. They also reported the following
* ~ Q
losses in activity at higher temperatures: 80% after 2 d at 22 C, 95%
after 2 d at 37°C or 9 h at 40°C,until at 55°C virtually all activity 
is destroyed in 10 min. These figures illustrate the increasing lability 
with increases in temperature but different values for the amount of 
inactivation at any one temperature have been obtained eg, at room 
temperature, full inactivation in 1 mth (Roberts and Ospeck, 1942), at 
40^C no significant reduction in toxicity after 3 h (Onoue, Kitagawa and 
Yamamura, 1963).
Since the first report that the toxin's activity was much 
reduced by heating at 55°C for 30 min (Bordet and Gengou, 1909) there
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have been many references to the stability of the toxin at temperatures 
in this region ie, that toxic activity is destroyed in 5-10 min at 
temperatures between 50-55°C (Wood, 1940; Evans and Maitland, 1937; 
Katsampes, Brooks and Bradford, 1942; Roberts and Ospeck, 1942;
Kuwajima, Iwamura and Hirai, 1951). Most results have been recorded 
at 56°C and not all of these are in agreement with the aforementioned 
results obtained at 50-55°C (table 8), However 30 min at 56°C seems 
adequate in most instances to inactivate HLT whilst in solution.
In view of the heat lability of the toxin undue generation of 
heat should be avoided eg, by excessive grinding whilst disrupting 
Be pertussis cells (Evans and Maitland, 1937),
Other physical factors may influence how active the toxin will 
remain. For instance, at pH 9.5 toxicity is destroyed (Yamamoto £t al, 
1953) and it is also unstable at acidic pH values (Onoue, Kitagawa and 
Yamamura, 1963) being least labile at pH 7.4 (Billaudelle et al, 1960). 
Yet HLT may be precipitated out, in an active form, at its isoelectric 
point which is well into the acidic pH range (4.0-4.8; Burrell, Robbins 
and Pillemer, 1948). The oxidative effect of ultrasonic treatment may 
also inactivate the toxin although this can be avoided if an atmosphere 
of hydrogen is used (Tournier 1948, M.D. Thesis, cited by 
Grabar, 1951 ). Kasahara £_t al^  (1938, cited by Billaudelle
et al, 1960) and Smolens and Flavell (1947) also found the toxic activity 
could be destroyed during ultrasonic treatment. Whether the degener­
ation in toxicity was due to the oxidative effect or excessive heating 
was not specified. Finally a combination of factors may result in 
detoxification although individually not sufficient to produce this 
effect eg, the combined influence of elevated pH and vigorous aeration 
in vortex-aerated cultures of B. pertussis (Lane, 1968a)*
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A variety of chemical agents have deleterious effects on the 
toxic activity of HLT: organic solvents; acetone, chloroform, cresol,
ethanol, ether, methanol, phenol, thymol and toluene (Bordet and Gengou,
1909; Evans, 1942; Anderson and North, 1943; Pennell and Thiele, 1951; 
Billaudelle et aT, 1960; Onoue, Kitagawa and Yamamura, 1963); the 
preservatives merthiolate (Evans, 1942; Anderson and North, 1943; Lane, 
1968a) and formalin (Introduction; section II, 8.1); the surface active 
agent sodium deoxycholate (Barta, 1963; Nakase et al, 1965). Sensitivity 
to inactivation by ethanol has been shown to be accentuated by the use of 
CaCl^ to clarify toxic extracts, lowering the pH or ionic strength, or by 
dilution (Pennell and Thiele, 1951).
HLT seems to be relatively stable while inside the cell and 
protected from injury, thus the toxicity of cresol or merthiolated cells 
persists longer than that of toxin in solution (Anderson and North, 1943; 
Munoz, 1963), On releasing HLT from the cell it may be difficult to keep it 
in an active state (Munoz, 1963),which makes its purification all the more 
difficult eg, Billaudelle e_t aA (1960). Nevertheless HLT can be main­
tained in an active form eg, by storage in a dried form (Bordet and Gengou, 
1909), Dried toxic culture filtrates have been kept at chillroom tem­
peratures for as long as 18 mth without loss of potency (Roberts and 
Ospeck, 1942). Anderson and North (1943) kept toxin for 12 mth without 
loss of activity by sealing in vacuo and storing at 2°C. Evans and 
Maitland (1937) also preserved freeze-dried toxin for long periods of time. 
Heat-labile toxin has also been stored frozen eg, 2 of 3 toxin solutions 
were relatively stable whereas the 3rd was partially inactivated within a 
short period of time (Kurokawa, Ishida and Asakawa, 1969). An alternative 
method of storing the toxin is in 50% glycerine or sucrose. Preparations 
stabilized in this manner were kept over a period of 17 mth without loss
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of potency (Roberts and Ospeck, 1942 and 1944), Toxin reconstituted 
in a 50:50 mixture of glycerol and broth with subsequent storage at 10°C 
proved after 1 mth to be just as potent as freshly reconstituted toxin 
(Cravitz and Williams, 1946),
8 Immunology
801 Production and measurement of antitoxin in animals
For many years after its discovery by Bordet and Gengou (1909)
HLT was considered to be non-immunogenic. Various attempts to raise 
antitoxin to HLT in animals had failed eg, Bordet and Gengou (1909);
Miller (1934); Evans and Maitland (1937); Wood (1940). However, in 
1929 Teissier e_t had demonstrated the production of neutralizing anti­
bodies to HLT in a sheep, a donkey and guinea pigs. Yet, aside from this 
isolated report, it was not until the 1940°s that the immunogenicity of 
HLT was firmly established (appendix 2).
Although antitoxin has been produced in a sheep, a donkey, guinea 
pigs (Teissier et al, 1929) and horses (Demnitz, Schluter and Schmidt, 1936 
cited by Weichsel et al, 1940; Proom, 1947) rabbits have been the pre­
ferred species. Rabbits were employed in at least 28 of 31 reports 
which referred to antitoxin production (appendix 2). On the other hand 
the active immunization of mice against HLT with either native or 
formaldehyde-detoxified toxin has not met with success (Wood, 1940;
Anderson and North, 1943; Ospeck and Roberts, 1944). Neither subcut­
aneous nor intraperitoneal injections of toxoid, identical to that effect­
ive in rabbits, were productive in spite of intensive immunization. The 
mice received in a course of 5 injections about 10 times as much toxoid, 
on an equal body weight basis, as the rabbits (Anderson and North, 1943).
A  review of the literature has identified 24 references on the 
production of antitoxin in animals by immunization with B. pertussis cells
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(5 citations), preparations of native or formaldehyde-detoxified HLT (9 
and 17 citations respectively) or combinations of these materials (3 
citations). In a further 7 references details of the material used were 
absent or ambiguous (appendix 2). It is difficult to assess which of 
B. pertussis cells, native or formaldehyde-detoxified HLT is superior in 
stimulating antitoxin production from the data available (appendix 2).
The validity of comparing the antitoxin titres to each of these immunogens 
is questionable as the influence of other factors must be considered eg, 
the route, frequency and dosage of injections, differences in the res­
ponsiveness of animals etc. However it must be noted that whilst the 
immune response to B. pertussis cells may produce antitoxic antibodies it 
often does not, even though a strong response has been made to other 
B. pertussis components (Bordet and Gengou, 1909; Evans and Maitland, 1937; 
Evans, 1942 and 1944; Verwey and Thiele, 1949). Moreover, except for 
one report of success with formaldehyde-killed cells (Flosdorf, Bondi 
and Dozois, 1941) antitoxic responses to B. pertussis cells have been 
achieved only with live organisms. For instance although immunizations 
with live organisms of strain No. 33 yielded antitoxin (Roberts and Ospeck, 
1944; Kuwajima e_t al, 1958) when killed cells were used (formaldehyde, 
phenol, merthiolate or heat-killed; 56 or 100°C for 30 min) no antitoxin 
was detected ie, a difference in titre of at least 16-fold (Kuwajima et al,
1958). Yet 30 times as many killed as live cells were used and sub­
stantial agglutinin titres were attained in response to the former. 
Therefore in conclusion B. pertussis cells would not seem to be as 
suitable in this context as native or formaldehyde-detoxified HLT. Of 
the 3, the toxoid is superior in eliciting an antitoxic response, 
according to Roberts and Ospeck (1944), The conditions used to make 
these toxoids are given in table 9. The concentrations of formaldehyde 
used ranged from 0.032-0.167. (w/v), averaging 0.1% (w/v)^ and the temp-
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Table 9 Conditions used to convert HLT with formaldehyde into 
toxoid
Reference
% (w/v) 2 
formaldehyde
temperature
(°c)
length of 
incubation
Teissier et al_, 1929 0.12 38 1 mth
Evans, 1940 0.08 37
0
1 wk 
3 wk
Strean and Grant, 1940 0.16 37 10 d
Evans, 1942 0.08 37 2 wk
Roberts and Ospeck,
1942 and 1944;
Ospeck and Roberts,
ND 40 ND
1944
Silverthorne and 0.12 37 10 d
Cameron, 1942
Anderson and North, 0.08 37 7 d
1943
Cravitz and Williams, 0.1^ 40 4 d
1946 0.15° 40 8 d
Yamamoto, Zenyoji and 0.16 37 25 h
Kato, 195 2b
Dolby and Standfast, 0.032 ND ND
1958 and 1961
ND No data
a Assuming formalin is 40% (w/v) formaldehyde
b,c Production of toxoid as described by Joslin and Christensen,
1940 and Weichsel et al, 1940 respectively.
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eratures from 37-40°C,although Evans (1942) followed an initial period 
of incubation at 37°C by storage at 0°Co These conditions are typical 
of those used in toxoiding other bacterial, protein toxins. The duration 
of the incubation period varies greatly from 25 h to 1 mth but detoxifi­
cation may be very rapid under these conditions being complete within 
20-25 h (Evans and Maitland, 1937; Yamamoto, Zenyoji and Kato, 1952b).
Typically the immunization schedules followed to obtain anti­
toxin in rabbits have consisted of a series of injections at 3-7 d inter­
vals with increases in dosage as the immunization progresses. Data, 
from the references already reviewed (appendix 2), reveals that the 
number of injections has ranged from as few as 5 (Anderson and North,
1943) to as many as 27 (Andersen, 1953b). An analysis of the injection 
routes employed (19 references, 23 citations) yields the following; the 
subcutaneous route 13 times, the intravenous route 6 times (including 
figures from 2 studies in which both routes were used; Flosdorf, Bondi 
and Dozois, 1941; Evans, 1942), both subcutaneous and intravenous routes 
in conjunction 3 times and the intramuscular route once (Silverthorne 
and Cameron, 1942). Strean and Grant (1940) and Evans (1942) have found 
subcutaneous injections to be superior to intravenous ones in eliciting 
an antitoxic response eg, 4-32 times higher titres could be obtained 
(Evans, 1942). Flosdorf, Bondi and Dozois (1941) made no distinction 
between the 2 routes merely commenting that antitoxin could be raised by 
either method. Adjuvants have only been used by Andersen (1953b) and 
Nakase e_t ^  (1969) who used Al (OH)^ and Freund's adjuvant respectively. 
One of the most promising immunization schedules seems to be that followed 
by lida and Okonogi (1971) with which antitoxin titres of 40,960 and 
6,400 units/ml were attained, reflecting the numbers of MRD's and MED's 
neutralized in guinea pigs and mice respectively. It is possible 
however that their success may be more closely associated with the use of
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their purified HLT as an immunizing agent. Unfortunately no details are 
provided which could clarify this point.
The development of antitoxic immunity to HLT has most often been 
measured by testing sera in toxin-antitoxin neutralization tests rather 
than challenging immunized animals with HLT (appendix 2)„ Rabbit anti­
sera have been assayed for their capacity to neutralize the dermonecrotic 
property of HLT with rabbits (12 references), guinea pigs (3) and suckling 
mice (Andersen, 1952 and 1953b) as the indicator species. Likewise 
guinea pig, donkey and sheep sera have been tested in guinea pigs (Teissier 
e_t 1929) and horse sera in rabbits (Proom, 1947). Measurement of 
the neutralization of the lethal effect of HLT vitro has been done in 
mice (12 references), suckling mice (Andersen, 1953b) and guinea pigs 
(Evans, 1940). The development of resistance to dermonecrosis has been 
measured in rabbits (8 references) and guinea pigs (Teissier ^  1929)*
Lawson (1933) also adopted this assay method but did not specify the 
animal species used. Other ways of demonstrating antitoxin include the 
in vitro neutralization of the lienotoxicity of HLT for mice (lida and 
Okonogi, 1971) or its cytotoxicity for tissue cultures (Strizova and 
Trlifajova, 1964). It has also been assayed by the passive immunization of 
guinea pigs (Evans, 1940) and mice (Ospeck and Roberts, 1944) to resist the 
lethal effect of HLT, and rabbits the lethal and dermonecrotic activities 
(Ospeck and Roberts, 1944). Actively immunized rabbits have also been shown 
to be resistant to killing by HLT (Evans, 1942; Ospeck and Roberts, 1944).
To determine antitoxin titres by neutralization of HLT vitro 
a constant dose of toxin may be titrated against graded amounts of anti­
toxin or constant serum with varying doses of toxin. Of the references 
listed in appendix 2 the constant toxin-varying serum technique was used 
16 times and the constant serum-varying toxin technique 9 times (3 of 
which were the publications by Roberts and Ospeck). Included in these
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figures were 4 references where both techniques were employed, in 2 of 
which were indicated a preference for the constant toxin-varying serum 
technique (Teissier e_t ad, 1929; Evans, 1940 cf„ Flosdorf, Bondi and 
Dozois, 1941; Smolensand Flavell, 1947). Irrespective of the technique 
used, neutralization is achieved by incubation at either 37°G for between 
1-2.5 h (5 references) or at room temperature for between 30 min to 3 or 
4 h (9 references), although Teissier ^  ^  (1929) held the mixtures at 
the latter temperature for 24 h. The only other conditions used have 
been 1 h at 32°G (Roberts and Ospeck, 1942 and 1944; Ospeck and Roberts,
1944) and overnight at 4°G (Nakase et al, 1969). HLT is neutralized 
in vitro according to the rule of multiple proportions (Evans, 1940;
Proom, 1947) eg, if 10 MRD is inactivated by a 1 in 50 serum dilution 
then 100 MRD would be inactivated by a 1 in 5 dilution of serum.
The relationship between the resistance of immunized rabbits to 
the dermonecrotic effect of HLT and the titres of antitoxin developed as 
assayed by vitro neutralization of dermonecrosis has been investigated 
by Ospeck and Roberts (1944). One hundred and five paired observations 
were made recording the titres of antitoxin and whether a dermonecrotic 
response was made to 3 mouse MLD of HLT. Where titres were as 10 units/ml 
(1 unit neutralizing 1 mouse MLD) only 10% of the rabbits were resistant 
to the skin reaction, at titres between 10 and 50 units/ml 80% were resistant, 
and at titres of over 100 units/ml 90% were resistant. Therefore, resist­
ance to dermonecrosis vivo whilst an index of antitoxic immunity does 
not necessarily go hand in hand with the antitoxin titres measured ^  vitro. 
Hence results such as those obtained by Silverthorne and Cameron (1942) 
where antitoxin was detected in the sera of rabbits which had given 
negative skin tests are possible. The relationship between these tests 
is also borne out in the results obtained by Evans (1942). In contrast, 
the correlation between antitoxic immunity as measured by in vitro neutral-
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ization of the dermonecrotic and lethal effects of HLT in rabbits and 
guinea pigs respectively, and by passive protection of guinea pigs from 
being killed with HLT,were good ie, 3 sera were arranged in the same 
order of potency by these methods (Evans, 1942). However such assay 
procedures do differ in their sensitivity in detecting antitoxin. The 
tests involving neutralization of dermonecrosis are ultimately more 
sensitive than those tests in which lethality is measured and also have 
the advantage of only requiring small amounts of serum.
8.2 Antitoxic immunity and protection in intracerebral and respiratory 
tract infections of mice
To establish whether HLT could act as a protective antigen 
against an intracerebral infection with B. pertussis as in the intracerebral 
mouse protection test, mice have been injected with native and modified HLT 
preparations ie, native toxin (Verwey and Thiele, 1949; Yamamoto £t al,
1952 and 1957), heat-inactivated toxin either by 30 min at 56°C or 5 min 
at 50-55°C (Yamamoto, Zenyoji and Kato, 1952c and Munoz, Ribi and Larson, 
1959 respectively), formaldehyde-detoxified HLT (Onoue, Kitagawa and 
Yamamura, 1963) and alum-precipitated formaldehyde-detoxified HLT (Nakase 
and Kasuga, 1962; Nakase et al, 1969). Except for Nakase £t al (1969)^ 
all of these workers have demonstrated varying degrees of protection in 
response to injections with the aforementioned preparations. However, 
protective and toxic properties can, to a large extent, be separated 
(Verwey and Thiele, 1949; Munoz, Ribi and Larson, 1959; Nakase and Kasuga, 
1962). Indeed Nakase ^  al (1969) found their purified HLT to lack 
protective activity. Overall the data so far are inconclusive: where 
protection has been demonstrated other B. pertussis components could be 
implicated and where it was absent the development of antitoxic immunity 
was not confirmed. The use of passive protection tests to determine the
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role of antitoxic immunity has likewise not been conclusive. The pro­
tection afforded by serum given before an intracerebral challenge with the 
intracerebrally virulent strain 18323 has been shown to be independent of 
the antitoxic content of the serum (Dolby and Standfast, 1958). Conse­
quently sera with high titres of antitoxin may lack protective activity 
(Kuwajima ajL, 1958), However whether protection could be afforded by 
antitoxin if serum and challenge were given mixed together has not been 
fully investigated. Yamamoto e_t aT (1955) found sera with very low 
titres of antitoxin protective in such IC/mix experiments but protection 
might have been due to antibodies other than those to HLT. Antitoxic serum 
given intracerebrally 2-5 d after the intracerebral challenge is without 
effect (Dolby and Standfast, 1961).
Antitoxin may be protective when given before an intracerebral 
challenge with the toxigenic intermediate phase strain No. 33 (Ospeck and 
Roberts, 1944; Kuwajima £_1, 1958), Whether the antibodies responsible 
were directed against HLT or other B. pertussis components is unresolved, 
as is the relationship between the protective effect being measured here 
and in the standard mouse protection test.
The importance of antitoxic immunity to B. pertussis respiratory 
tract infections in mice is also unresolved. Mice immunized with formal­
dehyde-detoxified HLT were protected against a lethal intranasal challenge 
with Bl, pertussis (Anderson and North, 1943). However, mice-immunized 
intensively with this material failed to exhibit any antitoxic immunity as 
measured by the development of resistance to the lethal effect of HLT.
Mice have also been passively protected against lethal and sub-lethal 
infections by the parenteral administration of antitoxic sera before or 
very shortly after an intranasal challenge with B. pertussis (Anderson and 
North, 1943; Evans, 1944; Proom, 1947). In 2 of these instances
once the sera were absorbed with B. pertussis cells,
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until all traces of agglutinins were gone, the protective activity was 
also lost although the antitoxic properties were retained (Anderson and 
North, 1943; Evans, 1944). In the 3rd instance some protection was 
claimed for an absorbed antitoxic serum but the data were not very con­
vincing (Proom, 1947). Antitoxic serum instilled intranasally up to 24 h 
before (North, 1946) or with the challenge (Evans, 1944; North, 1946;
Dolby and Standfast, 1958) were protective against lethal and sub-lethal 
infections even after absorption (Evans, 1944; North, 1946). However, 
North (1946) also demonstrated protection with an absorbed adult contact 
serum in which there had been no antitoxin. Therefore credit for the 
protection afforded by the absorbed antitoxic sera clearly cannot be, 
without reservations, attributed to anti-HLT antibodies.
8.3 Antitoxic immunity in humans
Little or no antitoxin, as assessed by assaying sera for neutral­
izing antibodies to HLT, is produced in response to pertussis. When 
Evans and Maitland (1939) and Evans (1947) tested 63 sera (23 and 40 
respectively) taken during the course of the illness,and Flosdorf, Bondi 
and Dozois (1941) pooled convalescent serum,no antitoxin was detected. 
However Weichsel, Katona and Liu (1942) detected antitoxin, albeit in low 
titres, in some of the sera taken from 16 children during and whilst con­
valescing from pertussis. Low titres of antitoxin have also been demon­
strated in children following recovery from the disease, Strean, Lapointe 
and Dechene (1941) recorded positive results with 7 of 10 sera and Cravitz 
and Williams (1946) with 3 of 24 sera. In contrast, Weichsel, Katona
and Liu (1942) found sera from children with and without a history of 
pertussis to be indistinguishable. Sera taken from adults, including 
contact sera and sera from persons with a history of pertussis, have shown
little (Weichsel, Katona and Liu, 1942) or no antitoxin (North £t al,
1939; Weichsel, Katona and Liu, 1942; Evans, 1947).
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The response to HLT injected into the skin may also be 
indicative of the absence or presence of antitoxic immunity to HLT, 
Antitoxin has been demonstrated in a small number of children who gave 
negative skin responses (7 and 3) but not in those in whom a skin 
reaction developed (3 and 2) (Strean, Lapointe and Dechene, 1941 and 
Cravitz and Williams, 1946 respectively). Also by the passive adminis­
tration of antitoxin, positive responders have been converted into 
negative responders (Strean, Lapointe and Dechene, 1941). Furthermore 
skin test results have correlated with the data on the histories of 
individuals as regards pertussis (Strean, 1940; Strean, Lapointe and 
Dechene, 1941; Kunstler, 1945; Cravitz and Williams, 1946) and with 
immunity as measured by opsonizing and agglutinating anti-pertussis 
antibodies (Cravitz and Williams, 1946). Mainly on the basis of skin 
test results it has been suggested by these workers that the newborn can 
possess passively acquired maternal antibodies to HLT. These results 
suggest that the development of antitoxic immunity is far more common than 
indicated in the aforementioned studies in which sera were assayed for 
neutralizing antibodies to HLT. On the other hand, it has been reported 
that the skin test may fail to differentiate between children with and 
without a history of pertussis (eg, Weichsel et al, 1940; Silverthorne, 
Fraser and Brown, 1944 cited by Evans, 1947). Moreover, the skin test 
was of no value in distinguishing between vaccinated and un-vaccinated 
children (Cravitz and Williams, 1946),
In response to active immunization with toxoided HLT or a 
vaccine with a toxoid component antitoxin has been produced in children 
(BuiIowa 2Ë £1.» 1942; Weichsel, Katona and Liu, 1942; Cravitz and 
Williams, 1946) and protection against pertussis demonstrated (Joslin 
and Christensen, 1940; Brereton, 1946; Lapointe, 1946). Likewise
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passively administered antitoxin has been claimed to be of value 
therapeutically,especially if given early in the disease (Strean, 
Lapointe and Dechene, 1941; Strean, 1942 and 1943), and prophylactically 
(BuiIowa et al, 1942),
OBJECT OF RESEARCH
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The heat-labile toxin (HLT) of Bordetella pertussis has been 
relatively neglected by most recent investigators studying this organism. 
Yet this is the principal toxin of B. pertussis as judged by the lethal 
toxicity test in mice. Its mode of action is undefined, its possible role 
in pathogenicity and immunity unclear^ and only one group of investigators 
claim to have obtained it in a pure state* The present limited study does 
not attempt to deal with all of these aspects where knowledge is lacking. 
Instead attention has been directed at the following questions
a) Is HLT production suppressed during antigenic variation?
b) Is there any uniquely suitable strain of B* pertussis for
maximal HLT production?
c) Is there a particular medium which favours HLT production and
what is the preferred time of harvest?
d) Does iron in the culture medium affect toxin production?
e) Can previously published methods for purifying HLT be 
repeated or adapted?
f) What is the molecular weight of HLT?
g) Can HLT be toxoided?
h) Is HLT toxoid immunogenic?
i) Does anti-HLT protect mice against experimental infection?
Some of these questions appear not to have been studied 
previously, others represent attempts to confirm earlier work*
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Before investigating any of the above, the following questions 
relating to the assay and storage of HLT were answered:-
i) Do mouse weight and sex affect the responsiveness of mice to the
lethal toxicity of HLT?
ii) Has HLT haemolytic activity?
o
iii) How stable is HLT on storage at -20 C?
MATERIALS AND METHODS
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SECTION I BACTERIOLOGICAL MATERIALS AND METHODS 
1 Organisms
Strain 18334, a vaccine strain, was obtained from Connaught 
Laboratories Ltd*, Toronto, Canada,
Strain 18323, the intracerebral challenge strain for the mouse 
protection test, was obtained from 3 sources, viz.,
i) Strain 18323 (BOB) from Dr. M. Pittman, Bureau of Biologies (BOB),
Food and Drug Administration, Bethesda, Maryland 20014, USA,
ii) Strain 18323 (L6d H2) from Dr. F*W. Sheffield, Division of Immuno­
logical Products Control, National Institute for Medical Research, 
London, England.
iii) Strain 18323 (L4a) from Dr. P. Kendrick, Michigan Department of
Public Health, Michigan 48909, USA.
Strain 134, used by Pillemer (1950) in the preparation of his 
protective antigen (adsorbed onto human red cell stromata).
Strain MAENO, supplied by Professor Y* Nakase, Kitasato Instit­
ute, 5-9-1 Shirokane, Minato-Ku, Tokyo 108, Japan.
Strain No. 28, provided by Dr* P. Novotny, Wellcome Research 
Laboratories, Beckenham, England.
Strain B-1593/57 from Dr. V* Spasojevic, Institute of Immuno­
biology and Virology, Torlak, Vojvode Stepe 458, Belgrade, Yugoslavia,
Strain 44122/7R, a streptomycin-res is tant mutant derived from 
a vaccine strain 44122/7 and used at the State Bacteriological Laboratory, 
Stockholm, Sweden. Obtained from Dr* Po Branefors, University of
I)
Goteborg, Institute of Medical Microbiology, Department of Bacteriology,
If
Guldhedsgatan 10, S-413 46 Goteborg, Sweden*
Strain 18904 L4, from Dr* P* Kendrick, Michigan Department of 
Health, Grand Rapids, Michigan, USA.
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Strains 77/18319 and 77/24833 were obtained as fresh isolates 
from Dr* R, Fallon, Department of Bacteriology and Immunology, Ruchill 
Hospital, Glasgow, Scotland*
Strains GL353Z, L84 I, 3865, D30042 I, D30042 IV, D3148 I and 
D3148 IV were originally supplied by Dr* J, Dolby, Clinical Research Centre, 
Harrow, England. The designation IV indicates phase IV variants.
2 Culture media
2.1 Bordet-Gengou medium
Twenty grams of dried Bordet-Gengou agar base (Gibco Bio-Cult 
Diagnostics Ltd., Paisley, Scotland) was added to 500 ml of a 1% (v/v) 
solution of glycerol (BDH, Poole, England) in distilled water. The agar 
base was dissolved by being heated to 100°C with frequent agitation* It 
was then sterilized by autoclaving at 121^C (15 psi) for 15 min* After 
cooling to 45-50^C, 100 ml of sterile, 37°C defibrinated horse blood (Gibco 
Europe) was added aseptically, mixed,and the completed medium poured into 
sterile, 50 or 90 mm diameter plastic petri dishes (Sterilin Ltd*, 
Teddington, Middlesex, England).
After the medium had solidified the plates were returned to the 
sterile plastic sleeves in which the empty dishes are supplied and the 
sleeves were sealed with tape* Plates were stored at 4°C and used within 
2 wk.
2.2 Charcoal agar
Dehydrated charcoal agar (Difco Laboratories, Detroit 1,
Michigan, USA) was suspended in distilled water to a concentration of 
62.5 g/1, heated to boiling with frequent stirring,and sterilized by 
autoclaving at 121°C (15 psi) for 15 min. After cooling to 45-50°C,the 
medium was swirled to obtain a uniform suspension of the charcoal and 
dispensed into sterile plastic petri dishes or universal containers to be
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slanted. The medium was stored at 4°C, the plates being wrapped as for 
Bordet-Gengou plates.
Both Bordet-Gengou medium and charcoal agar were prepared on 
occasions with nicotinic acid (BDH, Poole, England) added to a final con­
centration of 500 pg/mlo
2,3 Modified Hornibrook medium
This medium is a modification of the recipe of Hornibrook (1939) 
as described by Parton and Wardlaw (1975)*
Materials per 10 1
i Casamino acids, Difco technical 100 g
ii CaCl^ (anhydrous) 0*02 g
iii NaCl 50 g
iv KCl 2 g
V  Nicotinamide (BDH, Poole, England), 10 ml
0*1% (w/v) solution
vi MgCl^.bH^O, 1% (w/v) solution 25 ml
vii K^HPO^, 10% (w/v) solution 25 ml
viii Soluble starch (BDH, Poole, England) 10 g
ix Glutathione (Sigma Chemical Company, St* Louis,
MO, USA), 0.1% (w/v) solution 100 ml
The ingredients i-iv were dissolved in 800 ml of distilled 
water and the freshly prepared solutions v, vi and vii added. The starch 
was suspended in 25 ml of distilled water and this added, with immediate 
mixing, to 175 ml of boiling distilled water. This mixture was brought 
back to the boil and added to the rest of the medium* The volume was 
made up to I I and the pH adjusted to 7*0 with approximately 0*45 g of 
Na2C02. This 10 times concentrate was dispensed in 100 ml amounts in
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screw cap bottles, sterilized by autoclaving at 121°C (15 psi) for 15 min, 
cooled and stored at 4°C*
Prior to use 100 ml of concentrate was added to 890 ml of dist­
illed water in a 2 1 dimpled conical flask and autoclaved at 121°C (15 psi) 
for 15 min. Immediately before use 10 ml of Seitz filter sterilized 
glutathione solution (0.1% (w/v)) was aseptically added to give Hornibrook 
X-medium, Hornibrook C-medium was prepared by replacing the 50 g of NaCl 
with 50 g of MgSO^oyn^O, other ingredients being the same*
2.4 Stainer and Schblte (12G) medium
This is the chemically defined medium described by Stainer and 
Scholte (1971) except that the amount of Tris buffer has been reduced to 
one-quarter of that in the original formulation (a modification suggested 
by Stainer, 1977; personal communication) and L-cysteine replaces cystine.
Materials g/1
i L-glutamate, monosodium salt, (BDH, Poole,
England) 8*04
ii NaCl 2*5
iii KH.PO. 0.5
2 4
iv KCl . 0.2
V  M g C l 2 . 6 H 2 0  0.1
vi CaCl^ 0.02
vii Tris (hydroxymethyl) amino methane,
(Sigma Chemical Company, St. Louis, MO, USA) 1*52
viii L-cysteine (BDH, Poole, England) 0,04
ix Fe2S0^.7H20 0*01
X Ascorbic acid (BDH, Poole, England) 0,02
xi Nicotinic acid (BDH, Poole, England) 0*004
xii Glutathione (Sigma Chemical Company, St. Louis,
MO, USA) 0*1
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Ingredients i-vii were dissolved in 800 ml of distilled water 
and the pH adjusted to 7*6 with 2.5N HCl* The volume was made up to 
990 ml with distilled water and the medium sterilized by autoclaving at 
121°C (15 psi) for 15 min*
Immediately before use ingredients viii-xii were dissolved in 
distilled water, sterilized by membrane filtration (0.45 pm pore size; 
Millipore SA, Molsheim, France) and aseptically added to the remainder of 
the ingredients* To allow for losses during filtration more of the 
solution was made than the 10 ml required per litre of medium*
3 Growth of cultures 
3*1 Stock cultures
Freeze-dried cultures were reconstituted with sterile 1% ( w / v )  
casamino acids solution (see below) and plated onto Bordet-Gengou medium* 
Plates were incubated at 35°C for 3 or 4 d in a closed plastic box con­
taining a beaker of water to saturate the atmosphere* From this growth 
stock cultures were prepared on Bordet-Gengou plates or charcoal agar 
slopes. Cultures in sealed Bordet-Gengou plates or charcoal agar slopes 
remained viable at 4°C for 4-6 wk*
Casamino acids solution, 1% (w/v), was prepared as follows :- 
Materials g/1
Casein hydrolysate acid, peptone No, 5
(Gibco Bio-Cult Diagnostics Ltd*, Paisley, Scotland) 10,0 
MgCl^obH^O 0.1
CaCl^ 0*016
NaCl 5.0
The ingredients were dissolved in 950 ml of distilled water, 
the pH adjusted to 7,1 with IN NaOH and the volume was made up to 1 1* 
After dispensing into suitable volumes the solution was autoclaved at 
121°C (15 psi) for 15 min.
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3*2 Intracerebral and intranasal challenge cultures
Challenge cultures were prepared from stock suspensions of 
B* pertussis in casamino acids solution (see above) containing 20% (v/v) 
glycerol. These were stored frozen in sealed, sterile, plastic ampoules 
(Sterilin Ltd., Teddington, Middlesex, England) in liquid nitrogen* The 
frozen suspension was thawed at room temperature, plated onto 2 or 3 
Bordet-Gengou plates and incubated at 35^C for 3 d in a water saturated 
atmosphere* "Puddle plate" cultures were prepared from this growth as 
follows:- a heavy inoculum was emulsified in 3 or 4 drops of 1% (w/v) 
casamino acids solution on the surface of a Bordet-Gengou plate to give a 
confluent inoculum in the centre of the plate* Incubation proceeded as 
already described for 24 h and the growth used to prepare challenge 
suspensions *
3.3 Shake-flask cultures
For larger scale growth 500 ml or 1 1 volumes of medium in 2 1 
conical shake-flasks were used. These were inoculated with 24-48 h seed 
cultures either in the form of a generous loopful of Bordet-Gengou grown 
cells or as a liquid seed culture (1-5% (v/v) inoculum)* The flasks 
were then incubated at 35°C in an orbital shaker set at 80 rpm* Cultures 
were most commonly harvested after 48 or 72 h of growth* The purity of 
each culture was checked by Gram-staining and by inoculation onto Bordet- 
Gengou medium*
3*4 Roux bottle cultures
These were used on only one occasion* One hundred millilitre 
volumes of medium in Roux bottles were inoculated with a loopful of 
Bordet-Gengou grown cells and incubated laid flat at 35^C for 4 d*
Bottles were gently rocked once or twice a day to suspend any sedimented 
growth. Purity was determined as for shake-flask cultures*
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4 Harvest of cultures
Liquid cultures were harvested by centrifugation for 30 min at
10,000 X  g  and 4^C* The supernatant fluid was carefully decanted and the 
cell pellets were evenly suspended, unless otherwise stated, in Dulbecco 
"A" PBS (Oxoid Ltd,, England).
Cultures were harvested from solid medium by scraping the cells 
off with a loop or by suspending them in Dulbecco "A" PBS and sucking them 
off with a Pasteur pipette* If required, celIs were washed with Dulbecco 
"a " PBS to remove constituents of the medium before re-suspension*
5 Standardization of bacterial concentration by opacity
The concentration of bacterial suspensions was estimated by 
comparison with the 5th International Opacity Reference Preparation (desig­
nated as having an opacity of 10 international opacity units) . The opacity 
reference was supplied by the World Health Organization International 
Laboratory for Biological Standards (National Institute for Biological 
Standards and Control, London, England)*
The dilution factor necessary to obtain matching of the cell 
suspension with the reference preparation was multiplied by 10 to give 
the concentration of the undiluted bacterial suspension in opacity units 
(ou)* The matching was done visually with the 2 tubes held in front of 
a card bearing rows of bold print.
When a cell suspension was disrupted the concentration was 
still described in terms of opacity ie, opacity(unit equivalents (oue)): 
the concentration of the lysate being directly equivalent to the cell 
suspension from which it was derived*
6 Estimation of viable cell numbers
Serial dilutions of cultures were made in a 1% (w/v) casamino 
acids solution (for its preparation see Materials and Methods; section 
I, 3.1), and duplicate 0.05 ml amounts of appropriate dilutions spread on
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Bordet-Gengou plates and incubated at 35°C for 4 d in a water saturated 
atmosphere. Plates with countable numbers of colonies were selected and 
from these an estimate made on the number of colony forming units per ml 
of the original suspension,
SECTION II BIO-ASSAY METHODS
1 Mice
Mice were from a randomly-bred closed colony, originally 
derived from the Ham/ICR strain (Charles River, UK Ltd*). For the 
following bio-assays mice of either or both sexes were used. Where both 
sexes were used they were divided equally between test preparations to 
avoid possible bias*
2 Toxicity tests
2.1 Mouse lethal toxicity test
Mice of 3-4 wk of age were injected intraperitoneally with 0,5 ml 
volumes of graded doses of B* pertussis samples* Groups of mice were 
arranged such that the weight distribution of the mice in each group was 
similar* Deaths of mice were recorded in the 3 d post-injection period,
2.2 Haemorrhagic activity in suckling mice
Four day old mice were injected subcutaneously in the back of 
the neck with 0,05 ml volumes of graded doses of B* pertussis samples. 
Twenty-four hours later, any deaths were recorded and haemorrhagic reactions 
were scored on a l-f to 4+ scale (plate 8)*
Neutralization of the haemorrhagic reaction was used as an index 
of the antitoxin content of antisera. Dilutions of antiserum were mixed 
with equal volumes of toxin giving a final concentration of 1 minimum 
reactive dose (MRD) of toxin per 0,05 ml (ie, toxin producing a 1+ 
haemorrhagic reaction; see plate 8)* As a control, normal rabbit serum 
was titrated in parallel with the antiserum under test* Mixtures were
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Plate 8 Haemorrhagic effect of HLT in suckling mice
Haemorrhagic reactions are graded on a 1+ to 44- scale.
One minimum haemorrhagic dose of toxin produces a l-f reaction,
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incubated at room temperature (20-24^C) for 2 h and then assayed for toxin 
as already described* One unit of antitoxin was taken as the smallest 
amount of antiserum producing complete neutralization of 1 minimum haemorr­
hagic dose of toxin*
2,3 Haemolytic activity
HLT was assayed for its ability to lyse sheep, rabbit, horse, 
human (0^  rhesus +) and cod red blood cells suspended in either Dulbecco "A" 
PBS (Oxoid Ltd*, England) or citrate dextrose saline (cod red cells only)*
To doubling dilutions of HLT made in the U-shaped wells of a WHO tray were 
added equal volumes (0.5 ml) of washed (4 times) red cells at a concen­
tration of l7o (v/v). Control wells without toxin were included. After 
gentle mixing the cell suspensions were incubated at 35°C for 30 min before 
being examined for the development of haemolysis*
3 HSF assay
Mice of 7-8 wk of age were injected intraperitoneally with 0*5 ml 
of graded doses of vaccine, ie, heat-detoxified (56^0/30 min) B* pertussis 
cells or cell fraction. After heating, thiomersal (BDH, Poole, England) 
was added to a final concentration of 0*1 mg/ml and the preparation 
stored at 4°C.
Five days after vaccination the mice were challenged intra­
peritoneally with 3 mg of histamine dihydrochloride (Sigma Chemical 
Company, St. Louis, MO, USA) contained in 0*5 ml of Dulbecco "A" PBS (Oxoid 
Ltd., England)* Four hours later a count was made of the number of mice 
dead*
4 LPF assay
Groups of 5 mice of 4-5 wk of age were injected intravenously 
with 0*2 ml of graded doses of samples. Control mice were inoculated
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with Dulbecco "a " PBS (Oxoid Ltd*, England), ie, the diluent in which the 
4-fold dilutions of samples were made* Five days after inoculation mice 
were anaesthetized with ether and bled from the orbital plexus with 
heparinized capillary tubes (Harshaw Chemicals Ltd*, Daventry, England)*
The blood samples (40 pi) were immediately transferred with a Coulter 
pipette into plastic vials containing 20 ml of Isoton 11 diluent (Coulter 
Electronics Ltd*, Harpenden, England),
Immediately before counting, 6 drops of Zap-O-Globin (Coulter 
Electronics Ltd*, Harpenden, England) were added to each vial to lyse the 
red blood cells. Enumeration of leukocytes was done using a Coulter 
Counter, model FN (Coulter Electronics Ltd*, Harpenden, England)* Dup­
licate or triplicate counts of each diluted blood sample were made and 
the mean value calculated for each sample* To correct for coincidence 
losses during counting, mean counts above 10,000 were adjusted by consulting 
a coincidence correction chart* Mean background counts, from diluent 
alone, were subtracted from each corrected count to obtain the final 
corrected mean count for each sample*
5 Passive intracerebral mouse protection test
Rabbit antisera were tested for their ability to protect groups
of 10, 3-4 wk old mice against a lethal intracerebral challenge with
B* pertussis^viz.10^ cfu of the intracerebrally virulent strain 18323
L6d H2* This was notionally equivalent to 10^ organisms on the basis
that a suspension of 10 ou equals 10^^ organisms/ml* The virulence of
the challenge culture was checked by injecting groups of mice with 10^,
3 2
2 X 10 and x 10 organisms per mouse in addition to the challenge 
controls which received 10^ organisms* Mice were distributed so that
each cage contained animals representing each type of treatment* Intra­
cerebral injections (0,03 ml/ether anaesthetized mouse) were always
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completed within 3 h of harvesting the cells after which the viability of 
the organisms in the challenge suspensions was rechecked.
Antisera were assayed for their protective capacity either by 
giving 0,2 ml of undiluted serum intraperitoneally 1-4 h before the 
challenge (IP/IC) or by mixing equal volumes of heat-treated antiserum 
with the challenge organisms suspended in 1% (w/v) casamino acid solution 
(IC/mix). The heating of these sera (56°C/10 min) was to eliminate the 
possibility of complement mediated killing of the challenge. Cells were 
suspended in 1% (w/v) casamino acids solution for all IP/IC challenges and 
for IC/mix challenge controls* However cells suspended in normal rabbit 
serum were usually also included as controls for IC/mix experiments*
For 14 d after the intracerebral injections mouse deaths were 
recorded. Mice dying within 2 d of the challenge were excluded from the 
final count,not being considered "infection deaths"* Differences between 
the results from control and test groups were tested for their statistical 
significance by consulting 2 x 2  contingency tables (Finney 1963).
6 Passive intranasal mouse protection test
Rabbit antisera were tested for their ability to protect 3-4 wk 
old mice challenged with a sub-lethal intranasal dose of B. pertussis 18323 
(L6d H2 or L4a), The number of organisms instilled intranasally was 10^ 
cfu (or 10^ organisms on the assumption that a suspension of 10 ou equals 
10^^ organisms/ml)* The challenge was given to the ether anaesthetized 
mice in 2 (0*025 ml) drops from a dropping pipette (Cooke Engineering 
Company, Medical Research Division, Virginia, USA)* Mice were caged such 
that each cage contained animals representing each type of treatment. All 
challenges were completed within 3 h of harvesting the cells after which 
their viability was rechecked*
Antisera were also tested for their protective capacity when
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mixed with the challenge organisms (iN/mix), Equal volumes of cells 
suspended in 1% (w/v) casamino acids solution and heated antisera were 
mixed* Sera were heated (56°C/10 min) to prevent complement mediated 
killing of the challenge* Controls included cells suspended in 1% (w/v) 
casamino acids solution and, in most instances, cells mixed with heated 
normal rabbit serum* One antiserum (B) was also tested by injecting 
0*2 ml intraperitoneally into mice 1-3 h before a challenge with cells 
suspended in 17* (w/v) casamino acids solution*
The mice were inspected daily for 14 d and deaths recorded.
On day 14 the remaining mice were killed and the lungs inspected for signs 
of consolidation ie, greyish discoloured areas* Healthy lungs were 
scored as 0 and infected lungs from 1+ signifying a few small areas of 
consolidation to 44- for complete or almost complete consolidation in all 
lobes of the lungs. A snippet of lung from the smallest of the right 
hand lobes was also taken and the cut surface smeared onto a Bordet-Gengou 
plate. After 4-5 d of incubation at 35°C scores were allocated for the 
resultant B. pertussis growth viz* 0, no growth; 14-, 1-9 colonies; 24-, 
10-99; 34-, 100-semi confluent; 44-, confluent* The scores for lung
pathology and culture were combined, giving totals ranging from 0 to 8, 
and the statistical significance of differences in the results from control 
and test groups assessed in the Mann-Whitney U-test* The arithmetic mean 
of the combined scores was also calculated as an index of the severity of 
the infections. Differences in the numbers of mice infected in the 
control and test groups were tested for their statistical significance by 
consulting 2 x 2  contingency tables (Finney al_, 1963), Mice were 
considered to be infected if they had positive lung pathology and/or 
culture*
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SECTION III BIOCHEMICAL MATERIALS AND METHODS
1 Analytical
1*1 Protein estimations
For estimation of soluble proteins the method of Lowry e_t a_l 
(1951) was used* Where the protein content of cell— lysates or crude cell- 
envelope preparations was to be determined a slightly modified Lowry method 
was used (Herbert, Phipps and Strange, 1971)* Bovine serum albumin 
(Fraction V, Sigma Chemical Company, St* Louis, MO, USA) was used as a 
standard*
The protein content of fractions from chromatographic columns 
was monitored by measuring the absorbance at 280 run in a Pye Unicam SP500 
spectrophotometer with a quartz 1 cm flow through cell linked to a SP40 P 
automatic sample changer and a SP22 chart recorder,
1,2 Iron estimations
For the determination of iron in culture media the method of 
Herbert, Phipps and Strange (1971) was used.
Reagents (all from BDH, Poole, England)
2,2*-Bipyridyl : 1 g was dissolved in 100 ml of 1% (w/v) hydrochloric
acid
Reducing reagent : 3*5 g of hydroxyammonium chloride was dissolved
in 100 ml of distilled water 
Acetate solution ; 355 g of AR grade ammonium acetate was dissolved
in distilled water and diluted to 500 ml 
6M Perchloric acid ; 265 ml of 72% AR grade perchloric acid was diluted
to 500 ml with distilled water
Stock standard iron
solution , : 0,4318 g of AR grade ferric ammonium sulphate was
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dissolved and diluted to 100 ml with 0*1N hydro­
chloric acid to give a solution containing 0*5 mg 
iron/ml
Working iron standard: 10 ml of stock iron solution was diluted to 250 ml
with distilled water to give a solution containing 
20 |ig iron/ml* This was prepared freshly for 
each day of testing
Culture medium (10 ml, containing not more than 2 pg iron/ml)
5
was measured into a 6 x in.test tube and mixed with 1 ml of 6M per­
chloric acid* This was held at 4°C for 30 min after which the following 
additions were made with mixing at each step; ammonium acetate solution 
(1 ml), hydroxylamine solution (1 ml) and bipyridyl solution (1 ml)* The 
mixture was then diluted to 15 ml* After standing 15 min the extinction 
of the solution was measured at 525 mm against a blank solution containing 
distilled water in the place of the sample but all the other reagents 
added. Standards containing 5, 10, 15 and 20 pg of iron were treated in 
parallel with test samples and blanks*
1*3 Sodium dodecyl sulphate, polyacrylamide gel electrophoresis 
(SDS-PAGE)
Polyacrylamide slab gel electrophoresis in the presence of SDS 
(sodium dodecyl sulphate) was done using a discontinuous buffer system.
The method used was based on those of Laemmli (1970) and Ames (1974)*
Separating and stacking gels contained 11% and 5% (w/v) acryl- 
amide (BDH, Poole, England) respectively* Both the gels and the electrode 
buffers contained 0.1% (w/v) SDS* Gels were prepared in glass moulds 
8*0 X  7*0 X  0,3 cm, the separating gels being 5,5 x 7*0 x 0*3 cm*
Samples were adjusted to 2 mg protein/ml and 0.5 ml was added 
to 0.5 ml of solubilizing buffer and heated at lOO^C for 5 min* Samples
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of 25-50 pi were applied to the wells in the stacking gel and electrophoresed 
in a Uniscil slab gel electrophoresis unit (Universal Scientific Ltd*,
London) at a constant current of 15 rnA/gel for 2-3 h. For staining and 
destaining, the method of Weber and Osborn (1969) was used.
For molecular weight determinations marker proteins were run 
alongside the samples * The marker proteins included bovine serum albumin 
(mwt 67,000 Sigma Chemical Company, St* Louis, MO, USA), ovalbumin (mwt
44,000 Sigma Chemical Company, St* Louis, MO, USA), chymotrypsinogen 
(mwt 25,700 Miles-Serravac, Maidenhead, England), trypsin (mwt 23,300 
Armour Pharmaceuticals, Eastbourne, England) and horse heart cytochrome c 
(mwt 11,700 Koch-Light, Colnbrook, England),
For further details refer to appendix 3*
1*4 Molecular weight determination by gel filtration
The molecular weight of HLT was estimated from its movement on 
a column of Ultrogel AcA 44 (LKB-Produkter AB, Sweden)*
The column (1*5 x 84 cm) was equilibrated with 4°C, 0.15M, 
pH 7*4 potassium phosphate buffer (ie, 19 parts 0*15.M KH^PO^ to 81 parts 
0*15M K^HPO^). The void volume (Vo) was determined from the elution 
position of dextran blue 2000 (0.75 ml of 5 mg/ml buffer; Pharmacia Fine 
Chemicals Ltd*, Uppsala, Sweden)* Then the elution volumes (Ve) for 3 
standard proteins (Sigma Chemical Company, St* Louis, MO, USA) of known 
molecular weights were found viz. lysozyme (grade 1 reagent, mwt 14,400), 
ovalbumin (grade V reagent, mwt 44,000) and human serum albumin (fraction 
V, mwt 66,500), Samples (0*75 ml of 5 mg protein/ml buffer) were run 
individually. For each standard protein the ratio of elution volume (Ve) 
to void volume (Vo) was calculated and plotted against molecular weight 
to give a straight line* Finally the toxin, the 30-50% ammonium sulphate 
fraction from a B* pertussis lysate supernatant fluid, was applied to the
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calibrated column* As before a 0.75 ml sample was used (25 mg protein/ml 
buffer)* As for all other samples the flow rate was 2-3 ml.cm ^*h  ^ and
1 ml fractions were collected* From the ratio of Ve/Vo for the toxin a 
molecular weight value was obtained from the standard curve*
The elution of samples was monitored spectroscopically as 
described earlier (Materials and methods; section III, 1*1) with the 
wavelength set at 280 nm for protein samples and 620 nm for dextran blue* 
The position of the HLT was established by scanning fractions for their 
haemorrhagic activity in suckling mice*
2 Preparative
2*1 Use of the X-press and ultracentrifugation
B* pertussis cells suspended in Dulbecco "a " PBS (Oxoid Ltd*, 
England), unless specified otherwise, were lysed by 2 or 3 presses in an 
X-press (LKB Instruments Ltd*, South Croydon, England)* Lysates were 
centrifuged at 100,000 x g, for 1 h at 4°C to separate the crude cell- 
envelope material from the lysate supernatant fluid*
2*2 Ion-exchange chromatography.
The suitability of ion-exchange chromatography as a method of 
purifying HLT was investigated* The anion-exchange resin diethylamino- 
ethyl (DEAE) cellulose (grade DE 11; Whatman Biochemicals Ltd*, Maid­
stone, England) was chosen and a column (2.6 x 22 cm) was prepared at 4°C 
in pH 8*0, 0*005M phosphate buffer (ie, 5*3 parts 0.005M KH^PO^ to 94*7 
parts 0.005M K^HPO^)* Onto this was fed 26 ml of toxic lysate super­
natant fluid (5*7 mg protein/ml; 645 LD^^/ml) derived from cells suspended
in the 0*005M phosphate buffer used to equilibrate the column. This was
-2 -1
eluted, at a rate of 7 ml*cm ,h , in a stepwise fashion using a series 
of phosphate buffers of increasing ionic strength (0*02M, 0,05M or O.lM, 
and 0.2M, all pH 7.6 viz, 19 volumes KH^PO^ to 81 volumes K^HPO^ at the
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appropriate molarities) and finally by lowering the pH of the 0.2M buffer. 
Buffers were changed after the proteins discharged by the previous buffer 
had been eluted. The elution of the 6 ml samples was monitored at 280 nm 
(Materials and methods; section III, 1). The presence of HLT in 
fractions was determined by injecting 0.5 ml into 3-4 wk old mice and 
recording the deaths over a 3 d period.
2.3 Ammonium sulphate fractionation
In pceliminary experiments lysate supernatant fluids were 
fractionated by the addition of ammonium sulphate in the quantities used 
by Onoue, Kitagawa and Yamamura (1963). Ammonium sulphate was dialysed 
overnight (4°C) into the sample to a final concentration of 16% satur­
ation. The precipitate (16% ppt) was collected by centrifugation (17,300 
X g, 25 min, 4^C) and more ammonium sulphate was added to the supernatant 
fluid as already described. Again the precipitate (16-40% ppt) was 
separated from the supernatant fluid (40% S). During these "salting out" 
steps the pH was kept at 7.4, where necessary, by the addition of ammonium 
hydroxide. Finally precipitates were suspended and dialysed, as was 
the 40% S fraction, against Dulbecco "A" PBS (Oxoid Ltd., England) unless 
otherwise specified.
The figures given for the percentage saturation were determined 
from a nomogram for ammonium sulphate solutions (Dixon, 1953). These 
percentages (16% and 40%) do not however agree with those given by Onoue, 
Kitagawa and Yamamura (1963) ie, 12% and 32% respectively.
In subsequent experiments the lysate supernatant fluids were 
treated with DNase (DNase 1. EC 3.1.4.5; Beef pancreas, noncrystalline; 
Sigma Chemical Company, St. Louis, MO, USA) or DNase and RNase (RNase A; 
Bovine pancreas, type 1-A, protease free; Sigma Chemical Company, St. 
Louis, MO, USA). These were added to a final concentration of 50 pg/ml
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and allowed to act at 30°C for 15 min* Alterations were also made to 
the amount of ammonium sulphate added (eg, 30%, 50% and 70% saturation, 
as calculated for the percentage saturation at 0°C). Otherwise the method 
was kept the same*
2*4 Gel filtration
Gel filtration was used in the purification of HLT from the
ammonium sulphate 30-50% precipitates* Ultrogel AcA44 (LKB-Produkter AB,
Sweden), an acrylamide/agarose gel filtration medium with an effective
fractionation range of 10,000-130,000 daltons (for globular proteins), was
prepared as a 2,6 x 40 cm column in pH 7*4, 0.15M potassium phosphate
buffer at 4°C (ie, 19 parts 0*15M KH^PO^ to 81 parts 0*15M K^HPO^)*
In the first experiment a 6 ml sample (2.8% loading) was
-2 -1
applied, run through the column at 4*4 ml*cm *h and collected in 5 ml
fractions* In later experiments the sample size was decreased (to » 2,5
-  2 -1
ml a 1*2% loading) as was the flow rate (eg, 3*2 ml*cm ,h ) and the size 
of the fractions collected (ie, 3*1 ml)* The samples applied to the 
column contained between 20-30 mg protein/ml*
The eluant was monitored at 280 nm as already described 
(Materials and methods; section III, 1*1) and the toxicity of the fractions 
determined by testing them in suckling mice for haemorrhagic activity,
SECTION IV IMMUNOLOGICAL MATERIALS AND METHODS
1 Formaldehyde detoxification of HLT
Three experiments were completed to establish the time 
required to detoxify HLT held at either 4°C or 37°C with or without the 
addition of 1% (w/v) formaldehyde (BDH, Poole, England) to a final con­
centration of 0*1% (w/v). The HLT preparation used was a membrane
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filter (Millipore SA, Molsheim, France) sterilized lysate supernatant 
fluid adjusted to a final concentration of 2 mg protein/ml (ie, 65 LD^^/ml), 
Dulbecco "a " PBS was used for all dilutions* Samples were taken at 
different times throughout the treatment of the HLT under the 4 test 
conditions eg, 1, 3, 7, 9 and 14 d* Formaldehyde was removed by overnight 
dialysis of the samples at 4^C, in sterilized (121°C, 15 psi, 15 min) 
dialysis tubing,against Dulbecco "A" PBS* The sterility of samples was 
then checked by plating out onto Bordet-Gengou medium. Samples were 
stored frozen (-20^C) until required for toxicity testing* Mice were 
injected intraperitoneally with 0*5 ml volumes of neat and 1 in 10
dilutions of samples. Deaths were recorded over a 3 d period*
In subsequent experiments detoxification of lysate supernatant 
fluids (final concentrations 2 mg protein/ml) was achieved by incubation 
for 15 d at 4°C in the presence of 0*17* (w/v) formaldehyde* After 
dialysis to remove the formaldehyde the purity of the solutions was 
checked and samples were stored frozen (-20^C) for toxicity testing to 
confirm that detoxification had been achieved* The remainder of the 
solutions were stored at 4°C with thiomersal (0,017* (w/v) final concen­
tration; BDH, Poole, England)*
2 Immunization of mice
Groups of 3-4 wk old mice were immunized with toxoided lysate 
supernatant fluid (15 d, 4°C, 0*l%(w/v) formaldehyde)* A variety of 
immunization procedures were adopted viz* use of adjuvants (Al(OH)^,
Freund*s incomplete and complete adjuvants: see appendix 4 for their
preparation), injection route (intraperitoneal, subcutaneous, intra­
muscular), number of injections. How these variables were used can be 
seen in table 10,
In the first 2 experiments some mice received a single
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injection whilst the others received a booster injection after 4 wk*
These mice were challenged with 5 or 3 of toxin 3 wk after the 1st
injection or 2 wk after the 2ndo Where possible survivors were bled out 
and serum collectedo
In the 3rd experiment, injections were given at 1 and 3 wk 
intervals respectivelyo Two to 3 wk after the final injection half the 
mice were challenged with 3 of toxin and half bled out for their serum.
Survivors of the challenge were also bled out.
In all experiments unimmunized mice were included to check the 
challenge was of the correct potency* One group of control mice received 
the lethal challenge dose (5 or 3 LD^^) and another 1 of HLT*
Sera were produced by allowing the mouse blood to clot at room 
temperature for 1-2 h before being left overnight at 4°Co The serum 
could then be dravm off,
3 Immunization of rabbits
Four New Zealand White rabbits were immunized against the same 
batch of toxoid used to immunize the mice (ie, toxoided lysate supernatant 
fluid; detoxification by incubation for 15 d at 4°C in the presence of
0.1% (w/v) formaldehyde)* Rabbits A and B were injected according to
the immunization schedule outlined in the top half of table 11* In total 
they received 560 mouse equivalents of toxin in 10 mg protein.
Rabbits C and D received a larger amount of material ie, 896 mouse
equivalents of HLT in 16 jdg of protein.
Sera were produced by allowing blood to clot for 1-2 h at room 
temperature* If necessary the clot was freed from the side of the 
universal to allow it to contract,' It was then left overnight at 4°C 
before the serum was removed.
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4 Absorption of rabbit antisera
Two rabbit antisera (B,D) were absorbed with B. pertussis 134
ie, the strain used to produce the lysate supernatant fluid to which the
antisera were raised. The cells were harvested from 48 h cultures of 
B, pertussis 134 grown in Stainer and Scholte (12G) medium*
Each absorption step involved the addition of live cells (1 g 
wet weight) to 10 ml of heated (56°G/10 min) antiserum. An even cell 
suspension was formed by shaking with glass beads, and left at room 
temperature (20-24°C) for 1 h. The suspension was then centrifuged 
(15,000 X g, 20 min, 20°C) and the serum decanted off the top of the
pellet* This procedure was followed through 3 and 4 times for sera D
and B respectively* After each step the sera were monitored for the 
presence of agglutinins against Bordet-Gengou grown B. pertussis 134* 
Residual B, pertussis were removed from absorbed sera by membrane 
filtration (Millipore SA, Molsheim, France)* The sterility of these 
sera was confirmed by plating out onto Bordet-Gengou medium*
5 Bacterial agglutination tests
Antisera raised to a lysate supernatant fluid from B* pertussis 
134 were tested for the presence of agglutinins to that organism* The 
method used was based on that described by Preston (1970),
Doubling dilutions of sera were made in plastic disposable trays 
(Cooke Microtiter System, Sussex, England) and an equal volume of bacterial 
suspension (30 ou) was added to each dilution* Dulbecco "a " PBS (Oxoid 
Ltd., England) was used both to dilute antisera and to suspend the 
freshly harvested cells from 24 h, Bordet-Gengou grown cultures. Cells 
and sera were mixed at room temperature for 5 min at 200 rpm (fastened 
to an orbital shaker) before being incubated in a humidified, 55^C 
incubator for 30 min* However agglutination titres were only determined
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after overnight storage of the mixtures at 4°C* The agglutination end­
point was determined using a plate microscope and the reciprocal of the 
dilution corresponding to this point taken as the titre*
6 Immunodiffusion and immunoelectrophoresis
6.1 Comparative double diffusion
Molten gel diffusion medium (20 ml; see below for details of
its preparation) was poured into 90 mm diameter plastic petri dishes
(Sterilin Ltd*, Teddington, England) and allowed to set* Wells were cut
either with a no, 2 cork borer (Griffin and George Ltd*, Wembley, England) 
or with gel cutters arranged to give 4 sets of 6 wells around a central
well* The cork borer was used to cut 5 wells about a central well with
a 3 mm gap between the edges of the central and surrounding wells. After 
the wells were filled with antigens and antisera to a prearranged design 
diffusion was allowed to take place for 2 or 3 d at 4°C*
Preparation of the gel diffusion medium:
Constituents quantities
Ion agar no* 2 (Oxoid Ltd., England) 15 g
N a d  16 g
Dissolved in 1 1 of distilled water by steaming for 45 min 
before the addition of;-
Phenol-saline, 10% (w/v) 50 ml
Methyl orange (BDH, Poole, England) 0*12 g
Finally the medium was filtered through Whatman filter paper (grade 113) 
and dispensed in 20 ml amounts into universal containers*
6.2 Crossed-over electrophoresis
Molten barbitone agar (see below for its preparation) was 
evenly spread onto clean glass slides (14 ml of agar per 80 x 80 mm slide)
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sitting on a level surface. After solidification wells were cut with a 
5 mm gap between wells for antigen and the corresponding antiserum*
When the wells had been filled the slides were placed in the electrophoresis 
chamber (Shandon electrophoresis apparatus). The slides were orientated 
such that antigen wells were on the cathode side of the wells containing 
the corresponding antiserum* To complete the electric circuit the slides 
were connected to the barbitone buffer (pH 8*3; see below for its 
preparation) at each electrode by buffer soaked gauze* A constant 
voltage of lOOV was applied to the slides for 30 min. Slides were then 
inspected and precipitin lines recorded before being left overnight in 
barbitone buffer (pH 8*3) to remove unreacted protein. After 2 washes 
of 15 min in distilled water the precipitin lines were stained for 10 min 
with a saturated solution of amido black (Edward Gurr Ltd*, Michrome 
Laboratories, High Wycombe, Bucks) in 2% (v/v) acetic acid* Finally the 
slides were washed in 2% (v/v) acetic acid/17* (v/v) glycerol and dried 
at 37°C*
Preparation of barbitone buffer and agar:
The buffer comprised 8,5 g of sodium barbitone dissolved in distilled 
water to a final volume of 500 ml after the pH had been adjusted with 
IN HCl to 8*3, To prepare barbitone agar. Ion agar (Oxoid Ltd*, England) 
was dissolved,by heating, to a final concentration of 0.75% (w/v) in 
barbitone buffer (pH 8*3)*
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SECTION V STATISTICAL METHODS
1 Probit analysis
For analysis of dose-response relationships (eg, HSF and the 
lethal HLT assay data) where the response variable was a binomial proportion 
the probit transformation was used. Data were processed by the probit 
method (Finney, 1971) using a computer programme developed in the Department 
of Epidemiology and Biometrics, School of Hygiene, University of Toronto, 
Canada. The University of Glasgow ICL 2976 computer or Newcastle-upon- 
Tyne IBM 370/168 multiple access computer were used in this context.
The programme yielded ED^^ values and the potencies of samples, with 957* 
confidence limits, relative to a standard.
is1,1 Combining the results of data processed by probit analysl
Toxicity or HSF data from independent tests on the same set of
samples can be combined to give a better estimate of the relative potencies 
of the samples. To illustrate the procedure used, it is shown how results 
presented in table 18 (experiment 1) were derived from 2 sets of toxicity
test data processed by probit analysis (tables 12 and 13).
1,1*1 Combined estimate of relative potency (R)
The blocked-in figures in tables 12 and 13 are substituted into 
the following equation to give combined estimates of relative potency (R)
for C^ and C^ against X^ *^
  2  (W log R * log R)
log R = Z W log R
ie, for C,
(5.73x - 0.8324) +  (44.4x - 1,2603)
log R = 5,73 +  44,4
-  1*211 
. . R ~ 0* 062
Likewise for C^, where R = 0*040,
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Table 12 Combining the results of data processed by probit analysis 
toxicity test data 1
Preparation Dose bog^Q dose Tested Responding
(std.) 2.5000
1.2500
0,6250
0.3125
0.1562
0.3979
0.0969
-0,2041
-0.5051
-0.8063
20.000 
10o000
5.000
1.3010
1.0000
0.6990
20,000
10,000
5.000
1.3010
1.0000
0.6990
Re 1.pot. 957c limits EO50 log R
WlogR log EDjp WlogED^Q
0.53 -0.2765 20.46
0.147 0.072 0.490 3.60 -0.8324 5.73 0.5559 7.97
0.060 0.029 0.130 8.89 -1.225 9.64 0.9487 18.22
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Table 13 Combining the results of data processed by probit analysis 
toxicity test data 2
Preparation Dose bog^Q dose Tested Responding
X (std.) 2.5000
1.2500
0,6250
0,3125
0.1562
0.3979
0,0969
-0,2041
-0,5051
-0,8063
10
10
10
10
10
10
10
10
6
0
20,000
10,000
5,000
2,500
1.250
1.3010
1.000
0,6990
0.3979
0,0969
10
10
10
10
10
10
10
4
0
0
20.000
10.000
5,000
2,500
1,250
1,3010
1,0000
0.6990
0,3979
0.0969
10
10
10
10
10
Rel.pot. 957. limits
^1
C^ 0.055 
C^ 0,037
0.039
0.026
0.078
0.052
BD50
0,39
5,33
7.93
logR WlogR
-1,2603 44,40 
-1,4326 44.40
logED^Q WlogED^0
-0.5333 88.74
0.7270 88.85
0,8993 88.87
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Note the effect of the higher weightings for the second test 
(table 13) is to bring R (0,062 and 0.040, for and respectively) 
closer to the R values of test 2 (0,055 and 0.037) than those of test 1 
(0.147 and 0,060).
1.1.2 Estimation of 95% confidence limits
As the computer print out for "WlogR" incorporates the
2
student term "t" ie, WlogR = 1 / (ts) there is no t factor in the 
expression of the limits.
Limits = antilog (log R ^ 1 / V^ZWlogR )
For the limits = antilog ( -1,211 ^  1 / \/5.73 +  44,4 )
= antilog ( -1,211 ^  0,141 )
= antilog -1,352 and antilog -1,07 
= 0.044 and 0,85 
Likewise for , limits = 0.029 and 0.055.
2 Four-point parallel-line assay
The LPF activities of samples were compared by the 4-point 
parallel-line assay. This involved testing low and high doses of each 
preparation and analysing the data using a programme developed for use 
with a Programma 101 Electronic desk-top computer (British Olivetti Ltd,, 
London), The results of an analysis of variance were provided, and the 
potency and 957, confidence limits for one sample relative to the other.
In table 14 are the particulars relating to a comparison of the LPF 
contents of a heat-detoxified (56°C/30 min) toxin preparation and its 
formaldehyde-detoxified equivalent viz. the raw data of white cell counts 
(table 14a), detail? of the analysis of variance (table 14b) and the 
relative potency values with 95% confidence limits (table 14c^ and already 
presented in table 37, experiment 1).
Ill
Table 14 Four-point parallel-line assay of LPF test data
14a Log^Q individual white blood cell counts in relation to dose
Formaldehyde-detoxified HLT 
Low dose High dose
Heat-detoxified HLT 
Low dose High dose
4,390 4,790 4,035 4.672
4.310 4,820 4,177 4.412
4.284 5.029 4.088 4,559
3,319 4,800 4,094 4,457
4,205 4,708 4.249 4.478
14b Analysis of variance
Source of variation Degrees of freedom F-ratio values Probability
Between preparations 1 32.9 ^  0.01
Slope 1 116,2 =s 0.01
Parallelism 1 2,8 0,05
Residual 16 -
The tabulated F-values at 1, 16 degrees of freedom are 4.44 (P = 0,05) 
and 8.53 (P = 0,01). Therefore there is a highly significant slope but
no significant difference in parallelism, ie, the test was statistically 
valid,
14c Relative potency and 95% confidence limits
Formaldehyde-detoxified product 
Heat-detoxified product
1,00
0,48 (0.34 - 0.64)
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3 Mann-Whitney U-test
The Mann-Whitney U-test was used to compare certain types of 
data eg, scores from haemorrhagic toxicity assays,or lung pathology and 
culture scores for B. pertussis infected mice. The procedure followed 
was as described by Campbell (1974),
4 Use of 2 X 2 contingency tables
For the comparison of certain data in the form of proportions 
(eg, 9 out of 10 mice dead compared to 2 out of 10) 2 x 2  contingency 
tables were consulted (Finney et al, 1963), These were used to test 
the significance of differences in response for groups of mice given 
different treatments eg, passive protection afforded to groups of mice 
against an intracerebral or intranasal challenge with B. pertussis.
RESULTS
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1 Assaying the toxicity of HLT
1.1 Measurement of the lethal effect in mice
The effects of mouse sex and weight on their susceptibility to
the lethal effect of HLT were investigated. Any differences could be a
source of error if not recognized whereas if detected they could be used 
to increase the sensitivity of the assay.
1.1.1 Mouse sex
Groups of 3-4 wk old HAM/ICR male and female mice were injected 
intraperitoneally with 0.5 ml volumes of graded doses of B. pertussis 18334 
cell-lysates. The range and distribution of weights in each group were 
similar. Deaths were recorded over the 3 d post-injection period.
The results of 5 independent experiments are outlined in table 
15. The toxicity test values for the female mice relative to the male 
mice, which have been given a rating of 1.0, ranged from 0.8-1.6. There is 
no indication that the sexes responded differently to the lethal toxicity 
of the lysates.
1.1.2 Body weight
Three to 4 wk old HAM/ICR mice were arranged into groups accord­
ing to their body weight; low weight groups of 10.0-13.5 g and high weight 
groups of 18.0-23.0 g. Mice from both groups were injected intraperitone­
ally with 0.5 ml volumes of graded doses of B. pertussis 18334 cell-lysates. 
Doses were not weight adjusted ie, in any given experiment the same 
dilutions of lysate were used for both large and small mice. Deaths were 
recorded during the 3 d post-injection period.
The toxicity of the first lysate was estimated to be, in 2 
separate experiments, about 507. less when tested in the large rather than 
the small mice indicating that the lighter mice were the more susceptible 
(table 16, experiments 1 and 2). However the measurements made on the
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toxicity of the second lysate were rather similar irrespective of whether 
large or small mice were used in the determinations. The conclusion is 
that although weight is not a major determinant of mouse susceptibility it 
cannot be disregarded.
1,2 Measurement of the haemorrhagic activity of HLT, with or 
without added rabbit serum, in suckling mice 
This series of experiments stemmed from an observation made 
whilst testing antisera for their ability to neutralize the haemorrhagic 
activity of HLT. A cell-lysate supernatant fluid (100,000 x g, 1 h) was 
chosen as a source of HLT. To 0.5 ml of a suitable dilution of this toxic 
solution was added an equal volume of either PBS or normal rabbit serum. 
After mixing and 2 h incubation at room temperature 0.05 ml volumes of the 
mixtures were injected subcutaneously into suckling mice (4 d old) at a 
point behind the head. Twenty-four hours later the mice were inspected 
for the development of haemorrhagic reactions which were scored on a 1+ to 
4+ scale (plate 8) or for death 5+. The Mann-Whitney U-test was adopted 
to analyse these data to assess if differences between the mixtures were 
significant.
Marginally higher scores, reflecting more severe haemorrhagic 
reactions, were recorded where serum had been added to the toxic lysate 
supernatant fluid. In 4 out of 5 experiments these scores were 
significantly higher (table 17).
1.3 Testing HLT for haemolytic activity
To see if HLT might be responsible for the haemorrhagic zone 
surrounding colonies of B, pertussis on Bordet-Gengou medium, an HLT 
preparation was tested for haemolytic activity. To 0.5 ml volumes of 
doubling dilutions of a lysate supernatant fluid (100,000 x g, 1 h) were 
added equal volumes of 1% (v/v) suspensions of red blood cells from
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several species. After 30 min incubation at 35°C there was no evidence 
of lysis of sheep, rabbit, horse, human (O, rhesus +) or cod red cells, 
even in the presence of 2,5 mouse per ml of HLT. Subsequent transfer of
the cells into the cold room to test for hot-cold lysis did not result 
in haemolysis of any of the red cell species. The heat-labile toxin would 
not appear to be a haemolysin,
2 Storage-stability of HLT
In preparation for a series of fractionation experiments, the 
stability of HLT to storage in the freezer (-20°C) was investigated. Four 
samples of toxin, cell-lysates of B, pertussis 18334 which had been grown 
in modified Hornibrook medium, were assayed for their mouse lethal toxicity 
several times during their storage at -20°C. The lysates (a,b,c and d) 
were prepared from cell suspensions of 70, 70, 80 and 125 ou respectively 
which had been stored overnight (a, b and c) or for 10 d (d) at -20°C prior 
to X-pressing, Thereafter 5-17 d elapsed before they were used in the 
first toxicity test. Test samples were re-frozen after each toxicity 
assay for re-testing at a later date.
Figures 9a and b record the toxicity of the lysates during 
2.5-3 yr storage at -20^C, With 2 of the lysates (b and c) there was some 
loss of activity during this period as indicated by the increasing amounts 
of lysate required to kill the same number of mice. This reduction in 
toxicity is estimated at 19% and 24% per annum for preparations c and b 
respectively, as calculated from the slopes of the regression lines fitted 
to the toxicity data. The correlation coefficients for the lines b and c 
are 0.70 and 0.73 respectively. Lysates a and d showed no signs of 
having lost activity and indeed the very shallow slopes on these 
regression lines indicates a very slight increase in toxicity. However
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Figure 9 Storage-stability of HLT
The toxicity of the lysates are expressed in terms of the 
oue of lysate which in a 0.5 ml volume is equivalent to 
1 LD^g. The figures in parentheses indicate the numbers 
of mice used per dose of lysate in each toxicity determination.
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this is almost certainly not meaningful* Taken collectively the data 
indicate an annual loss of toxic activity of about 10% during storage at
-20°C.
3 Antigenic variation and HLT production
3*1 Antigenic modulation
B. pertussis cultures were grown in parallel in modified 
Hornibrook medium with either NaCl as the principal salt (X-medium) or 
MgSO^ (C-medium) to produce X-and C-mode cells respectively* These were 
then tested for their toxicity to see if HLT, like several other B. pertussis 
components, would be lost during antigenic modulation (Introduction; 
section I, 6.1ol)o
Cell suspensions of X-and C-mode cells were prepared in PBS and 
standardized by opacity before being divided into 3 portions; one for 
conversion into lysate for subsequent toxicity testing, another for SDS- 
PAGE analysis for the presence or absence of the 28K or 30K cell— envelope 
polypeptides with the final sample being made into vaccine for HSF 
determinations* The levels of both the 28K and 30K cell-envelope poly­
peptides and the HSF were monitored to ensure modulation had been achieved*
A summary of 7 independent growth experiments, 4 with B* pertussis 
18334, 2 with strain 18323 (BOB) and 1 with strain 134 is presented in 
table 18* The figures for the C-mode preparations are given as a percent­
age of their X-mode counterpart* The toxicity test results prior to 
statistical evaluation appear in appendix 5* It is clear that growth in 
C-medium is accompanied by a substantial reduction in the toxicity of 
X-mode B. pertussis cells. Moreover this phenomenon is reproducible in 
2 senses* Firstly, it has been shown to apply to more than just one 
strain of B* pertussis ie, strains 18334, 18323 and 134* Secondly, with
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Table 18 A comparison of the toxicity and HSF content of X- and 
C-mode cells
Bopertussis 
s train
Experiment Relative potency and 95% confidence limits 
of C-mode preparations (X = 100%)
Toxicity HSF
18334
^a,b
6.2 (4.4-8.5) 0.3 (0.0-1.5)
4o0 (2.9-5.5) 0.2 (0.0-1.1)
6.8 (4.8-9.6) 0.7 (0.0-2.5)
6.9 (4.9-9.6) 0.5 (0.0-1.8)
2^ 4.2 (2.5-6.3) lo9 (0.6-2.7)
3 3.2 (0.6-8.9) >.0^
3.7 (0.8-12.5) ■*= f).0^
4 3,7< 0.4 (0.0-1.2)
18323 5 4.0 (2.3-6.8) 3.4 (0.4-9.8)
6 3.8 (2.0-6.9) 0.8 (0,1-2.4)
134 7 2.4^
:,d,e
3.1 (1.8-4.4)
a Best estimates from 2 toxicity tests
b In this experiment 4 preparations were compared ie, X^ vs C^, C^ 
and X^ vs C^ ,^ C^
c No 95% confidence limits are given as the test was not statistically 
valid (F-tests for heterogeneity failed)
d No mice became sensitized (died) at the highest dose of C-mode 
vaccine (cells) tested
e Cells and not cell-lysates were tested for their toxicity
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strain 18334 in particular it has been demonstrated that this result can 
be obtained consistently. Overall the relative toxicities for the C-mode 
samples, as measured by their lethality in 3-4 wk old mice, ranged from 
2o4-6o97o (average 4o4%). The toxicity detected in X-mode samples was 
heat-labile. With one particular lysate the was 0.5 ml of 0.43 oue.
After 20 min heating at 56°C doses as large as 0.5 ml of 30 oue failed to 
kill mice.
The culture supernatant fluids were in general atoxic. Only 
those collected from X-mode cultures of strain 18323 contained toxin, but 
less than that associated with the cells. C-mode culture supernatant 
fluids from all 3 strains were atoxic.
The HSF data show, in conformity with previous work (Parton and 
Wardlaw, 1975; Wardlaw, Parton and Hooker, 1976), that the C-mode vaccines 
made from each harvest were also much reduced in this component. Taking 
the results from all 3 strains into consideration the relative potencies 
of C-mode vaccines, in assays which permitted a value to be determined, 
ranged from 0,2-3.47.. Likewise analysis of cells by SDS-PAGE revealed 
in all cases loss of the 28K and 30K cell-envelope polypeptides from 
C-mode cells as reported previously (Parton and Wardlaw, 1974 and 1975; 
Wardlaw, Parton and Hooker, 1976). Typical electrophoretic profiles of 
X- and C-mode cells are shown for B. pertussis 18334 in plate 10.
3,2 Nicotinic acid induced modulation
B, pertussis 134 was exposed to modulation by growth on either 
Bordet-Gengou medium or charcoal agar to which nicotinic acid had been 
added to a concentration of 500 pg/ml. This was to establish if, as 
reported by Pusztai and Joo (1967), HLT levels would remain unchanged.
Cells were cultured for 24 h on both Bordet-Gengou medium 
and charcoal agar with and without the added nicotinic acid. They were
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Plate 10 Electrophoretic profiles (SDS-PAGE) of B. pertussis
18334 grown in X- and C-media
28K, 30K The 28,000 and 30,000 dalton
cell-envelope polypeptides
X c
30 K 
28K
$
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then harvested, washed and re-suspended in PBS, and standardized by 
opacity, A portion of the suspension was stored for SDS-PAGE analysis 
for the presence or absence of the 28K and 30K cel1-envelope polypeptides 
whilst a further portion was converted into vaccine for HSF determinations. 
The remainder was stored frozen for toxicity testing viz, lethality to 
3-4 wk old mice.
Growth on either medium supplemented with nicotinic acid 
resulted in a significant reduction of about 60% in the toxicity of the cells 
(table 19)o The loss of the 28K and 30K cell-envelope polypeptides and, 
in at least the Bordet-Gengou grown cells, the HSF (table 20) verified that 
modulation had occurred. If there had been sufficient material it might 
have been possible to show that there was a significant reduction in the 
HSF content of the cells grown on the nicotinic acid supplemented charcoal 
agar, even if less of a reduction that that obtained with the Bordet-Gengou 
grown cells,
3,3 Phase variation
The phase IV forms of strains D30042 and D3148 had -=207, and 
5,17, respectively of the toxicity of their phase I counterparts, as 
observed with cells from 48 h Bordet-Gengou grown cultures (table 21),
This confirms the work of others (Introduction; section II, 4.3),
4 HLT production and purification
4.1 Production
As a prerequisite for the purification of HLT it was decided 
to examine the factors most likely to influence toxin production so that 
starting material of the highest potency would be available.
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Table 19 The effect of growth on a high nicotinic acid containing
medium on the toxicity of cells of B. pertussis 134
Dose/mouse 
(ou of 0.5 ml 
injected)
Number of deaths / numb er of mice injected
BG BG-NA500 CA CA-NA500
5 5/5 5/5 4/5 3/5
2.5 5/5 0/5 5/5 0/5
1.25 2/5 0/5 0/5 0/5
0,625 0/5 0/5 0/5 0/5
0.312 0/5 0/5 0/5 0/5
“ 50
1,29 3.52 2,16 4.94
Relative toxicity and 100 36.8 100 43.7
95% confidence limits (23.4-59 o9) (19.1-79,4)
BG, BG-NA500
CA, CA-NA500
Botdet-Gengou medium without and with added nicotinic 
acid respectively.
Charcoal agar without and with added nicotinic acid 
respectively.
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Table 20 The effect of growth on a high nicotinic acid containing 
medium on the HSF content of cells of B, pertussis 134
Dose of vaccine/mouse Number of deaths / number of mice injected
(ou of 0,5 ml injected) BG BG-NA500 CA CA-NA500
32 0/5 5/5
8 0/5 4/5
2 0/5 0/5
0,5 0/5 0/5
2.4 4/5 5/5
1.2 0/5 1/5
0,6 0/5 0/5
0,3 0/5 0/5
HSD^o 1,99 >  32 1,42 6.77
Relative potency and 100 <  6 100 21
95% confidence limits (15-696)
BG, BG-NA500 Bordet-Gengou medium 'without or with added nicotinic
acid respectively.
CA, CA-NA500 Charcoal agar without or with added nicotinic acid
respectively.
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Table 21 A comparison of the toxicity of the phase I and IV
variants of B, pertussis D30042 and D3148
Dose/mouse Number of deaths / number of mice injected
(ou of 0,5 ml
injected) D30042 I IV D 3148 I IV
20 NT NT NT 3/4
10 NT NT NT 2/4
5 3/3 0/3 3/3 0/4
2,5 3/4 0/4 3/3 0/4
1,25 3/4 0/4 4/4 0/4
0,625 1/3 0/3 2/4 NT
0,312 0/3 0/3 0/3 NT
0.516 0/3 0/3 0/3 NT
^^50
1.0 >  5.0 0.62 12.15
Relative toxicity and 100 <  20 100 5.1
95% confidence limits ( 2.3-10.2)
NT Not tested
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4.1.1 Strains
Different strains of toxigenic bacteria may vary widely in their 
ability to produce toxin (van Heyningen, 1970), Hence it was considered 
worthwhile to screen B. pertussis strains for their ability to produce HLT. 
Altogether 14 strains were tested, several of which had been pre-selected 
from larger assemblages of strains as being potentially of high toxigen- 
icity eg,
Strain MAENO, used by Nakase ejt aT (1969) as a source of HLT for their 
purification studies
Strain No, 28, discarded as a vaccine production strain because of its 
toxicity (Novotny, 1977 personal communication)
Strain B-1593/57, selected by Spasojevic (1977) as the most toxic of 
201 strains in her collection
Strains 77/18319 and 77/2483 were recent isolates and might therefore be 
expected to yield high levels of HLT as bacterial toxin production often 
declines with repeated subculture (van Heyningen, 1970; Bernheimer, 1970), 
In most experiments (table 22, table 23 experiments 1-3) small 
groups of Bo pertussis strains were grown and toxicity tested in parallel 
with strain 18334, After 48 h growth on Bordet-Gengou medium the strains 
were harvested, standardized by opacity and stored frozen until assayed in 
the mouse lethal toxicity test. In the first series of 3 experiments 9 
strains in addition to reference strain 18334 were tested in small groups 
of mice (table 22; for the toxicity data prior to statistical evaluation 
see appendix 5), The differences between strains were small when com­
pared on an equal opacity basis. With strain 18334 being arbitrarily 
assigned a toxicity of 1,0 the most toxic strain rated 2,6 and the least 
toxic 0,8, a modest 3-fold difference. Strains 134, No, 28 and MAENO were 
retested using larger numbers of mice as they promised to give the
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Table 22 Toxicity test data for several strains of B, pertussis grown 
on Bordet-Gengou medium
Experiment Bo pertussis 
s train
Relative toxicity and 95% confidence 
limits of Bo pertussis strains 
(strain 18334 = 1,0)
1 77/18319 1,2 (0,6-2,4)
77/24833 0.8^
18904 L4 1.1*
2 D30042 I 0.9 (0.3-2,2)
3865 0,9 (0,3-2.2)
134 2,4 (0.9-6.7)
3 D3148 I 1.4 (0,8-2.4)
No. 28 2,6 (1.5-4.6)
MAENO 2.0 (1.2-3.6)
4 134 2.3 (1,3-4,2)
No. 28 2,1 (1,1-3,7)
MAENO 2,7 (1,5-5.I)
5 134 3.1*/2.5*
No. 28 2.3 (1,3-4.!)^
MAENO 2.8 (1.5-5,2)^
No 95% confidence limits are given as the results were not analysed 
together with those obtained for reference strain 18334 as such joint 
analyses proved to be statistically invalid (ie, F-test invalidity). 
The relative toxicity values given are based upon the values
obtained by analysing the results for each strain independently.
Best estimates from 2 toxicity tests.
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highest yields of toxin (table 22, experiment 4 and appendix 5), Again 
these samples proved 2-3 times as toxic as reference samples of 18334,
In each of the two comparisons made per strain with 18334 the differences 
in toxicity were, with one exception (experiment 2, strain 134), signifi­
cant. Further confirmation of these findings was obtained in a separate 
growth experiment (table 22, experiment 5 and appendix 5), Although 
significant differences were apparent between strains 134, No, 28, MAENO 
and 18334 there were no appreciable differences among the 3 selected 
strains. However strain 134 was preferred as it gives good yields of 
cells.
Four other strains were tested subsequently in conjunction with 
some of the aforementioned strains (table 23 and appendix 5), They were 
either grown on Bordet-Gengou medium as already described or for 4 d in 
Roux bottles of modified Hornibrook medium. Only strain 44122/7R appeared 
to be similar in toxicity to B, pertussis 134 which was yet again shown to 
be more toxic than strain 18334, B« pertussis strains GL353Z and L84 I 
although not directly compared to strain 134 would appear to be among the 
least toxic strains tested as judged from their toxicity relative to 
strains D3148 I and D30042 I,
4,1,2 Culture medium and time of harvest
As culture media have a considerable influence on the yields of 
bacterial toxins (van Heyningen, 1970) B, pertussis were grown on 4 media 
and the HLT levels monitored. In 3 separate experiments strains 18334, 
77/18319 and 134 were grown on Bordet-Gengou medium, charcoal agar and in 
modified Hornibrook medium and the chemically defined Stainer and Schblte 
(12G) medium. The latter 2 media were dispensed in 500 ml volumes in 
2-litre shake flasks and inoculated with 5 ml of a seed culture grown in 
modified Hornibrook medium. Seed cultures for the solid media were
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Table 23 Toxicity test data for Bordet-Gengou and Hornibrook 
grown Bo pertussis strains
Experi­ Growth Bo pertussis Number of mice Relative toxicity and
ment medium strain per dose 95% confidence limits
1 B-G 18334 14 loO
• 134 7 2.0 (1.2-3.I)
B-1593/57 7 loO (0,5-1.7)
2 B-G 18334 15 1,0
44122/7R 10 1.6 (1.0-2.6)
3 B-G 18334 15 1.0
134 10 1.5 (1.0-2.0)
44122/7R 10 1.9 (1.5-3.1)
4 H D3148 I 4 1.0
D30042 I 4 1,0 (0,4-2.8)
GL353Z 4 0,7 (0.2-1.9)
L84 I 4 0.3 (0,1-0,9)
B-G Bordet-Gengou medium
H modified Hornibrook medium
132
prepared by growth on the same type of medium onto which they were to be 
inoculated. Cells were harvested from all 4 media after 24 h and 72 h, 
standardized by opacity and frozen until required for toxicity testing.
It is immediately obvious from table 24 (see appendix 5 for the 
toxicity data prior to statistical evaluation) that no one medium is, in 
comparison with the other media tested, especially suitable for providing 
highly toxigenic B. pertussis. Relative to cells grown on Bordet-Gengou 
medium for either 24 h or 72 h the equivalent cells from charcoal agar, 
modified Hornibrook medium and Stainer and Schblte (12G) medium had 
toxicity ratings ranging from 1,0-1,6, 0.7-2,7 and 0.9-2,3 respectively. 
However on charcoal agar cells of strains 134 and 77/18319 appeared very 
marginally, but not significantly, more toxic than their Bordet-Gengou 
grown counterparts whereas strain 18334 yielded equally toxic cells on 
either medium. The strains did not always respond uniformly, strain
18334 gave 1.5-and 2,5-fold better yields in Stainer and Schblte (12G) 
medium than in modified Hornibrook medium whilst the converse held for 
strain 134. (1,5-fold differences in yields).
The effect of the time of harvesting cells on their toxicity is
better defined. In table 25 where the data has been re-arranged so that
the toxicity of the 72 h harvests are expressed relative to the 24 h 
harvests the effect is more apparent. With the solid media the 24 h 
samples were generally (5 out of 6) more toxic than the 72 h samples.
With the liquid media the converse applied, 5 of the 6 72 h samples were 
more toxic than their 24 h equivalents and the 6th was of equal toxicity. 
Note that these differences were not large, never more than 1,9-fold, and 
individually were not statistically significant. However they occurred 
consistently and it seems reasonable to conclude that with solid media,
24 h cultures were more toxic than 72 h cultures whereas in liquid media 
the converse held.
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During growth in the liquid media culture supernatant fluids were 
taken and tested for their toxicity. Only with the 72 h samples from 
cultures of strains 18334 and 134 grown in modified Hornibrook medium was 
there any HLT detected and even then only at low levels,
4,1,3 Iron content of medium 
High concentrations of iron in culture media inhibit the 
production of diphtheria toxin (Pappenheimer and Johnson, 1936), tetanus 
toxin (Mueller and Miller, 1945), Clostridium perfringens cc-toxin (Pappen­
heimer and Shaskan, 1944), Shigella dysenteriae neurotoxin (van Heyningen 
and Gladstone, 1953), Streptococcus pyogenes erythrogenic toxin (cited by 
van Heyningen, 1970) and Pseudomonas aeruginosa exotoxin A (Bjorn ^  al, 
1978), It therefore seemed advisable to investigate the role, if any, 
of iron in the production of B, pertussis HLT, This was done in Stainer 
and Schblte (12G) medium modified with 6 different concentrations of FeSO^ 
(A-F), including the usual formulation (B), The chemically defined 
Stainer and Schblte (12G) medium was chosen in preference to modified 
Hornibrook medium because with the former the iron content could be altered 
merely by changing the amount of iron to be added. The medium would not 
require to be de-ferrated to achieve very low concentrations of iron.
The quantity of iron in each medium was checked by taking 10 ml samples 
for a colorimetric assessment of their iron content. Culture supernatant 
fluid from the seed culture was also assayed in this manner and was found 
to be effectively iron free, A 2% (v/v) inoculum of a 48 h Stainer and 
Schblte (12G) culture of B, pertussis 134 was used to seed each 500 ml of 
medium which was then incubated for 72 h. Cells were then harvested, 
suspended in PBS, standardized by opacity and stored frozen until required 
for toxicity testing. Culture supernatant fluids were also stored frozen. 
From the results obtained in table 26 it can be seen that there
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is a fairly good correlation between the known amount of iron added to 
the medium and that assayed colorimetrically with 2,2*bipyridyl„ The 
toxicity test only involved 4 groups of 5 mice per sample and a 4-fold 
dilution series in expectation of possible large differences in the 
toxicities of the samples. However it is immediately apparent from the 
results that iron has not the pronounced effect on HLT production in 
B, pertussis 134 as it has on, for instance, the production of diphtheria 
toxin which is maximal at iron levels of 0,1 mg/1 (Pappenheimer, 1947),
All the culture supernatant fluids were atoxic except for that 
of medium A  which was toxic when tested undiluted but not at 1 in 4,
4,2 Purification
Because of the intracellular location of HLT it was necessary to 
release it in soluble form to provide starting material for purification,
4,2.1 Disruption of B. pertussis and release of HLT
Cells were disrupted by passage through an X-press and the 
toxicity of the lysates compared with that of the intact bacteria.
In the first series of experiments lysates were prepared from 
freshly harvested, Stainer and Schblte (12G) grown cells of B. pertussis 
134 by 3 passages through an X-press, These lysates were significantly 
more toxic than the cell, suspensions from which they were derived, of 
the order of 8 times as toxic (range, 4-14 fold) (table 27), The smallest 
difference (4,1-fold, experiment 3) was observed with cells and lysates, 
prepared from 72 h not 48 h cultures, which had been stored for 5,5 mth 
at -20°C prior to toxicity testing instead of being tested on the day of 
their preparation. In a further series of experiments where lysates were 
prepared from Bordet-Gengou grown cells which had been stored overnight 
at -20^0 prior to X-pressing there was only a slight enhancement in
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toxicity (table 28), In only 2 of the 4 determinations, 1 of which used 
B, pertussis 134, were there significant differences (range, l,7-3o3 fold). 
All samples were stored at -20°C until the toxicity tests were performed, 2 d 
after the cells had been harvested, 1 d after the preparation of the lysates. 
In one final experiment lysates prepared from frozen cells of Hornibrook 
grown Bp pertussis were actually no more toxic than the cells from which 
they were made.
Bo pertussis cells appear to be relatively resistant to lysis or 
even killing by freezing (-20°C) and thawing (room temperature). Portions 
of the cell suspensions from experiments 1 and 2 (table 27) were subjected 
to 5 cycles of freezing and thawing, yet there was no reduction in viability 
relative to cells held at 4*C for the same length of time. Nor was their 
toxicity appreciably altered (table 29),
4,2,2 Ultracentrifugation as a preparative step
Ultracentrifugation (100,000 x g, 1 h, 4°C) was used to sediment 
debris from the cell-lysates produced by X-pressing, The distribution of 
the toxicity between the pellet and the supernatant fluid is shown in 
table 30 and the toxicity test data upon which these figures were based in 
appendix 5, Also included in table 30 is the percentage of protein 
recovered in the supernatant fluids. The combined figures for the amount
of HLT in the supernatant fluids and pellets ranged from 64-123%, When
the percentages obtained from each of the 4 experiments are averaged a 
recovery figure of 96% is obtained, with 71% being in the supernatant fluid 
and 25% in the pellet. Thus there is about 2,8 times as much HLT (range, 
1,9-3,3) in the lysate supernatant fluids as in the pellets. In contrast 
most of the protein was associated with the pellet and only 33-43% in the 
supernatant fluid. Consequently in experiments 1, 2 and 3 the ultra­
centrifugation step produces apparent purifications of 1,3, 1,6 and 2.2-
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fold respectively. However these figures are slightly misleading since 
there is some justification for adjusting the estimated potencies to give 
totals of exactly 100% with deviations from this being attributable to 
the imprecision of the toxicity test. If this is done for the 3 experi­
ments the degrees of purification become 2,0, 1,8 and 2,1 respectively, 
an average of almost 2,0,
Typically 10 p.g of lysate supernatant fluid protein represented 
1 LD^Q in 3-4 wk old HAM/lCR mice, but occasionally values as low as 5 pg 
were obtained,
4,2,3 Ion-exchange chromatography
Column chromatography using diethylaminoethyl (DEAE) cellulose 
ion-exchange resin was used in the successful purification of HLT by Nakase 
et al (1969), This method was therefore explored.
Bo pertussis cells were X-pressed in low ionic strength (0.005M) 
phosphate buffer, the lysate ultracentrifuged, the 100,000 x g, supernatant 
fluid adsorbed onto a column of DEAE-cellulose and eluted with a series of 
phosphate buffers of increasing ionic strength although the final material 
was eluted by lowering the pH,
Figure 11 shows the elution profile from such an experiment.
Where there was sufficient HLT in fractions for 0,5 ml to be lethal to 
mice this has been indicated. The toxin was found spread over 3 of the 
5 major peaks (c, d and e) but only the toxic fractions from c and the 
first half of peak d were pooled as this was the area within which most of 
the toxicity was supposed to reside (Nakase e_t £ l , 1969), However, only 
4% of the original HLT was recovered from these fractions and 13% of the 
protein. The other toxic fractions only accounted for a further 9% of 
the HLT,
In a further experiment the 0,05M phosphate buffer was replaced
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Figure 11 DEAE-cellulose column chromatography of 
lysate supernatant fluid
^280 elution profile
-j Areas within which fractions 
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with O.IM phosphate buffer in an attempt to elute the toxic fractions 
associated with peaks c and d of figure 11 in a single peak. In fact 
24% of the HLT was recovered in this peak with 15% of the protein. The 
other toxic fractions only contributed a further 1% of the original HLT 
applied to the column. As the overall recovery of HLT was considered to 
be too low for the purification achieved (1.6-fold) this procedure was 
abandoned.
4.2.4 Fractionation with ammonium sulphate
With the failure of the attempt to follow the method of Nakase 
et al (1969) to purify HLT, fractionation with ammonium sulphate was 
investigated. Initially the method of Onoue, Kitagawa and Yamamura (1963) 
was used to fractionate cell-lysate, 100,000 x g supernatant fluids. 
Ammonium sulphate was added to the toxin solution in 2 stages and the 
precipitates formed after each addition were collected as was the final 
supernatant fluid ie, a 16% ppt, 16-40% ppt and a 40% S fraction (super­
natant fluid). In the first 2 experiments more than 95% of the toxicity 
recovered was in the 16-40% precipitate with only 37% and 42% of the 
protein. Moreover an ultraviolet scan of the 16-40% precipitate revealed 
a marked reduction in the absorbance at 260 nm compared to the lysate 
supernatant fluid. The method looked promising and was therefore explored, 
In the first of the subsequent experiments it was decided to 
pre-treat the lysate supernatant fluids with DNase. Although the ammonium 
sulphate fractionation on its own apparently separated most of the DNA 
from the toxin its complete removal early in the purification was 
desirable to prevent it from interfering in later precipitation steps.
DNase (DNase 1, Beef pancreas, noncrystalline) was added to a final concen­
tration of 50 pg/ml and the mixture incubated for 15 min at 30°C. The 
DNase had no effect on HLT activity (table 31) but it altered the way
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Table 31 The effect of DNase on the toxicity of lysate
supernatant fluid
Dose (|il)/mouse Number of deaths/number 
supernatant
of mice injected with 
fluid
before treatment after DNase treatment
346 15/19
173 10/15
86 1/12
43 0/16
500 14/16
250 12/16
125 3/16
62 3/16
^^50
'
175 175
Relative toxicity and loO 1.0
95% confidence limits (0.7-1.5)
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proteins in general and HLT in particular were precipitated with ammonium 
sulphate. In the 16-407. precipitate there was now only half as much
protein (197.) and HLT as before. The other 507. of the original HLT was
recovered in the 407. supernatant fluid (table 32).
As the salting out procedure adopted originally was no longer
appropriate, information on the behaviour of HLT on fractional precipit­
ation of DNase/RNase treated lysate supernatant fluids was gathered. 
Unfortunately, although the results of the fractionation were favourable 
the initial incubation of the toxin with 50 pg/ral of RNase (RNase, type 1-A, 
Bovine pancreas, protease free) and DNase (as before) led to a significant 
reduction in toxic activity of about 507. (table 33). Of the residual 
toxicity, most (707.) was recovered in the 30-507. precipitate as was 477. of 
the protein (a 1,5—fold purification). Considerably less HLT (11%) was 
recovered in the 30% fraction which contained 10% of the protein, and none 
in the other 2 fractions. The toxicity test data upon which the results 
given in table 33 are based are presented in appendix 5,
4.2.5 Gel filtration
Ultrogel AcA 44 was chosen as a gel filtration medium likely to be 
of value in separating HLT from other B. pertussis components as it had an 
effective fractionation range of 10,000-130,000 daltons, a range within 
which it was reasonable to assume HLT would fall. On this gel filtration 
medium 30-50% ammonium sulphate fractions yielded 4 major peaks, with HLT 
being eluted as a single peak on the front shoulder of the second and 
largest protein peak (figure 12),
In the initial run there was a recovery of 58% of the original 
toxicity (table 34) and 377. of the protein, a 1.6-fold purification.
However on the next run (figure 12) the resolution was improved by 
decreasing the size of the sample applied (from a 2.8% to a 1.2% loading)
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Table 32 Distribution of HLT in ammonium sulphate fractions of 
DNase-treated lysate supernatant fluid
Dose (|j.l)/mouse
Number of deaths/number of mice injected with
DNase-treated lysate 
supernatant fluid
16-40%
precipitate
40% supernatant 
fluid
68 14/16
34 12/16
17 3/16
8,5 3/16
140 8/8
70 7/8
35,5 3/8
17,8 0/8
500 7/8
250 8/8
125 8/8
62.5 8/8
31.2 0/7
^^50
23,6 42,5 40.7
Distribution of HLT (%) 100 56 58
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Table 33 The effect of DNase/RNase on the toxicity of lysate super­
natant fluid and on the distribution of HLT and protein 
after ammonium sulphate fractionation
Fraction Relative toxicity (%)• 
and 95% confidence 
limits
Protein 
Content (%)
Lysate supernatant fluid 100 100
DNase/RNase treated lysate 47 (32.67) 100
supernatant fluid
DNase/RNase treated lysate 
supernatant fluid
100 100
30% ppt 11 (7-18) 10
30-50% ppt 70 (44-117) 47
50-70% ppt 2 24
70% supernatant fluid <  3 16
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Figure 12 The elution profile for ammonium sulphate 30-507,
precipitates fractionated on Ultrogel AcA 44
Absorbance at 280 nm
Toxicity, Reciprocal of dilution 
giving a 2+ haemorrhagic response
Fractions pooled
Bed dimensions 
Eluant 
Flow rate 
Sample volume 
Fraction volume :
2,6 X 40 cm
0,15m  potassium phosphate buffer, pH 7,4
-2 -1 
3,2 ml.cm .h
2.5 ml
3.1 ml
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-2 “1 -2 -I.
and the flow rate (from 4.4 ml,cm .h , to 3,2 ml,cm oh ), The
fractions to be pooled were also selected more carefully with only those from
the front edge of the very large 2nd peak being included (ie, 28-31
inclusive)o By leaving out the toxic fractions which had a high protein
content there was some reduction in yield (from 58% to 34%; experiment 1
cf. 2, table 34) but this was more than compensated for by an even larger
reduction in protein (from 37% to 7-8%) to give a 4-5 fold purification
5 Molecular weight estimation by gel filtration
The molecular weight of HLT was determined by gel filtration of a 
partially purified preparation (a 30-50% ammonium sulphate precipitate) on 
a column of Ultrogel AcA 44 previously calibrated with human serum albumin 
(m.wt 66,500), ovalbumin (m.wt 44,000) and lysozyme (m^wt 14,400), as marker 
proteins, and dextran blue to measure the void volume. The point at which 
the toxin was eluted was located by monitoring the fractions for haemorr­
hagic activity in suckling mice. The peak of toxicity lay within the 
area between fractions 69-76, This gives Ve/Vo coefficients of 1,17 and 
1.29 which corresponds to a molecular weight of 89,000 daltons ( - 10% ), 
as can be seen in figure 13,
6 Production and characterization of toxoided HLT
6,1 Detoxification of HLT - the effect of temperature and formaldehyde
The detoxification of HLT by formaldehyde was investigated as a 
method for the production of a toxoid suitable for immunizing mice or 
rabbits. Most previous investigators have incubated the toxin at 37°C with 
0,1% (w/v) formaldehyde. Under these conditions detoxification is very 
rapid and is complete within 1 d. It was suspected that heat inactivation 
of the toxin may have had some part to play in the rapidity of this process. 
As heated toxin (56°C, 30 min) is ineffective for stimulating the production
153
Figure 13 Estimation of the molecular weight of HLT by-
chromatography on Ultrogel AcA 44
A plot of the logarithm of the molecular weight 
of standard proteins against the ratio of elution 
volume (Ve) to void volume (Vo),
HSA = Human serum albumin (mwt = 66,500)
0 = ovalbumin (mwt = 44,000)
L = lysozyme (mwt = 14,400)
elution behaviour of HLT as measured by the
haemorrhagic activity of fractions in 
suckling mice
Ve/V0
2-5
HSA
HLT
0
20 10010 200
( d  a I t o n s  x  1 0 ^ )
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of neutralizing antibodies to HLT (Evans, 1942) the use of the relatively 
high temperature of 37^C for the toxoiding of HLT might be inadvisable. 
Consequently, the effect of temperature in the detoxification at 37^C was 
investigated by comparing the rates of detoxification at this temperature 
with and without 0*1% (w/v) formaldehydeo This was complemented by doing
a similar test at 4°C. Altogether 3 separate experiments were performed 
but using the one batch of toxin throughout, a 100,000 x g Millipore- 
filtered lysate supernatant fluido In each experiment a portion of this 
toxin was taken and divided into the 4 samples required to test the toxin 
under each condition. Each sample was adjusted to a final concentration 
of 2 mg protein per ml, which was equivalent to 65 mouse LD^^ per ml, as 
determined from 4 independent estimations on the stock toxin solution (table 
35)o Portions of each sample were removed at intervals tlroughout a 14 d
period to assess their toxicity but before this could be done they had to
be dialysed to remove formaldehyde (if present), and part taken to confirm 
they were bacteriologically stérile*
The combined results of the 3 experiments performed are 
depicted in figure 14* At 4°C there was no appreciable loss of toxicity 
over the 14 d test period, even 1 in 10 dilutions of the 14 d samples were, 
in a dose of 0*5 ml, still toxic despite initially containing only about 
3 LD^Q, However there was a gradual detoxification during storage at 4^C 
with formaldehyde* By the 3rd day samples diluted 1 in 10 were no longer 
toxic and by day 9 all toxicity was lost. At 37°C detoxification with
formaldehyde was very rapid, all activity being destroyed within 1 d*
The control sample held at 37°C without added formaldehyde showed a 
different pattern of loss; although 1 in 10 dilutions were atoxic by day 3, 
the undiluted samples still had residual toxicity at day 14*
Thus it was confirmed that HLT was detoxified fairly quickly at 
37°C and, when formaldehyde was added, very quickly* Whereas HLT held at
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Table 35 The toxicity of the HLT preparation used to study the
effect of temperature and formaldehyde on HLT 
detoxification
Dose (fj,l)/ml
Number of <ieaths/number of mice injected. in experiment
1 2 3 4
40 NT NT 11/15 8/9
20 7/10 6/9 9/15 9/10
10 3/10 2/10 7/15 2/10
5 0/10 0/10 0/15 0/10
2*5 0/10 0/10 NT NT
LD^^/ml,
individual test
results 69 63 59 68
geometric mean value 65
NT Not tested
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Figure 14 Detoxification of HLT : the effect of temperature and
formaldehyde
O        O  4°C, undiluted toxin
• —  # 4^C, 1 in 10 diluted toxin
^  4°C 4- formaldehyde, undiluted toxin
^ ^  ^  formaldehyde, 1 in 10 diluted
toxin
B  —  ------- - ®  37^C, undiluted toxin
p  —-------------------" □  37°C, 1 in 10 diluted toxin
X  —-------- - X  37°C +  formaldehyde, undiluted and
1 in 10 diluted toxin
The figures In parentheses show the number of mice tested 
per point
(4)
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4°C was relatively stable, unless formaldehyde was present, and even then 
the detoxification proceeded relatively graduallyo Subsequently, a 
further two batches of toxin (lysate supernatant fluids) were treated with 
0.1% (w/v) formaldehyde at 4°C, since this latter temperature seemed to be 
potentially better than 37^C for producing toxoided HLTo After 15 d the 
toxicity of both preparations had fallen to 1-3% of that originally present 
(table 36; see appendix 5 for the data before statistical evaluation), 
a level of activity which would not perhaps have been detected in the initial 
detoxification experiments which used less potent starting material* The 
residual toxic activity would appear to be due to HLT since when the first 
of these latter mentioned batches of toxoid, which were free from formalde­
hyde, was tested in suckling mice it elicited a haemorrhagic response*
However when this material was heated (56°C, 15 min) there was no reduction 
in its lethal toxicity for 3-4 wk old mice, as if HLT had acquired heat- 
stability*
6*2 HSF and LPF activity in formaldehyde-detoxified HLT preparations
Having established that 15 d incubation at 4°C with 0.1% (w/v) 
formaldehyde inactivated HLT, it was decided to see what effect this treat­
ment had on the activity of the HSF and LPF present in lysate supernatant 
fluids* To do this, both batches of the above mentioned toxoid were 
assayed against the toxin from which they were prepared, although as native 
toxin was too toxic for use in HSF and LPF assays heated toxin (56^C, 30 min) 
was used instead* Unexpectedly the heated preparations were only about 
one-half as active as their formaldehyde-detoxified counterparts (table 37; 
see appendix 5 for the HSF data prior to statistical evaluation). If HSF 
and LPF are heat-stable, requiring treatment at 80°C for inactivation, 
these results suggest formaldehyde treatment enhances their activity*
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Table 36 Reduction in HLT activity after 15 d incubation at 4 C 
with Ool7o (w/v) formaldehyde
Expt. Sample Test
Mouse LD^g/ml
Individual test 
result
Sample 
geometric mean
1 Untreated HLT 1 125 111
2 98
3 113
Formaldehyde treated 1 2*5 1.7
HLT 2 1.4
3 1.5
2 Untreated HLT 1 294 285
2 322
3 245
Formaldehyde treated
HLT 1 3*6 3.6
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Table 37 HSF and LPF activities in formaldehyde-and heat-
(56 C, 30 min) detoxified lysate supernatant fluids
Pathophysiological Relative potency and 95% confidence limits of heat-
activity detoxified sample (formaldehyde treated samples =
100%)
Exp to 1 Exp t. 2
HSF 40 (27-61) 76 (27- 213)
LPF 48 (34-64) 36 (15-61)
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6*3 Immunogenicity of formaldehyde-detoxified HLT in mice
Mice were actively immunized with the formaldehyde-detoxified 
HLT described above (experiment 1, tables 36 and 37), in an attempt to 
produce animals with demonstrable levels of anti-HLT, and thereby confirm 
that in detoxifying HLT a toxoid had been made, and provide animals for 
assessing whether antitoxin might have protective activity in experimental 
Bo pertussis infections of mice*
In. the initial two experiments a variety of immunization 
conditions were tested, viz* the use of adjuvants (Freund's complete and 
incomplete, AlOH^), injection routes (intraperitoneal, subcutaneous, intra­
muscular) and number of injections (1 or 2), These mice received either
100 or 200 jig of protein, which corresponded to 5*6 or 11*2 mouse LD^^
equivalents of HLT, However, with a few exceptions, these mice were 
unable to resist an intraperitoneal challenge with 5 or 3 mouse LD^^ of 
HLT (tables 38 and 39). Moreover, sera taken from those mice which 
survived the challenge did not show any sign of toxin-neutralizing capacity
when mixed with 5 suckling mouse MRD of HLTo However most of the sera
contained precipitins to the toxoid as demonstrated by crossed-over electro­
phoresis, and therefqre had at least made an immune response to the 
"toxoid", if not to HLT itself.
In a further experiment the number of immunizing injections was 
increased to 3 and the dosage of toxoid to 14 mouse LD^^ equivalents*
Four different immunization protocols were followed, using 80 mice in all,
4 of which died during the course of the immunization* Forty of these 
mice, 10 from each type of immunization followed, were challenged with 
3 of a previously titrated toxin preparation, although this was
checked by including unimmunized mice in the test and giving them undiluted 
or 1 in 3 diluted challenge toxin (table 40)* Five of the 40 immunized mice
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challenged died within a few hours of the challenge, too soon to be 
toxicity deaths, probably anaphylactic deaths* This further verifies 
the intensity of the immunization procedures used. However the immunizat­
ion was still insufficient to protect mice from a challenge with HLT, only 
2 survived. These mice were bled and their serum pooled (serum E) and 
tested for antitoxin. There was some indication that when serum E was 
mixed with one suckling mouse MRD of HLT there was neutralization, but this 
was unconfirmed as there was insufficient material for re-testing. Pooled 
sera were also prepared from the remaining 35 mice which had been immunized 
but not challenged with HLT; there was a serum for each of the 4 immunizat­
ion protocols followed (ie, A, B, C and D)* However all 4 lacked anti­
toxin, being unable to neutralize even one suckling mouse MRD of HLT* 
Nevertheless, the mice had made a stronger immune response than in the 
initial two experiments* On crossed-over electrophoresis of sera A, B, C 
and D with toxoid, precipitin lines were both more numerous and stronger 
than before* That precipitins had been produced can also be shown by 
comparative immunodiffusion (plate 15) although fewer lines can be resolved*
6*4 Immunogenicity of formaldehyde-detoxified HLT in rabbits
Having failed to produce mice with demonstrable levels of 
circulating antitoxin by active immunization, it was decided to do so by 
passive immunization, provided antitoxin could be raised to the formaldehyde- 
inactivated HLT viz* that the latter was a true toxoid. Consequently, 
the same "toxoid" used with the mice was given to rabbits, a species known 
to be capable of producing antitoxin. Two rabbits (A and B) received 
560 mouse LD^^ equivalents of "toxoid" or 10 mg of protein, whilst two others
(C and D) were given 914 mouse LD^^ equivalents or 16*3 mg of protein* All
4 rabbits were then bled, and serum from each tested for its ability to
neutralize the haemorrhagic activity of HLT*
]63
Plate 15 Comparative immunodiffusion analysis of sera from mice injected with 
toxoided HLT
©
1
1 Toxoided HLT, 1 mg protein per ml
Sera raised to:-
A Plain toxoid (3 doses)
B Toxoid/AlOH^ (2 doses) 4- plain toxoid (1 dose)
C Toxoid/Freund's incomplete adjuvant (2 doses) +
plain toxoid (1 dose)
D Toxoid/Freund's complete adjuvant (1 dose) +  Toxoid/
Freund's incomplete adjuvant (1 dose) +  plain toxoid (1 dose)
E Plain toxoid (3 doses) +  an intraperitoneal challenge with
3 LDrn of toxin 50
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On discovering that at least two of the rabbit antisera contained 
antitoxin, portions of each were absorbed with live B. pertussis cells to 
leave as few antibodies as possible to B. pertussis components other than 
HLTo This was of great importance if anti-HLT antibodies were to be 
assessed in experimental B. pertussis infections for protective activity.
Altogether 7 sera were titrated for their antitoxin content; the 
4 rabbit antisera described above (A, B, C and D), their absorbed derivatives 
(B^^ and and finally the US standard antipertussis serum which was to
be included as a reference preparation in the passive mouse protection 
tests* In the final analysis it was found that antisera from 3 of the 4 
rabbits contained antitoxin (tables 41 and 42)* Antisera B, C and D had 
mean HLT neutralizing titres of 1,000, 120 and 100 units per ml respect­
ively, whilst antiserum A lacked antitoxic activity ie, <  40 units per ml 
(40 units per ml corresponds to 0.025 ml of undiluted serum in the 0,05 ml 
injection mixture)* With the exception of antiserum B the antitoxic 
response was poor, especially when it is considered that the development of 
the haemorrhagic reaction in suckling mice is one of the most sensitive ways 
of assaying HLT* The size of the response was not apparently determined by 
the amount of toxoid given* Rabbit B received 40% less toxoid than either 
C or D, yet antiserum B had about 10 times the antitoxic activity of anti­
sera C and D, Somewhat surprisingly, after repeated absorption with live 
cells of B, pertussis 134 antiserum B (1,000 units of antitoxin/ml) lost 
75% of its antitoxic activity and antiserum D (100 units of antitoxin/ml) 
actually became toxic* The US standard antipertussis serum lacked antitoxic 
activity.
The agglutination titres of all 7 antisera were also determined, 
since agglutinin might also exert a protective effect in the passive mouse 
protection tests. Three separate paired titrations were completed for
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each antiserum using the method of Preston (1970) with B. pertussis 134 
as the indicator organism. This was the strain, from which the toxoid 
used to immunize rabbits A-D had been prepared, and with which antisera 
B and D were absorbed. As can be seen from table 43, the antisera raised 
to the toxoid had fairly low agglutination titres (600-1,200), much lower 
than the titre of about 8,000 for the US standard antipertussis serum.
As expected there was no detectable agglutinin in the absorbed sera.
However as another index of how successful the absorption had been, these 
antisera were compared with the others by immunodiffusion (plate 16), The 
large numbers of antigens present in the crude toxoid and the extent of 
the immune response made to them is clearly shown. The maximum number 
of precipitin lines which could be resolved for the interaction between
toxoid and each antiserum were as follows: A, 8; B, 6; 3; C, 7;
3-Td
D, 5; D , 3; the US standard antipertussis serum, 5„ Absorption of
antisera B and D resulted in the loss of at least 3 and 2 precipitin lines
respectively. Additional precipitin lines did form however, between 
these absorbed sera and neighbouring sera, indicating the acquisition 
during absorption of B. pertussis components.
In plate 17 the antisera have been allowed to interact with both
toxoid and the toxin from which it was derived. It is obvious that the
toxoiding process has not grossly altered the antigens in the crude HLT 
starting material,
7 Antitoxic immunity and protection of mice against intracerebral and 
intranasal challenges with B. pertussis
The role of antitoxic immunity in B. pertussis infections was 
investigated by assaying the antisera described in the preceding sections 
for their ability to protect mice against lethal intracerebral (IC) and
Table 43 Characterization of rabbit antisera : antitoxin and
agglutinin titres
170
Antiserum Mean antitoxin titre^ 
(units/ml)
Mean agglutinin titre
A "*= 40 1280
B 1000 570
B^^ 240 -= 1
C 120 640
D 100 800
Toxic after absorption <  1
US <  40 8130
1 Where a unit is the smallest amount of antitoxin required to
neutralize one MRD of toxin in suckling mice. The geometric mean 
values presented are based on the data given in tables 41 and 42
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Plate 16 Comparative immunodiffusion analysis of rabbit sera against crude 
toxoided HLT
3b
b©  ©  ©"
© ©
©  © a b  @  ©
©
1 Formaldehyde-detoxified HLT preparation (2 mg protein/ml)
A,B,C and D Undiluted rabbit sera raised to 1
B^^ and Undiluted rabbit sera B and D after absorption
with B. pertussis 134 
US US standard antipertussis serum
\V
17:
Plate 17 Comparative inimuriodiffusion analysis of rabbit sera against 
crude toxoid and the toxin from which it was made
©  ©
© ©
© © © © 
© ©
©  ©
© ©
1 Formaldehyde-detoxified HLT preparation (2 mg protein/ml)
2 Active HLT preparation (2 mg protein/ml)
A,B,C and D Undiluted rabbit sera raised to 1 
3 Id
B Undiluted rabbit serum B after absorption with
B, pertussis 134 
US US standard antipertussis serum
w
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sub-lethal intranasal (IN) challenges with B. pertussis 18323, The antisera 
were given either diluted 1 in 2 with the challenge organisms (IC/mix or 
IN/mix) or undiluted in a 0,2 ml volume, intraperitoneally 1-4 h before the 
challenge (IP/IC or IP/IN). In the mix tests heat-treated antisera (56^C,
10 min) were used, to prevent complement mediated killing of the challenge,
7.1 Passive protective activity of rabbit antisera in B. pertussis
intracerebral infections of mice
Of the 5 antisera (A, B, C, D and the US standard antipertussis 
serum) tested in the IC/mix experiments only the US standard antipertussis 
serum gave substantial protection as shown by a highly significant 
(P c  0,005) reduction in mortality. When mixed with 250 of the
challenge organism only 1 of 30 mice died during the 14 d test period as 
compared to the 100% mortality experienced in the groups of control mice 
(table 44), In sharp contrast to the high protective potency of the 
standard antiserum, which contained no antitoxin, was the lack of protect­
ive activity (35 deaths out of 40 mice tested) associated with antiserum B, 
which had an antitoxin titre of 1,000 units per ml. Antibodies against 
HLT would seem therefore to have no protective effect in the IC/mix test.
Even the few mice which did survive when given antitoxic serum B are 
unlikely to have done so because of anti-HLT antibodies, since this effect 
was also evident with antisera which contained less than 15% of the anti­
toxin present in B but which were raised to the same toxoid as B ie, A,C 
and D. The type of protective antibody which these latter mentioned 
antisera lack but which the standard antiserum so obviously contains 
could be agglutinin. Against B. pertussis 134 the standard antiserum had 
a titre of 8,130 as compared to 1,280 for antiserum A, the antiserum with 
the next highest titre. However antibodies directed at other components 
of B. pertussis cannot be ruled out.
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Table 44 Passive protection of mice against a lethal intracerebral 
challenge with B. pertussis 18323 (L6d H2), by rabbit 
antisera
Test Serum
Number of deaths/number of mice challenged, for 
experiments 1-6
1 2 3 4 5 6 Total
IC/mix A 9/10 10/10 NT NT NT NT 19/20
B 8/10 10/10 8/10 NT 9/10 NT 35/40
C 9/10 9/10 NT NT NT NT 18/20
D 9/10 10/10 NT 8/10 NT 10/10 37/40
US 1/10 0/10 NT NT NT 0/10 1/30
IP/IC B NT NT 5/10 NT 8/10 NT 13/20
D NT NT NT 6/9 NT 9/10 15/19
IC/mix Normal 10/10 10/10 10/10 10/10 10/10 10/10 60/60
Control None 10/10 10/10 10/10 10/10 10/10 10/10 60/60
1/10^ None 10/10 10/10 9/10 9/10 9/10 10/10 57/60
1/50^ None 8/10 10/10 10/10 9/10 10/10 9/10 56/60
1/250^ None 3/10 6/10 4/10 7/10 6/10 4/10 30/60
a Dilutions of the challenge culture used to confirm that a 250 LD 
challenge was being used
50
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Only two antisera (B and D) were tested for protective activity 
in the IP/IC test. With antitoxic serum B (1,000 units of antitoxin/ml) 
there was a highly significant (P <  0,005) reduction in mortality ie, 
only 13, instead of 20 out of 20 dead. With antiserum D, which contained 
only 10% of the antitoxin present in B but had about the same agglutinin 
content, there was also protection (P -= 0,05), Unfortunately further 
experimentation which may have clarified the relative protective properties 
of these two antisera was prohibited by the fact it was a rather extrava­
gant use of scarce antisera. For the same reason, the experiments with
antiserum B could not be followed up using its absorbed but antitoxic 
derivative, antiserum B^^,
7o2 Passive protective activity of rabbit antisera in sub-lethal,
B. pertussis respiratory tract infections of mice
The antitoxic antiserum B was also tested for its protective
properties in IN/mix and IP/IN tests in mice. On the 14th d after the
5 +intranasal administration of 10 cfu of B, pertussis 18323 ( - antiserum )
mice were sacrificed, and their lungs cultured and examined for signs of
consolidation. Both these features were scored on a 0-4 basis and the
combined scores taken as an index of the severity of the infection (0 =
no infection, 8 = very severe infection). In table 45 the protective
properties of antiserum B are assessed by comparing the mean lung scores
of the animals in the test and control groups of mice. Antiserum B
exerted a significant (P j^ 0,05) protective effect in the IN/mix tests
and to a lesser extent in the IP/IN tests. When the same data is
interpreted taking into consideration only whether mice were infected (ie,
with lung scores ^ 1 )  or not, and disregarding the grade of infection
the results shown in table 46 are obtained. Again, in this a more
severe test of protective activity, it can clearly be seen that
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antiserum B was effective. In IN/mix tests, it gave substantial and
statistically, highly significant protection (P <  0,005), The combined
data for experiments 1-4 show that there was a reduction in the numbers
of mice infected, from 90% (34 infected out of 38) for the challenge
control mice which received no serum, to 33% (12 infected out of 36),
Even if only the experiments ( 1 + 2 )  which included controls given normal
serum are considered, there was still a marked reduction in the number of
mice infected viz, from 85% (17 out of 20 infected) for the normal serum
mix controls, to 40% (8 out of 20 infected). In the IP/IN tests, it was
found once more that antiserum B was less effective than in the IN/mix
tests, but it still gave significant protection (P «c 0,05) viz, only b07o
of the mice given antiserum B were infected (18 out of 30), compared to
93% (26 out of 28) in the corresponding control mice.
However, although antitoxic antiserum B was protective, it was
by no means certain that this effect was mediated by anti-HLT, To try
and clarify the relationship between antitoxin and protection, several
antisera with varying degrees of antitoxic activity were tested for
protective activity in the IN/mix test. It was of particular interest
3-b
to see how antiserum B , the absorbed but still antitoxic derivative of
antiserum B, performed. Once more antiserum B was shown to be protective,
although on this occasion there was only a significant reduction (P 0,05)
in the severity of the infection and not in the actual numbers of mice
ab
infected (table 47), However, antiserum B completely lacked protective 
activity, which suggests that antibody to some component other than HLT 
was conferring the protection given by antiserum B, This interpretation is 
supported by the finding that antiserum A was protective, whilst lacking 
antitoxin and having been raised to the same toxoid as used to produce 
antiserum B,
Table 47 Passive protection of mice by various antisera
in the sub-lethal IN/mix test
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Antiserum Proportion of mice infected P Mean lung scores P
A 4/10 0.01 0.6 0.05
B 6/9 0.05 0.8 0.05
B^^ 10/10 0.05 6.2 >  0.05
C 4/10 - 0.01 0.4 ^=0.05
D 6/9 0.01 1.9 zs 0,05
10/10 0.05 5.1 > 0 . 0 5
US std 1/10 - 0.01 0.2 ^  0.05
Normal 10/10 5.2
None 8/9 5.1
Protection was assessed by the combined lung culture and pathology scores 
(maximum score - 8,0), and animals with any score ^  1 were counted as 
infected
DISCUSSION
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1 Assaying the toxicity of HLT
1.1 Measurement of the lethal effect in mice
There are two well established ways of assaying HLT, namely by 
its mouse lethality and its dermonecrotic/haemorrhagic activity. Although 
not as sensitive as the dermonecrotic assays, the mouse lethal toxicity 
test was chosen here as the standard procedure. It is simple and gives 
clear-cut results that are amenable to statistical analysis. Moreover the 
local facilities were geared to providing mice rather than the guinea pigs 
or rabbits normally used for the assay of dermonecrosis.
Although the choice of injection route and observation period 
were based upon the experiences of others, few data were available on the 
influence of mouse sex or weight upon the response to HLT. Therefore 
experiments were performed to provide information on these points. B. per­
tussis cell-lysates were used as a source of HLT. That HLT was the 
principal toxin in these lysates was shown by the fact that 98% or more of 
the lethal toxicity was destroyed by heating at 56°C for 20 min.
Both male and female, 3-4 wk old HAM/ICR mice were equally 
sensitive to the lethal toxicity of B. pertussis cell-lysates ie, HLT, 
Nevertheless to err on the side of caution mice of one sex were used where 
possible in subsequent work or, when both sexes had to be used, they were 
distributed evenly between preparations.
When non-weight adjusted doses of lysates were given to groups 
of 10.0-13,5 g and 18,0-23.0 g, 3-4 wk old HAM/ICR mice, two somewhat 
conflicting results were obtained. With one sample of HLT there was about 
a 50% lower toxicity in the large mice, but with another sample this could 
not be confirmed. It is possible that the two HLT preparations both of 
which were derived from Hornibrook-grown cultures of B. pertussis 18334 
were qualitatively different in some way, or the result may have arisen
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purely by statistical fluctuation. In any case the difference was not 
large. The matter was not therefore explored any further, but in sub­
sequent tests, mice of different weights were always distributed evenly 
among the various test preparations. It may be noted that there is not 
necessarily a simple proportional relationship between susceptibility to 
a toxin and body weight. For instance, no systematic proportionality 
exists between body weight and the response of mice to botulinal toxins 
(Lamanna, Jensen and Bross, 1955).
1.2 Measurement of the haemorrhagic activity in suckling mice
Where circumstances dictated that only small amounts of HLT be 
utilized, the toxin was assayed by its haemorrhagic activity in suckling 
mice (eg, Katsampes, Brooks and Bradford, 1942), This assay was at least 
10 times more economical than the lethality test in 3-4 wk old mice; 0.05 ml 
of a toxin solution containing 1 mouse LD^q iu 0.5 ml, as measured in 
weaned mice, gave a definite haemorrhagic reaction in suckling mice. 
Applications of the haemorrhagic assay included the screening of fractions 
for HLT activity during purification by column chromatography and for 
testing antisera for HLT-neutralizing antibodies. This latter category 
of experiment led to an unexpected finding. In 4 out of 5 experiments,
HLT elicited a slightly, but significantly, more severe haemorrhagic response 
when diluted 1 in 2 with normal rabbit serum instead of PBS, However, 
because this enhancement effect was relatively small, it was not explored 
further. Nevertheless the possibility was considered that HLT may exist 
as a precursor or zymogen which must be activated for toxicity to be mani­
fest, as suggested by Anderson and North (1943). Alternatively, the serum 
may have prevented HLT being lost by adsorption onto glassware. Results 
presented by Nakase £t a^ (1969) could be viewed as supporting this latter 
interpretation since the rabbit dermonecrotic activity of their purified
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HLT was 2-4 fold greater when any one of normal rabbit serum, bovine serum 
albumin, B. pertussis agglutinogen or heated sonic extract was included 
in the injection mixture. It should be possible to avoid the loss of HLT 
by adsorption onto glassware by using gelatin containing buffer as diluent. 
However, although the addition of extraneous proteins to purified HLT may 
be important for this reason it seems less plausible as an explanation 
where a crude HLT fraction is in use ie, a lysate supernatant fluid con­
taining 50 [ig protein per ml. Irrespective of the mechanism behind the 
enhancement phenomenon, it necessitates the use of dilutions of normal 
serum in parallel with dilutions of antiserum when titrating the latter 
for HLT-neutralizing antibodies.
Prior to the adoption of the haemorrhagic suckling mouse assay, 
a few adult hairless mice (Hr/Hr) which were available in the department 
were injected intradermally with 0.05 ml of a toxic 100,000 x g lysate 
supernatant fluid. A dermonecrotic response developed. The most 
prominent feature of the reaction in the first few days was a raised pale 
spot. With the larger doses small pinpoints of necrosis were evident 
within this area and they gradually developed and coalesced to form necrotic 
plaques. These irregular depressed necrotic lesions did not lend them­
selves to being measured. Likewise the pale spots although well defined 
blebs at low doses were not well defined at high doses. Note that this is 
in contrast to the report that mice are resistant to the dermonecrotic 
effect of HLT (Violle,1950 cited by Munoz, 1971), although it is not clear 
whether this refers to adult or suckling mice. Primarily for reasons of 
convenience, and the distinctiveness and rapidity of appearance of the 
haemorrhagic lesion in 4 d old mice, the latter were used.
1.3 Testing HLT for haemolytxc activity
One of the major drawbacks with investigations on HLT is the
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dependence on animal experimentation for titrations of the toxin. If 
the haemolytic activity of B. pertussis was a property of HLT it would be 
possible to develop a simple, rapid and inexpensive assay. However it 
was found that neither sheep, rabbit, horse, human (0, rhesus +) nor cod 
red cells lysed in the presence of as much as 2.5 mouse LD^^ per ml of 
toxin (100,000 x g, lysate supernatant fluid). Neither was there a hot- 
cold lysis. It therefore does not seem likely that HLT has haemolytic 
activity. With hindsight it might have been useful to have looked for 
haemolysis with HLT in a cysteine-containing buffer, in case the haemolysin 
was oxygen-labile.
Another possible assay for HLT that was considered was the 
lethality test in intravenously injected embryonated eggs, which according 
to Novotny (1977, personal communication) are particularly sensitive to 
killing by this toxin. However such an assay would be less convenient 
than the 3-4 wk old mouse lethality test or the haemorrhagic assay in 4 d 
old mice. Another more promising possibility would be to assay HLT by 
its cytotoxicity for tissue culture cells. Although perhaps not as 
convenient or inexpensive as a haemolytic assay, it would enable experiment­
ation on a scale unlikely to be realized by animal-based tests. Some 
groundwork has already been done in showing that certain mammalian cell- 
lines are susceptible to HLT (eg, HeLa and primary cultures of mouse 
embryonic tissue : Angela, Rosso and Giuliani, ,1962a and b ; Strizova 
and Trlifajava, 1964) but these reports require confirmation.
2 Storage-stability of HLT
The stability of HLT (cell-lysates) to storage at -20°C for 
periods up to 3 yr was investigated. Of the 4 different samples tested,
2 showed no decrease in activity whilst 2 lost activity at rates of 
about 207. per annum. Taken collectively the data indicate an annual loss
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in toxicity of about 10% under these conditions, which included repeated 
freezing and thawing of the samples. Alternatively, the results could be 
said to show that genetic drift in the test mice had made them more resist­
ant to HLT but this explanation seems improbable since it would predict 
that all 4 lysates would respond as one and this was not the case. In 
conclusion, storage at -20°C is satisfactory, as the rate of decay was slow
enough to have little appreciable effect over a year or two, but storage
after freeze-drying or in 50% glycerine or sucrose may be equally good..
3 Antigenic variation and HLT production
3.1 Antigenic modulation
It is generally accepted that B. pertussis cells injected intra­
peritoneally into mice do not multiply and that death is due to a toxaemia 
(eg, Anderson and North, 1943; Proom, 1947), On this basis we can inter­
pret the results of Lacey (1960) who reported that the intraperitoneal
mouse of strain H5 B, pertussis when in the X-mode was *'ca. 2 x 10^ '*
g
and while in the C-mode "ca. 2 x 10 One part of the present invest­
igation was to demonstrate more directly that growth of B. pertussis in the
high magnesium sulphate C-medium results in markedly reduced levels of HLT,
The toxicity being measured when X-mode B, pertussis cell-lysates 
were injected intraperitoneally into mice was heat-labile (56°C, 20 min), 
at least to the extent of 98%. Presumably the residual 2% toxicity in 
56°C heated preparations is due to endotoxin and/or pertussigen. The 
work done in this investigation showed that during antigenic modulation the 
heat-labile toxin was quite definitely lost. In the 3 strains of 
B. pertussis examined, in a series of 7 independent growth experiments, 
there was a reduction in the toxicity of the C-mode samples to 2.4 - 6.9% 
(mean 4,4%) of their X-mode counterparts. This loss of HLT was not due 
to excretion into the surrounding culture medium since the C-mode culture
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supernatant fluids were atoxic. The residual 4-5% toxicity in C-mode 
cells was not tested for 56^C stability and therefore it is not possible 
to say whether the loss of HLT was absolutely complete, or whether the 
C-mode cells contained endotoxic (LPS) activity plus 2-3% of the original 
HLT of the X-mode cells.
Hitherto most of the changes associated with the X- to C-mode 
transition have involved components or features of the cell surface or 
envelope of B, pertussis ie, the agglutinogens and haemagglutinin, PA, HSF, 
LPF, adjuvant(s) for reaginic antibody and hyperacute EAE, adenylate 
cyclase, cytochrome d-629 and the 28K and 30K polypeptides. Also, C-mode 
cells autolyse more rapidly and are less readily agglutinated by AuCl^ and 
HgCl2 which again indicates changes in the exterior regions of the cell.
The present work shows that HLT which is a cytoplasmic component (Cowell, 
Hewlett and Manclark, 1979) is also lost during antigenic modulation. 
Therefore the changes which take place during antigenic modulation are 
not restricted to the cell— envelope. It may also be noted that C-mode 
colonies on blood containing medium are non-haemolytic, which suggests 
that a diffusible haemolysin may also be affected by antigenic modulation.
3,2 Nicotinic -acid induced modulation
During growth in media with high levels of nicotinic acid, 
changes may be induced in B, pertussis which are similar to those seen 
during growth in high-Mg induced (antigenic) modulation (Pusztai and Joo, 
1967; Wardlaw, Parton and Hooker, 1976). However there are differences 
between high-Mg and high-nicotinic acid grown cells. According to 
Pusztai and Joo (1967) the latter retain their full toxicity.
In the present investigation B. pertussis 134 was grown, in 
two separate experiments, in media with high levels of nicotinic acid 
(500 |ag/ml)o Cells grown in these media showed loss of the 28K and 30K
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cell-envelope polypeptides and in one instance at least the loss of HSF, 
as is characteristic for modulated cells. In the other experiment it was 
not clearly established whether HSF was lost or not. There was certainly 
not the 16 or more fold decrease that accompanied modulation in the first 
experiment but a more modest reduction seems to have occurred. However 
levels of HSF often fail to decline as markedly during nicotinic acid 
induced modulation as compared to antigenic modulation (Pusztai and Joo, 
1967; Wardlaw, Parton and Hooker, 1976). But to come to the main point,
it was found that the high nicotinic acid grown cells were 60% less toxic
than their normally grown counterparts. These differences were statistic­
ally significant. This observation should be investigated more fully 
with strain 134 and with other strains. The differences between the 
observations made here and those of Pusztai and Joo (1967) might be
explained by the different strains used. It would be of particular
interest to discover the response of strain 18323 which is specifically 
reported as not modulating during growth in media with high concentrations 
of nicotinic acid (Pusztai and Joo, 1967),
The control mechanisms which regulate magnesium- and nicotinic 
acid-induced modulation are not known. However it appears that HLT 
production is controlled to some extent independently from the production 
of HSF and the 28K and 30K cell-envelope polypeptides.
4 HLT production and purification
4.1 Production
4.1.1 Strains
Before embarking on the purification of HLT it was considered 
worthwhile to screen a selection of B. pertussis strains to choose the best 
producer of HLT, With certain other toxigenic bacteria outstandingly 
good toxin producers exist such as Wood 46 for a toxin production by
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Staphylococcus aureus (Bernheimer, 1970) and PW8 for toxin production by 
Gorynebacterium diphtheriae (Zabriskie, 1970). At present, no univers­
ally accepted HLT-producing strain of B. pertussis has come to the fore.
In the initial screening, 10 strains of B. pertussis were 
tested in a series of small trials that permitted rapid assessment of 
their HLT producing potential. Among these strains were some selected as 
being potentially useful,including two recently isolated strains, a 
strain used in a purification study (Maeno) and another discarded as a 
vaccine strain because of its toxigenicity (No. 28). However all the 
strains tested were very similar in their toxicity with only a 3-fold 
difference between the least and most toxic. It is of interest that the 
two recently isolated strains were unremarkable in their toxicity relative 
to the established laboratory strains and despite the possibility that 
repeated subculture may lead to reduced toxigenicity (van Heyningen, 1970). 
However, of the 3 strains which looked promising (ie, Maeno, No. 28 and 
134) there were 2 which had been pre-selected as being potentially good 
toxin producers. On re-assessing the toxicity of the strains Maeno, No. 28 
and 134 by re-testing the original samples and twice testing samples from a 
further growth experiment, the original findings were confirmed. These 
strains were 2-3 times more toxic than the arbitrarily chosen reference 
strain 18334, More often than not this 2-3 fold difference was statistic­
ally significant. However the 3 strains themselves could not be put in 
any rank order and this led to B. pertussis 134, which grew well, being 
chosen.
A further 4 strains were tested at various times after this 
initial selection process. There were no indications that any of these 
contained more HLT than strain 134, although strain 44122/7R appeared to 
be of similar toxicity. Included in one of these later tests was strain 
B-1593/57 which Spasojevic (1977) found to be the most toxic of the 201 
strains which she had examined.
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The assumption is made throughout, from evidence already presented, 
that the toxicity measured here by intraperitoneal injection of mice with 
B, pertussis cells is due, essentially completely, to HLT.
4.1,2 Culture medium and time of harvest
Since no particular medium has been proved superior for the 
cultivation of B. pertussis, 4 media were investigated since it is known 
that medium composition influences HLT production viz. when the levels of 
either glutamate or proline in the IG +  IP medium of Stainer and Schblte 
(1971) were increased by 12-32 fold the amount of HLT produced was 
increased (Stainer, 1977 personal communication). In this study Stainer 
and Scholte (12G) medium, modified Hornibrook medium, Bordet-Gengou medium 
and charcoal agar were compared, B. pertussis cells were harvested after 
24 h and 72 h g-'-owth as it had been reported that greater yields of toxin 
are obtained per cell when cultures are harvested prior to reaching peak 
opacity (Stainer, 1977 personal communication). In this appraisal of the 
different cultural conditions on HLT production 3 strains were used to 
confirm that the findings were applicable to more than just one strain of 
B, pertussis. These strains were B, pertussis 134, selected from 14 
strains by its toxigenicity, the recent isolate 77/18319 and strain 18334, 
a routine vaccine strain from Connaught Laboratories, Toronto.
None of the media tested was outstanding in its ability to 
promote HLT production. All yielded cells of similar toxicity. There 
were indications however that strain 18334 gave 1.5-2.5 times more toxin 
in Stainer and Scholte (12G) medium than in modified Hornibrook medium, 
whereas a reversal of this trend was apparent with strain 134 (1,5 fold- 
differences in yields). Similarly if choosing between charcoal agar and 
Bordet-Gengou medium for producing toxigenic organisms of strain 134 or 
77/18319 charcoal agar would possibly be a marginally better choice.
However with such small differences, it would have taken extensive toxicity
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tests to obtain fully conclusive data and this was not done. Nevertheless 
on solid media, cells collected after 24 h growth were generally more toxic 
than at 72 h, whereas the opposite occurred in the two liquid media. 
Recently Cowell, Hewlett and Manclark (1979) related toxin production in 
Stainer and Scholte (16G + IP) liquid medium to the growth cycle of batch 
grown Bo pertussis. Cells were most toxic during the mid-exponential 
growth phase and varied as much as 10-fold in specific activity.
In all experiments the toxicity of the culture supernatant 
fluids was examined also. There was little sign that HLT was excreted 
into the surrounding medium in any of the cultures. Only in B, pertussis 
18334 and 134, 72 h Hornibrook-grown cultures was there evidence of HLT 
in the supernatant fluids. This may reflect release by autolysis as 
opposed to active excretion. The recently isolated B, pertussis strain 
77/18319 showed no signs of HLT release either by lysis or excretion.
Of the 3 strains just mentioned, this latter might have been anticipated 
to be the most likely to do so, for if HLT is involved in the pathogenesis 
of pertussis it would seem necessary for toxin to be released. Of 
course, this may occur readily vivo but not under the conditions used 
here,
4.1,3 Iron content of medium
With at least 6 toxigenic bacterial species, the iron content 
of the growth medium is critical for toxin production, with high levels 
suppressing the amount of toxin made (page 44). With all 6 of these
species the optimal concentrations of iron lie between 0.1 and 1.0 mg per
litre of medium. For instance, with diphtheria toxin the optimal concen­
tration has been given as 0.14 mg/1. However if the iron level is
increased to 0.5 mg/1 there is complete inhibition of toxin production 
(Pappenheimer and Johnson, 1936), The production of HLT by B. pertussis
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appears to be independent of the amount of iron in the medium over a
wide range of concentrations, from 0,03 to 6.3 mg per litre. None of
the cells or the culture supernatant fluids from any one of the 6 test 
media were appreciably more toxic than the others. However there is a 
case for further investigation of other than just B. pertussis 134 to which
this study has been confined since this lack of responsiveness may be a
strain peculiarity. Mueller and Miller (1945) identified a strain of 
Clostridium tetani which did not manifest the sharp dependence on a low 
and definite iron concentration for toxin production as is typical for 
this species.
However the iron content of the medium did influence B. pert­
ussis 134 in other ways. Growth in the iron deficient medium yielded 
fewer cells, and when pelleted, these cells were very pale especially in 
comparison to cells from the iron rich medium which when pelleted were 
rusty brown. As the colouration was uniform throughout the pellet this 
indicates changes in the bacteria, perhaps in their cytochrome content, 
and not merely precipitated ferric hydroxide.
4.2 Purification
4.2.1 Disruption of B. pertussis and release of HLT 
The first step in most purifications of HLT is disruption of 
the bacteria. Several methods have been used by other investigators to 
lyse B. pertussis cells to release the toxin (appendix 1) but an X-press 
was used throughout this work. Features of the X-press which make it 
suitable include
i) No heat generation or frothing during disruption
ii) very effective disruption eg, 3 pressings of B, pertussis cell-
paste provides complete ( >  99%) disintegration
iii) large quantities of cells can be processed ie, 10-20 ml of a
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concentrated cell suspension or even a cell-paste*
When freshly harvested B. pertussis was lysed by 3 passages 
through the X-press there was a marked increase in toxicity. With 3 
samples tested on the day of X-pressing this increase ranged from 8-14 
fold. With a 4th sample which was stored frozen prior to toxicity 
testing a 4,1-fold increase was noted but it is not possible to conclude 
from the data whether this value is significantly smaller. On several 
other occasions when X-pressing was done to cells which had been already 
stored overnight at -20^0, there was little (lo7-3,3 fold) increase in 
toxicityo There were no indications that these latter cells had lysed 
appreciably after being stored frozen overnight; cell suspensions after 
X-pressing became very viscous and the turbidity decreased considerably 
but there was no evidence for either of these events having occurred* 
Moreover no difference was found in the viability or toxicity of cells 
stored at 4°C for a few hours and those subjected to 5 cycles of freezing 
(-20°C) and thawing (room temperature)* Evans and Maitland (1937) found 
no difference in toxicity even after 25-30 cycles of freezing and thawing* 
Perhaps when freshly harvested cells are lysed, HLT is converted by 
proteolytic action from an inactive to an active form, but when cells are 
stored frozen the proteolytic activity is impaired* Although conjectural, 
this would agree with the suggestion made earlier that serum protease may 
be responsible for enhancing the haemorrhagic activity of HLT (Discussion, 
1.2)* This hypothesis could be tested by adding freshly lysed cells to a 
lysate which had been stored frozen and looking for activation of the 
latter* Alternatively the size of the increase in toxicity on X-pressing 
may be related to the cultural origin of the cells eg, growth in Stainer 
and Schblte (12G) medium compared to Bordet-Gengou agar. Whatever the 
explanation it is apparent that differences in the enhancement of toxicity 
after X-pressing cannot simply be due to the efficiency of disruption or
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the degree of inactivation of HLT during disruption* Nevertheless 
increases of 20-fold or more have been reported after sonication and by 
the use of a lysozyme/freeze-thaw technique (Cowell, Hewlett and Manclark, 
1979)*
4*2.2 Ultracentrifugation as a preparative step
Ultracentrifugation was introduced to remove insoluble material 
from lysates preparatory to subsequent purification. The data from 4 
different lysates showed that about 71% of the HLT was recovered in the
100,000 X g supernatant fluid* This association of HLT with the cyto­
plasmic fraction is in conformity with the results obtained by Munoz,
Ribi and Larson (1959), Billaudelle e^ a_l (1960) and Cowell, Hewlett and 
Manclark (1979)* These latter workers gave a figure of 737* as being 
typical of the amount of dermonecrotic activity recovered in 75,000 x g 
(30 min, 5°C) lysate supernatant fluids* As only about 387* of the total 
protein ends up in the soluble fraction, the ultracentrifugation step 
provides a 2— fold purification.
One anomaly in these results is the 25% of the original HLT 
in the ultracentrifugation pellet if cellular disruption is almost 100% 
effective and if the toxin is indeed a cytoplasmic component* The two 
most obvious explanations are that HLT although mainly cytoplasmic may be 
partly localized or trapped in the cell-envelope or that it becomes bound 
to the cell debris*
4.2.3 Ion-exchange chromatography
Nakase e_t ^  (1969) fractionated supernatant fluids from 
sonically disrupted B* pertussis on a column of DEAE-cellulose, by stepwise 
elution with increasing concentrations of phosphate buffer, as the first 
step in their purification of HLT* This ion-exchange chromatography step 
was claimed to produce a 10-fold purification with 80% recovery of toxicity
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(Nakase and Kasuga, 1962)* However in two separate attempts to repro­
duce these results most of the HLT activity was lost, presumably by 
destruction or retention on the column* In the most successful attempt, 
only one-quarter of the total HLT activity was recovered and the purity 
was enhanced only 1*6-fold* In both experiments HLT activity could be 
found, in varying amounts, in each of the last 3 of the 5 peaks eluted* 
Nakase and Kasuga (1962) observed this also* From this it could be 
interpreted that HLT exists in several molecular forms, but these results 
may simply show that HLT has a tendency to form aggregates or become 
associated with other cellular components. This latter suggestion is 
consistent with the proposal that when B* pertussis cells are lysed a 
disproportionate percentage of the HLT becomes associated with the 
particulate material which can be spun down by ultracentrifugation*
Perhaps the successful recovery of HLT from DEAE-cellulose is dependent 
upon the proportion of the toxin in association with B. pertussis components 
with a strong affinity for DEAE-cellulose viz, the higher the percentage 
of un-associated HLT the higher the yields* It is noteworthy that other 
investigators have obtained variable results in the purification of HLT 
on DEAE-cellulose. Thus in addition to Nakase e_t aT (1969), Onoue,
Kitagawa and Yamamura (1963) and lida and Okonogi (1971) used DEAE- 
cellulose successfully but Billaudelle aT (I960) and Banerjea and Munoz
(1962) had disappointing results* The lack of success experienced here
led to alternative methods for purifying HLT being explored*
4*2*4 Fractionation with ammonium sulphate
Ammonium sulphate fractionation has previously been used in the 
purification of HLT* Onoue, Kitagawa and Yamamura (1963) increased the 
purity of their HLT 4-5 fold by fractional precipitation with ammonium 
sulphate whilst recovering 70% of the toxicity* In the present invest-
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igation the concentrations of ammonium sulphate specified by these workers 
were used in the fractionation of a 100,000 x g, lysate supernatant fluid* 
Two preliminary experiments gave promising results with essentially all 
the toxicity being recovered in the 16-40% saturation precipitate as had 
been reported. This represents an effective purification of 2-2.5 fold, 
as about 40% of the original protein was recovered in this fraction* The 
fact that Onoue, Kitagawa and Yamamura (1963) achieved a 4-5 fold 
purification may be related to the pre-treatment of their sample with 
calcium phosphate gel* Nevertheless even a modest 2-2.5 fold purification 
is worthwhile if the yields, as here, are excellent especially with such a 
technically simple method. Furthermore an ultraviolet scan of one of the 
toxic fractions suggested that DNA was being removed* However to ensure 
a more complete removal of DNA the next lysate supernatant fluid was pre­
incubated with DNase* This was done to eliminate interference from DNA 
in later purification steps* Unfortunately this altered the amount of 
ammonium sulphate required to salt out the HLT and a further experiment 
had to be completed to re-define the conditions required. With the intro­
duction of RNase into the pre-incubation step of this experiment, the 
toxicity was halved* As the conditions were otherwise identical the 
RNase would seem to have been the culprit* As HLT is a protein the obvious 
conclusion must be that the RNase (from bovine pancreas) was contaminated 
with protease(s) in spite of being described by the manufacturer as a 
“protease free" RNase preparation* The fractionation step did however 
provide the information sought* Relative to the nuclease-treated 
starting material, 11% of the HLT was precipitated out at 30% saturation 
of ammonium sulphate and 70% in the 30-50% precipitate* In these, the 
only toxic fractions, there was 10% and 47% of the protein respectively* 
Consequently when fractionating a nuclease-treated sample it would be 
advisable simply to take a “50%“ precipitate, as the purification achieved
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would not be appreciably different from the figure of 1,5 for the 30-507* 
precipitate yet the yield would be slightly better*
Thus as an early step in the purification of HLT, ammonium 
sulphate fractionation is of limited but definite value. The purity is 
increased about 2-fold without any evidence of any overall loss of toxic 
activity, since the yields ranged from 81-1147** As marginally higher 
purifications were achieved when samples were fractionated directly, and 
not after treatment with nucleases, there may be a slight advantage in 
not using the nucleases until after the salting out step, but the problem 
encountered with the RNase would have to be resolved first*
4.2*5 Gel filtration
Although not a particularly difficult or troublesome technique, 
gel filtration had not hitherto been used in the purification of HLT. To 
assess its potential, samples of ammonium sulphate fractionated lysate 
supernatant fluid (30-507* ppt*) were run through a column of Ultrogel AcA 44 
(effective fractionation range 10,000-130,000 daltons)* On elution of 
the column, the toxin appeared as a single peak on the front shoulder of 
the first peak after the void volume material* In the second of two runs 
a purification of 4-5 fold was obtained with 347* recovery of the HLT*
Higher yields were possible but with less purification. The resolution 
could possibly be increased somewhat by re-chromatography of the sample.
The potential increase in purity expected from using the 
various purification steps in succession was unfortunately never achieved 
in practise* However in table 48 is given a set of figures for such a 
purification based upon actual figures obtained for the individual 
purification steps* Under ideal conditions the end product would be 
expected to have a specific activity of 1,000 mouse LD^^ per mg protein* 
Expressed differently 1 LD^^ would be equivalent to 160 ng N* How this
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would compare with some of the most active fractions reported in the liter­
ature is shown in table 49, It will be seen that the purified HLT that is 
potentially available by the methods used in this investigation would have 
a specific activity of about one-quarter of that of Nakase's material, 
assuming that a specific activity of 1.5 guinea pig MRD per ng N is 
equivalent to 44 mouse LD^^ per ng N. Nakase*s material was claimed to be 
100% pure.
The introduction of a step to separate the various components 
by their charge might be productive. Perhaps chromatography on DEAE- 
cellulose would now work at this stage in the purification. Alternatively 
preparative acrylamide gel electrophoresis might be useful. Also a 
substantial increase in the purity of the starting material may be possible
simply by harvesting the cells at the correct point in their growth cycle
(Cowell, Hewlett and Manclark, 1979).
5 Molecular weight estimation by gel filtration
The molecular weight of HLT was estimated by gel filtration on 
Ultrogel AcA 44 (effective fractionation range 10,000-130,000 daltons) to 
be 89,000 daltons - 10%. Unfortunately because of this relatively high 
molecular weight it was not possible to include, at short notice, a protein 
within the narrow molecular weight range of 100,000-130,000 daltons as a 
standard. Ideally for such determinations the protein of interest should 
be intermediate in molecular weight between two or more standards. In 
this instance the use of a gel with a higher overall fractionation range 
would have more readily enabled the inclusion of the required high molecular 
weight standards, A molecular weight estimate has never been given for 
HLT. The only pointer to its molecular weight until now was from sedi­
mentation coefficients. Nakase et al (1969) gave a 1.4S value to their 
purified HLT although they cited values of 13S and 20S as being obtained 
by others (Sato et al, unpublished data; Kuroya et al, 1959). This
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Table 49 The purification of HLT : a comparison of several protocols
Reference Specific
Guinea pig 
MRD
activity (ng N)
Mouse
^^50
Increase in 
purity
Yield (%)
Robbins and
Pillemer, 1950 NA 190 13*2 66
Onoue, Kitagawa and
Yamamura, 1963 1*0-1*3 44 60-80 5-10
Nakase et al.
1969 1*5 NA 80 NA
lida and Okonog i,
1971 0*9 50-100 90 (6-12)^’^ 11 (1)^'^
Livey NA 160 20^ 25^
a The figures given are based upon the dermonecrotic and lethal activities 
(in parentheses) respectively*
b Calculated with lysate as the starting material and not extracts from 
lysates or whole cells as used by others
NA Not available
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suggests yet again that the toxin has a tendency to form associations 
with other B. pertussis components during fractionation. The value 
obtained by Nakase e_t ^  (1969) does not appear to be compatible with HLT 
being a protein of around 90,000 daltons* Perhaps the toxin examined here 
was also associated with other material but this seems unlikely as the 
toxicity would surely in such an instance be eluted over a wide range of 
fractions due to the heterogeneity of the associated proteins.
Alternatively HLT may have a sub-unit construction and Nakase e_t a_l (1969) 
may have purified a sub-unit* Such a component would have to be able to 
function independently of the other sub-unit(s)* Another possibility 
would be that HLT may have a peculiar shape or contain lipid, although the 
chemical analyses of Nakase eh aT (1969) would seem to discount the latter 
possibility. Either of these properties might give to a large protein a 
low sedimentation coefficient* Pure HLT will be required for the 
molecular weight estimation made here to be confirmed eg, again by gel 
filtration and by polyacrylamide gel electrophoresis, where the inclusion 
of sodium dodecyl sulphate would provide information on the polypeptide 
construction,
6 Production and characterization of toxoided HLT
6*1 Detoxification of HLT - the effect of temperature and formaldehyde 
Toxoided HLT is a better immunizing agent for stimulating 
antitoxin production than native toxin (Roberts and Ospeck, 1944)* To 
produce toxoided HLT most investigators have incubated HLT at 37°C with 
around 0 *1% (w/v) formaldehyde for up to 1 mth although detoxification can 
be complete within 1 d (Evans and Maitland, 1937; Yamamoto, Zenyoji and 
Kato, 1952b)* There seems to have been little or no experimental manipu­
lation of the conditions eg, using different concentrations of formaldehyde 
or other temperatures. As the temperature of 37°C seemed inappropriate
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for a heat-labile toxin and the rate of detoxification unusually rapid, 
it is possible that heat inactivation of the toxin could be occurring 
under the conditions of toxoiding used by previous investigators* As 
Evans (1942) had demonstrated that heat-inactivated toxin (56°C, 30 min) 
did not give rise to HLT-neutralizing antibodies, it was decided to follow 
the inactivation of HLT with and without 0.1% (w/v) formaldehyde at both 
37°C and 4^C* The samples without formaldehyde were Millipore-filtered 
and checked for bacteriological sterility to avoid any complication from the 
growth of contaminants*
At 37^C with formaldehyde, toxicity was completely lost within 
1 d as reported previously (Evans and Maitland, 1937; Yamamoto, Zenyoji and 
Kato, 1952b)* Without formaldehyde the samples containing 3*25 LD^^ per 
mouse dose (0,5 ml) became atoxic (ie, 1 LD^^ per 0*5 ml) within 3 d at 
37°C, Yet the undiluted (32*5 LD^^ per 0,5 ml) samples were still toxic 
(iesK1 LD^0 per 0*5 ml) at 14 d* At 4°C there was no detectable loss of 
activity during the 14 d (ie, ^ 1  LD^^ per 0,5 ml) even for the sample 
initially with only 3*25 LD^^ in 0,5 nil* This is in agreement with 
previously published information on the stability of HLT at 4°C (page 65), 
The toxicity of the samples held at 4°C with formaldehyde decayed in the 
first 3 d at a rate -similar to that observed with the 3,25 LD^^, 37°C 
samples but in this instance there was complete detoxification within 9d,
One interpretation of these data is that there are two toxins which are 
inactivated by formaldehyde at both 4°C and 37°C but which differ in their 
heat-stability* The major toxin, HLT, is heat-labile and masks the 
presence of the minor toxin unless HLT is selectively inactivated (by 
incubation at 37°C, for instance)* The minor toxin cannot be endotoxin 
(lipopolysaccharide) as this would be expected to be resistant to the 
formaldehyde treatment but it could be pertussigen (Munoz, 1976) or 
"pertussis toxin" ie, HSF-LPF-IAP (Pittman, 1979)* Alternatively, the
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higher protein content of the undiluted (32,5 per 0*5 ml) 37°C sample
could have had a stabilizing effect on the HLT and enable toxicity to 
persist longer than predicted from the rate of inactivation of the 1 in 10 
diluted sample* This effect would not seem to be applicable to formaldehyde 
detoxification of HLT at 4°C*
Mere incubation at 37^C gave a fairly rapid detoxification of 
HLT and, when formaldehyde was present, detoxification was extremely quick*
In comparison, detoxification with formaldehyde at 4°C was much slower and 
perhaps therefore a gentler process* Consequently it was decided to use 
incubation at 4°C with formaldehyde to make toxoid from HLT in preference 
to the higher temperature treatment* Therefore a further 2 batches of 
toxin were treated at 4°C with 0.1% (w/v) formaldehyde (final concentration) 
for 15 d to ensure complete detoxification* However it was discovered that
1-3% of the original toxicity still persisted* This was probably not 
detected in the earlier tests because of the low activity of the starting 
material (32*5 mouse LD^^ per 0*5 ml injection volume). When one of the 
samples was tested in suckling mice for haemorrhagic activity it elicited 
a positive response* The residual toxic activity was therefore attribut­
able to HLT except that heating the sample (56°C, 15 min) gave no reduction 
in lethal toxicity* As the formaldehyde had been dialysed from the 
sample on day 15 to stop the reaction it was not responsible for the 
haemorrhagic response* Perhaps the residual HLT had been partially 
stabilized against heat-inactivation by changes induced by the formaldehyde*
6*2 HSF and LPF activity in formaldehyde-detoxified preparations of 
crude HLT
The two batches of toxin which had been incubated for 15 d 
at 4°C with formaldehyde were examined to determine what effect this 
treatment had had on the HSF and LPF in those samples. As the untreated
202
samples were toxic, they could not be used directly to assess the 
original HSF/LPF activity* Therefore heated preparations (56°C, 30 min) 
of the same material were substituted. Histamine-sensitizing factor and 
LPF are generally considered to be heat-stable, requiring treatment at 
80°C for inactivation* Therefore the discovery that the heated samples 
were less active than the formaldehyde-treated material was unexpected 
and does not appear to have been noted in the literature. In one 
experiment the figures of 48% and 40% were returned for the LPF and HSF 
contents respectively for the heated relative to the formaldehyde-treated 
sample. In the other experiment the HSF content was not determined 
accurately but the LPF content of the heated sample was, at 36%, signifi­
cantly less than its formaldehyde-detoxified counterpart.
There are at least two possible explanations for these results* 
At its simplest, it would appear that HSF/LPF is inactivated more 
completely at 56°C for 30 min, than at 4°C with 0.1% (w/v) formaldehyde 
for 15 do Although as suggested in the preceding section HSF/LPF may be 
even more stable at 37°C than under either of these two circumstances*
On the other hand the HSF and LPF may not be inactivated at all by 30 min 
at 56^C nor by the formaldehyde treatment* What is perhaps being observed 
is an enhancement of HSF/LPF activity after exposure to formaldehyde due 
to a reduced susceptibility to proteolytic destruction by tissue enzymes 
in the mouse. Which of these suggestions is likely to be correct could ♦ 
be assessed by comparing the relative HSF/LPF activities of both samples 
with a further preparation which had been heated then formaldehyde treated. 
If the latter sample was, like the heated sample, less active than the 
formaldehyde-treated sample then this would be consistent with the first 
proposal* If only the heated sample was of reduced activity this could 
indicate that the second suggestion was applicable* It is assumed that
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heating would not interfere in the way the HSF/LPF interacted with formal­
dehyde. The correctness of the second proposal could also be checked by 
testing the susceptibility of both heated and formaldehyde-treated preparations 
to degradation by proteases such as trypsin* It would be expected that a 
heated sample's susceptibility would be increased relative to that of a 
formaldehyde-treated sample.
6.3 The immunogenicity of formaldehyde-detoxified preparations of 
crude HLT
The initial aim of this study was to examine, more critically 
than has been done in the past, the question of whether anti-HLT might have 
protective activity in experimental pertussis infections of mice. In 
particular, whether animals actively immunized with HLT-toxoid and with 
demonstrable levels of circulating anti-HLT might be protected against an 
intracerebral or intranasal challenge. To do this required the production 
of mice with demonstrable levels of circulating antitoxin. Unfortunately 
as has been the experience of others (Wood, 1940; Anderson and North,
1943; Ospeck and Roberts, 1944), there was a singular failure to raise 
anti-HLT neutralizing antibodies in mice. Nevertheless other antibodies 
were produced, as shown by the development of precipitins* Attention was 
turned next to passive immunization experiments in mice with anti-HLT raised 
in rabbits - a species that is known to respond to HLT toxoid (appendix 2)*
The same batch of toxoid that had been unsuccessful in the mice was there­
fore used to immunize rabbits* Out of the 4 rabbits subjected to immuniz­
ation with crude HLT toxoid in Freund's adjuvants, 1 gave a fairly good 
response (1,000 units of antitoxin per ml), 2 responded with low titres and 
1 failed to respond* Yet each rabbit had received only about one-half as 
much toxoid as the mice on an equal body weight basis ie, the mice which 
were given the maximum dosage of 250 pg of protein had a toxoid (pg protein)
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to body weight (g) ratio of 10:1 whereas for the 2*5 Kg rabbits this was 
nearer to 5:1* It would appear that the mouse is the much less responsive 
of the two species, although the need to test pooled rather than individual 
mouse sera might have hidden the occasional responding animal* Anderson 
and North (1943) likewise raised antitoxin in rabbits to a batch of toxoid 
which was ineffective in mice in spite of the mice having received, on an 
equal body weight basis, about 10 times as much toxoid*.
The rabbits immunized with the crude toxoid gave variable 
responses in terms of the relative proportions of antitoxic antibodies and 
agglutinins. Interestingly, the only rabbit that failed to make a demon­
strable amount of circulating antitoxin produced the antiserum which gave 
the highest titre of agglutinin (1,280), whilst the antiserum with the 
highest antitoxic activity was consistently tested as having only half this 
level of agglutinin* Neither were the responses related to the dosage of 
toxoid given. The highest antitoxin and agglutinin titres were obtained 
with antisera from the two rabbits which received the lower dosage ie,
40% less toxoid than the others. These results illustrate the well knowm 
variability in the way individuals within a species may respond to a 
given immunogen*
When the rabbit antisera were tested for the development of 
precipitins, both to the toxoid to which they were raised and the native 
toxin from which the toxoid was prepared, reactions of complete identity 
were evident between the two antigen preparations* Obviously the formal­
dehyde detoxification did not grossly alter the major antigenic components 
in the toxin preparation* However although it is desirable to retain a 
high percentage of native determinants the amount of polymerization of 
proteins by formaldehyde can be an even more important factor in deciding 
how effective an immunogen a toxoid will be (Warren, Spero and Metzger, 
1973; Warren 'et al , 1975). Future investigators
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may wish to study the effects of pH and the time that the formaldehyde is 
left in contact with HLT on the formation of these polymers and their 
immunogenic ity.
7 Absorption of antitoxic sera
Two of the antitoxic rabbit sera prepared for use in the bacterial 
infection experiments were absorbed with live, whole cells of B. pertussis 
134, the strain from which the toxoid used to immunize the rabbits was 
derived. It was hoped to remove as many antibodies as possible to 
B. pertussis components other than HLT, especially agglutinins. However 
antiserum B (1,000 antitoxin units/ml) lost 75% of its antitoxic activity 
in this process of absorption and the less active antiserum D (lOO 
antitoxin units/ml) actually acquired haemorrhagic activity as demonstrated 
in suckling mice. This raises the question of why, if HLT is cytoplasmic, 
whole-cell absorption should remove HLT-neutralizing antibodies. It is 
improbable that there is leakage of HLT from the cells through complement- 
mediated cytolysis. The antisera were heated at 56°C prior to absorption 
to prevent just such complement-mediated activity. It is therefore 
possible that HLT occurs to some extent on the cell surface although having 
a mainly cytoplasmic location. This would make sense from a pathogenicity 
point of view if the toxin produces ciliary paralysis as has been suggested 
(standfast, 1958). Moreover the toxin has been recovered in cell washings 
(appendix 1) and antitoxin has been raised on a few occasions in response to 
immunization with B. pertussis cells (appendix 2). However it is not 
possible from the data to differentiate between whether HLT occurs as an 
integral component of the cell-envelope or just becomes associated with the 
outer surfaces of some of the bacteria after being released by lysis of others
In the experiments outlined here the absorptions were done with 
fairly large quantities of bacteria ie, 3 or 4 g wet weight of cells being
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used to absorb 10 ml of undiluted serum. Indeed in the immunodiffusion 
tests between these absorbed sera and neighbouring antipertussis sera, 
precipitin lines developed demonstrating that B. pertussis antigens had 
been acquired by the serum during the absorptions and in sufficient 
quantities to be visualized in this test. If fewer cells had been used 
in the absorption it might have been possible to retain most of the anti­
toxin whilst still removing just as effectively the other antibodies shown 
to be lost by immunodiffusion and bacterial agglutination tests* Alter­
natively heated or formaldehyde killed cells might not have absorbed out 
HLT-neutralizing antibodies*
8 Antitoxic immunity and protection of mice against intracerebral and 
intranasal challenges with B. pertussis
Protective antigens and antibodies can be assessed in the intra­
cerebral mouse protection test and in experimental respiratory tract 
infections of mice (page 5)* In this investigation, antisera, particularly 
antitoxic antisera, were assessed in both these tests viz* the lethal intra­
cerebral and the sub-lethal intranasal mouse protection tests. Implicit 
in the testing of antitoxic sera is the assumption that by neutralizing 
HLT, the initiation or development of these experimental B. pertussis 
infections might be prevented or ameliorated* Although the involvement of 
HLT in the pathogenesis of pertussis is unclear there are some ways in which 
it could aid in the establishment of the infecting dose and its subsequent 
multiplication (page 28), For example, HLT may play a part in the lodge­
ment of the organisms among the cells of ciliated epithelia by paralysing 
the cilia (Standfast, 1958). Although there has been no direct confirmation 
of this last mentioned report it should not prove too difficult to test 
crude HLT and a heat-inactivated control sample for ciliostatic activity 
eg, on the ciliary activity of tracheal organ cultures or even in mussels
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(Mytilus edulis) which are used by cell-biologists to study the action of 
cilia* Another possible mechanism by which HLT could act would be by 
interference with the development of immunity through toxic action on the 
spleen and lymph nodes (Munoz, 1971)*
When B . pertussis is injected intracerebrally into mice about 
107* of the challenge remains in the brain to multiply among the ciliated 
cells on the ependymal lining of the ventricle (Berenbaum, Ungar and
5
Stevens, 1960; lida e_t al_, 1962)* When the infecting bacteria reach 10 
or 10^ cfu, the blood-brain barrier breaks down* Apparently, it is only 
then that circulating antibodies to B. pertussis gain access to the 
infecting bacteria (Dolby and Standfast, 1961), However the effect of 
antipertussis antibodies on the early stages of such infections can be 
tested by administering antiserum mixed with the challenge organisms 
(ie, the IC/mix test). The rabbit antisera discussed earlier and the 
US standard antipertussis serum were tested in this way* Only the latter 
serum afforded a significant (P-= 0*005) degree of protection as measured 
by a reduction in mortality at the end of the 14 d test period* This 
standard antiserum contained no detectable antitoxin* All 3 of the rabbit 
antisera which had demonstrable levels of antitoxin were essentially non-pro­
tective against an intracerebral challenge, even that antiserum containing
1,000 units of antitoxin per ml as measured in suckling mice* The only 
other report in which an antitoxin-containing antiserum was tested in this 
type of experiment was performed by Yamamoto al_ (1955)* They found an 
antiserum from a rabbit whose skin was resistant to 8 MRD of toxin was 
protective when given mixed with the challenge organisms to mice. From 
the results presented here it would appear that antibodies other than those 
to HLT were responsible for the protection measured by Yamamoto et al, and 
that antitoxin is an unlikely candidate as a protective antibody in this 
system* Moreover anti-HLT is not protective when given intracerebrally
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2-5 d after an intracerebral challenge (Dolby and Standfast, 1961)* This 
is not to say that it is theoretically impossible for antitoxin to be 
protective, but merely that the conditions used were not right for this 
to be demonstrated* When antiserum B and D (1,000 and 100 antitoxin 
units per ml respectively) were given intraperitoneally in 0.2 ml volumes 
to mice a few hours before the intracerebral challenge both gave signifi­
cant levels of protection* Unfortunately there were insufficient quan­
tities of antiserum B after it had been absorbed for this to be tested*
As it contained antitoxin it would have been interesting to see how it 
performed in this test since it was devoid of antipertussis components 
found in B* However the results of Dolby and Standfast (1958) and Kuwajima 
et al (1958) indicate that passively administered antitoxin is not pro­
tective against an intracerebral infection* For antitoxin to be effect­
ive in these IP/IC tests it would have to be capable of clearing an already 
established infection as the site of the infection is sealed off until the 
blood-brain barrier breaks down.
Turning to the intranasal (sub-lethal) challenge test, anti­
serum B gave significant protection when 0*2 ml was given intraperitoneally 
a few hours before the intranasal instillation of a sub-lethal dose of 
B. pertussis* Moreover this antiserum was even more effective if given 
mixed with the challenge organisms perhaps this allowed it to be present
at the site of the infection in relatively high concentrations from the 
very start* This IN/mix protective activity was lost after the antiserum 
had been absorbed with live B* pertussis* Perhaps the 4-fold reduction in 
the titre of antitoxin caused by absorption was the reason for the loss of 
protective activity, but more likely it was due to the loss of antibodies 
to other B* pertussis components. Antibodies raised to the same batch 
of toxoid used to produce antiserum B were present in antiserum A which 
contained no detectable antitoxin and this latter antiserum was protective 
in IN/mix experiments.
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The question of whether high levels of antitoxin might confer 
protection in either of these experimental infections of mice, and by 
inference in man, is therefore still open* The major limiting factors in 
these studies have been, and still are, the lack of a purified HLT toxoid 
and the apparent inability of mice to respond effectively to this particu­
lar antigen* Nakase e_t a_l (1969) reported, without giving data, that 
mice were not protected against intracerebral challenge by previous injection 
of purified, alum-precipitated HLT-toxoid* However their failure could 
have been due to the mice not making anti-HLT antibodies rather than to the 
intrinsic lack of protective activity of anti-HLT, Perhaps the only 
practical resolution of this question would be to give mice large quantities 
of pure anti-HLT raised in rabbits since this species does at least respond*
A further possibility is that anti-HLT might be unable to 
prevent multiplication of the bacteria in B, pertussis infections but still 
be able to prevent some of the manifestations of the disease. Let us 
suppose that the toxin produces local tissue damage in the respiratory 
tract and that this is a pre-condition for the entry of the HSF-LPF-IAP 
complex into the systemic compartment to produce lymphocytosis and other 
changes* Anti-HLT if available locally might thus prevent some of the 
clinical signs without interfering with the growth of the bacteria* This 
idea could be tested as follows: the development of histamine-sensitization
and lymphocytosis could be monitored in mice actively or passively immunized 
to purified HLT toxoid and in an untreated group of control animals* If the 
test mice failed to respond to the infection by not becoming sensitized to 
histamine or developing a lymphocytosis, this would be compatible with 
HLT acting in the manner described*
In none of the above discussion has any particular attention 
been paid to the class of immunoglobulin to which the anti-HLT belongs*
Yet this might be crucial in determining its potential protective activity.
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In particular, antibodies of the IgE class specific for HLT might be 
protective by binding to tissue cells and neutralizing the postulated 
ciliary-paralysis effect of HLT, which as discussed above may be located 
on the surface of B. pertussis* Likewise, secretory IgA specific for HLT 
and continuously present in the mucous secretions of the respiratory tract 
might exercise a protective function*
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Appendix 1
Literature review on the use of culture fluids and cells as a source of HLT
1 Culture filtrates and supernatant fluids (9 citations)
Joslin and Christensen, 1940; Weichsel et al, 1940; Wood, 1940; 
Roberts and Ospeck, 1942; Weichsel, Katona and Liu, 1942; Ungar and 
Muggleton, 1949b; Kuwajima, Iwamura and Hirai, 1951; Imamura, 1952; 
Kuwajima ejb aj^ , 1958,
2 Extracts from intact organisms (7 citations)
Evans and Maitland, 1937; Katsampes, Brooks and Bradford, 1942; 
Roberts and Ospeck, 1942; Burrell, Robbins and Pillemer, 1948; Robbins 
and Pillemer, 1950; Yamamoto, Zenyoji and Kato, 1952c; Billaudelle e_t al, 
1960.
3 Extracts from cells disrupted by
301 Grinding (14 citations)
Bordet and Gengou, 1909; Teissier ^  al, 1929; Lawson, 1933; 
Miller, 1934; Evans and Maitland, 1937; Evans, 1940^, 1942^, 1947^; 
Silverthorne and Cameron, 1942^; Anderson and North, 1943^; Proom, 1947^; 
Abrosimov, 1961; Onoue, Kitagawa and Yamamura, 1963; Strizova and 
Trlifajova, 1964»
a involved freeze-thawing prior to grinding
302 Freeze-thawing (9 citations)
Evans and Maitland, 1937; Strean and Grant, 1940; Smolens and 
Flavell, 1947; Yamamoto, Zenyoji and Kato, 1952a; Yamamoto et al, 1952, 
1953, 1957; Kasuga e_t 1954; Uchida et al, 1957,
3.3 Sonication (14 citations)
Flosdorf and Kimball, 1940; Flosdorf, Bondi and Dozois, 1941; 
Ehrich et al, 1942; Smolens and Flavell, 1947; Verwey and Thiele, 1949;
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Robbins and Pillemer, 1950; Fennel and ThMe, 1951; Kuwajima ejt a]^ , 1958;
Munoz, Schuchardt and Verwey cited by Munoz, Ribi and Larson, 1959;
Nakase and Kasuga, 1962; Nakase e_t al, 1965; Sato and Nagase, 1965;
Nakase e_t al, 1969; lida and Okonogi, 1971.
3o4 Hughes press ( 6 citations)
Frappier, Guerault and Repentigy, 1955 cited by Billaudelle 
et al, 1960; Billaudelle e_t al, 1960; Dolby and Standfast, 1958 and 1961;
Dolby, Thow and Standfast, 1961; Standfast and Dolby, 1961,
3.5 X-press (1 citation)
Billaudelle e_t al, 1960,
3.6 Mickle disintegrator (4 citations)
Andersen 1952 and 1953b; Munoz, Ribi and Larson, 1959;
Banerjea and Munoz, 1962,
3.7 Rotary disintegrator (1 citation)
Novotny, 1977 personal communication
3.8 Pressure cell (1 citation)
Munoz and Ribi cited by Munoz, 1971
3.9 Lysozyme freeze-thaw technique (1 citation)
Cowell, Hewlett and Manclark, 1979
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Appendix 2
The production of antitoxin to HLT in animals
Live Bo pertussis, native or toxoided HLT preparations,or 
combinations of these factors have been used as immunizing agents to raise 
HLT neutralizing antibodieso In tables 50 - 52 are cited references 
in which each of these immunogens or combinations of immunogens have been 
used. Antitoxin titres are given where possible, either in the form 
presented by the author(s) or as estimated from their raw data assuming 
where necessary that antitoxin neutralizes in multiple proportions (Evans, 
1940; Proom, 1947). Only the highest antitoxin titres obtained are cited. 
Titres are presented as units of antitoxin per ml where a unit of antitoxin 
is defined as the smallest amount required to neutralize, unless stated 
otherwise,
i 1 MRD in rabbits or, if in parenthesis, in guinea pigs
ii 1 MLD in mice or, if in parenthesis, LD^^ in mice
or alternatively
iii as the number of MRD of HLT to which immunized rabbits were resistant
In the absence of quantitative data the symbols + and - are used
to indicate whether antitoxin was or was not produced. Where antitoxin 
was not assayed by a particular method the symbol ND (not determined) is 
used.
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Appendix 3
Sodium dodecyl sulphate, polyacrylamide gel electrophoresis (SDS-PAGE)
1 Chemicals
BDH, Poole, England; acrylamide, NN*methylenebisacrylamide, 
glycine, sodium dodecyl sulphate (SDS), bromophenol blue, 
B-mercaptoethanol, glycerol, N*,N',N',N*tetramethylethylene- 
diamine.
Sigma Chemical Company, St. Louis, MQ, USA: Tris (hydroxymethyl)
amino methane, ammonium persulphateo
Hopkins and Williams, Chadwell Heath, England: HCl, glacial
acetic acid, ethanol, methanolo
Searle Diagnostics, High Wycombe, England; Coomassie blue R250o
2 Stock solutions
Acrylamide solution
Acrylamide 30 g
NN'methylenebisacrylamide 0*8 g
Dissolved in 100 ml of distilled water, filtered,and stored at 4°C in a 
dark brown bottle,
IM Tris/HCl buffer, pH 8,8
2M Tris (hydroxymethyl) amino methane 50 ml
IN HCl approx 16.2 ml
Made up to 100 ml with distilled water,
Q,5M Tris/HCl buffer, pH 6.8
IM Tris (hydroxymethyl) amino methane 50 ml
IN HCl approx 45 ml
Made up to 100 ml with distilled water.
Tris/Glycine running buffer, pH 8.3 (10 x concentrated)
Glycine 144.13 g
Tris (hydroxylmethyl) amino methane 30,28 g
Made up to 1000 ml with distilled water.
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Ammonium persulphate: 0.8% (w/v) in distilled water,
made up fresh each time.
SDS: 20% (w/v) in distilled water,
Bromophenol blue: 0,1% (w/v) in distilled water.
Overlay solution
Ethanol 5 ml
Distilled water 95 ml
Solubilizing buffer
0.5M Tris/HCl buffer, pH 6.8 25 ml
SDS, 20% (w/v) 20 ml
B-mercaptoethanol 10 ml
Glycerol 20 ml
Bromophenol blue, 0,1% (w/v) 2 ml
Distilled water 23 ml
Fixing-staining solution (Weber and Osborn, 1969)
Coomassie blue R250 1,25 g
50% (v/v) methanol 454 ml
Glacial acetic acid 46 ml
Destaining solution
Methanol . 50 ml
Glacial acetic acid 75 ml
Distilled water 875 ml
3 Preparation of gels
The glass moulds for the gels were prepared as follows 
2 glass plates ( 8 x 7  cm) separated by spacers were secured on 3 sides 
with special adhesive tape. The bottom corners were then sealed by 
dipping in molten paraffin wax.
The separating gel solution was prepared next:-
I
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Acrylamide solution 36,7 ml
IM Tris/HCl buffer, pH 8,8 37.5 ml
20% (w/v) SDS 0.5 ml
N *  , N *  , N *  , N *  tetramethyletheylenediamine 25 p.1
0.8% (w/v) ammonium persulphate 10 ml
Distilled water 15.3 ml
The ingredients were mixed thoroughly but without aeration and the gel 
plates were filled up to a height of 5.5 cm. The gel was then overlaid 
with 5% (v/v) ethanol so a perfectly flat gel surface was obtained.
Whilst the separating gel polymerized the stacking gel was prepared:- 
Acrylamide solution 16.7 ml
0.5M Tris/HCl buffer, pH 6.8 25 ml
20% (w/v) SDS 0.5 ml
N * , N ' , N * , N * tetramethylethylenediamine 25 |il
0.8% (w/v) ammonium persulphate 10 ml
Distilled water 47.8 ml
The ingredients were mixed without aeration. Then the overlay solution 
was poured off the fully polymerized separating gel. This was blotted 
dry if necessary. The stacking gel was then poured over the separating 
gel, to within 3-4 mm from the top of the plate. Sample "combs" were 
suspended in the solution and any spaces which remained were filled with 
more gel solution. After polymerization the combs were carefully removed 
under the running buffer and the sealing tape was removed from the base of 
the gel plates.
4 Conditions of electrophoresis
The stock Tris/glycine running buffer was diluted 1 in 10 and 
20% (w/v) SDS added to a final concentration of 0,1% (w/v). The lower 
electrode vessel was filled with approximately 2,5 1 of this buffer. The
244
gel plates were then inserted into the top electrode, using a liberal 
amount of grease around the gasket to prevent leakage. Then the top 
electrode vessel was put into position and filled with the running 
buffer. Samples of 25-50 pi were pipetted into the wells in the stacking 
gel. Finally the electrode unit was connected to the power supply (lower 
vessel was the anode) and run at constant current (15 mA/gel) for 2-3 h 
ie, until the tracking dye reached the end of the gel,
5 Fixing-s taining/des taining
Once removed from the glass moulds the gels were immersed in 
fixing-staining solution for 60-90 min. They were destained by soaking 
in several changes of destaining solution.
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Appendix 4
Adjuvants
1 Aluminium hydroxide, Al(OH)^
The method described by Weir (1978) was used.
Aluminium sulphate 5% (w/v) 25 ml
Sodium hydroxide 5% (w/v) 10 ml
The aluminium sulphate solution was added to the sodium hydroxide solution 
whilst stirring vigorously and the resultant precipitate washed twice by 
centrifugation and décantation, resuspended in Dulbecco "A" PBS (Oxoid 
Ltd., England) and sterilized by autoclaving (121°C, 15 psi, 15 min).
The immunization mixtures were prepared by mixing equal volumes of antigen 
and AI(OH)2.
2 Freund's incomplete adjuvant
Five volumes of mineral oil (Bayol F; Esso Petroleum Company Ltd., 
Purfleet, England) whre mixed with 1 volume of emulsifying agent ( Aracel A; 
Atlas Powder Company, Wilkington, Delaware, USA). Only then were 5 volumes 
of antigen solution introduced into the mixture. A water-in-oil emulsion 
was obtained by sonicating the mixture (100 Watt ultrasonic disintegrator; 
Measuring and Scientific Equipment Ltd., London) until a thick, creamy
fluid was formed. Before use the mixture was checked to ensure that it
was a true water-in-oil emulsion. This was done by injecting some of the 
mixture into or onto cold water to show that discrete drops developed.
3 Freund's complete adjuvant
This was prepared as for Freund's incomplete adjuvant except that the 
mineral oil contained the tubercle bacillus. A stock suspension of 
Mycobacterium tuberculosis was prepared in Bayol F (Esso Petroleum Company 
Ltd., Purfleet, England). Mixing was achieved by sonication (100 Watt
ultrasonic disintegrator; Measuring and Scientific Equipment Ltd., London) 
For use the stock suspension was diluted 1 in 10 with Bayol F (Esso Petrol­
eum Company Ltd., Purfleet, England) to give 200 pg mycobacteria/ml.
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Appendix 5
presented in tables; 18, 22, 23. 24. 30, 33, 36 and 37 were based
Table 53 Toxicity test results for the data presented in table 18}
experiment 1 : the toxicity of X- and C-mode cells
Dose of lysate/mouse Experiment la Experiment lb
(oue of 0.5 ml injected)
^2 s %1 X2 C, 2^
20 4/4 3/4 10/10 9/10
10 4/4 4/4 10/10 9/10
5 3/4 0/3 4/10 1/10
2.5 4/4* 4/4 10/10 9/9 0/10 0/10
1.25 4/4 4/4 10/10 9/10 0/10 0/10
0.625 3/4 0/4 10/10 9/10
0,312 0/4 0/4 6/10 1/10
0.156 0/4 0/4 0/10 0/10
a Number of deaths/number of mice injected
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Table 56 Toxicity test results for the data presented in table 22,
experiments 1-3 : the toxicity of B. pertussis strains
Experiment B.pertussis Dose of cells (ou of 0,5 ml injected / mouse)
s train 5.0 2.5 1,25 0.625 0.3125 0.156
1 18334 4/4* 4/4 3/4 0/4 0/4 NT
18904 L4 2/3 3/3 4/4 1/4 0/3 0/3
77/18319 3/3 3/3 3/4 1/4 0/3 0/3
77/24833 2/3 3/3 3/4 0/4 0/3 0/3
2 18334 4/4 4/4 4/4 0/4 0/4 NT
134 3/3 3/4 4/4 3/3 1/3 1/3
3865 2/3 4/4 2/3 2/4 0/3 0/3
D30042 I 3/3 3/4 3/4 1/3 0/3 0/3
3 18334 4/4 4/4 4/4 0/4 0/4 NT
D3148 I 3/3 3/3 4/4 2/4 0/3 0/3
No. 28 3/3 3/3 4/4 4/4 1/3 0/3
MAENO 3/3 3/3 4/4 3/4 1/3 0/3
a Number of deaths/number of mice injected 
NT Not tested
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Table 57 Toxicity test results for the data presented in table 22,
experiments 4 and 5 : the toxicity of B. pertussis strains
Experiment Bo pertussis Dose of cells (ou of 0.5 ml injected/mouse)
strain
2,5 1.25 0,625 0,312 0,156
4 18334 13/15* 14/15 8/15 4/15 NT
MAENO NT 10/10 9/10 6/10 4/10
134 NT 8/10 ■ 8/10 8/10 4/10
NOo 28 NT 10/10 9/10 6/10 1/10
5a 18334 4/4 2/4 1/4 0/4 0/4
MAENO 3/4 2/4 4/4 0/4 0/4
134 3/4 4/4 3/4 3/4 0/4
No, 28 3/4 3/3 2/4 0/4 0/4
5b 18334 8/10 9/10 5/10 2/10 NT
MAENO NT 9/10 10/10 8/10 7/10
134 NT 7/10 9/10 6/10 3/10
No. 28 NT 10/10 10/10 5/10 4/10
a Number of deaths/number of mice injected 
NT Not tested
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Table 61 Toxicity test results for the data presented in table 33 ;
the toxicity of lysate supernatant fluids before and after 
DNase/RNase treatment and ammonium sulphate fractionation
Dose
( n D /
mouse
Number of deaths/number of mice injected
Lysate super 
natant fluid
DNase/RNase treated lysate 
supernatant fluid
307, ppt 30-507, ppt
60 16/16 8/10
30 15/17 2/10
15 5/15 1/10
7,5 0/16 0/10
500 6/10
250 5/11
125 0/10
62,5 0/10
142,8 8/10
71,4 8/9
35,7 2/10
17,9 0/10
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Table 62 Toxicity test results for the data presented in table 36,
experiment 1 : the detoxification of HLT with formaldehyde
Dose
((ii)/
mouse
Untreated HLT Formaldehyde-treated HLT
test 1 test 2 test 3 test 1 test 2 test 3
13,1 3/4*
6,6 2/4
3o3 0/4
1.6 0/4
0.8 0/4
16.4 9/10
8,2 3/10
4.1 0/10
2.1 0/10
28.9 16/16
14.4 15/17
7.2 5/15
3.6 0/16
1000 r NT NT 8/10
500 9/10 2/10 3/10
250 0/10 0/10 NT
125 0/10 0/10 NT
a Number of deaths/number of mice injected
NT Not tested
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Table 63 Toxicity test results for the data presented in table 36,
experiment 2 : the detoxification of HLT with formaldehyde
Dose 1(p,l)/mouse
Untreated HLT Formaldehyde-treated HLT
test 1 test 2 test 3 test 1
10.9 4/5*
5.4 4/5
2.7 3/5
1.4 0/5
6.8 7/10
3.4 7/10
1.7 3/10
0.8 0/10
4.5 7/10
2.2 0/10
1.1 0/10
0.6 0/10
500 7/9
250 6/10
125 0/10
62.5 0/10
a Number of deaths/number of mice injected
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